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1 Introduction   
1.1  The Drug Development Process 
The development of an innovative drug is a long-lasting process with many stages being 
involved (Figure 1.1-a) [Ng, 2004]. It often starts with the identification of a target (receptor, 
enzyme, etc.) that has to be modulated to treat a particular disease. Under physiological 
conditions, the target itself is modulated by endogenous ligands mostly in a relatively 
unselective manner, that is, a particular ligand interacts with more than one receptor or 
enzyme. Exogenous ligands which subtype-specifically affect a given target can be detected 
by high throughput screening (HTS) or computational methods (Section 1.5). They are 
referred to as “hits” and have to be further refined to a “lead candidate” in a lead optimization 
process according to their potency, metabolic stability and ADME (absorption – distribution – 
metabolism – excretion) -properties. The development work has to follow Good Laboratory 
Practice (GLP) to ensure that proper quality systems are established. Animal models serve as 
inevitable tools to experimentally test whether or not a given lead candidate evokes the 
desired effects in a living individual. The drug designated for clinical trials and large-scale 
production has to be manufactured according to Good Manufacturing Practice (GMP). Here 
the leading compound is brought into an optimal drug delivery system (e.g., tablet, parenteral 
solution, etc.), which denotes the final stage of the preclinical phase. 
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Figure 1.1-a. Schematic representation of the different stages involved in the development of 
a modern drug [Druquest, 2005]. 
 2 
The following clinical development encompasses three phases of clinical trials in which a 
drug is tested at humans according to three important parameters: harmlessness, effectiveness 
and quality. Clinical trials are conducted in accordance with Good Clinical Practice (GCP) 
and they follow regulations and guidelines from the FDA and other approval agencies. Once a 
drug has successfully passed these stages the manufacturer can apply for a product license 
followed by a product license approval provided by an approval agency. Phase 4 describes 
clinical trials that aim at evaluating new indications for the drug.  
Today, roughly half of all drugs receiving product license approval are targeted against 
GPCRs and a considerable number of the best selling prescription drugs act at GPCRs 
[Klabunde & Hessler, 2002] making them to a promising class of targets for pharmaceutical 
industries.  
 
1.2  G-protein Coupled Receptors 
G-protein coupled receptors (GPCRs) are the largest family of cell-surface receptors 
involved in signal transmission. They have been successful during evolution in recognizing a 
wide range of stimuli from photons to large glycoproteins [Bockaert & Pin, 1999]. These 
receptors transduce extracellular signals in cellular responses via heterotrimeric G proteins. 
Several different signal transduction pathways as well as second messengers are involved in 
GPCRs function, which are even different among the subtypes of a given receptor. This is a 
reason for the broad therapeutic potential of GPCRs. Numerous diseases have been linked to 
specific mutations within the genes encoding GPCRs, marking these receptors as targets for 
specific therapeutic interventions [Schoneberg et al., 2002; Rattner et al., 1999]. Today 50% 
of all recently launched drugs are targeted against GPCRs with annual worldwide sales 
exceeding $50 billion annually [Med. Ad News Staff, 2004].  
All GPCRs share a common central domain composed of seven transmembrane helices, the 
heptahelical domain (HD), which is also referred to as the transmembrane region [Baldwin, 
1993]. On the basis of sequence similarity, mammalian GPCRs have been classified into three 
major categories, namely the rhodopsin/ β-adrenergic receptors (family 1) which contain 
many receptors for classical neurotransmitters, the secretin receptor family (family 2) 
comprising receptors for distinct hormones and peptides and family 3 comprising 
metabotropic glutamate receptors [Wess, 1998].  
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1.3  Family 3 G-protein Coupled Receptors  
Apart from metabotropic glutamate receptors (mGluRs), family 3 G-protein-coupled 
receptors (3-GPCRs) comprise the γ-aminobutyric acid type B receptors, (GABABR1 and -2) 
[Jones et al., 1998; Kaupmann et al., 1998], the parathyroid calcium sensing receptors (CaSR) 
[Brown et al., 1993] and the vomeronasal receptors [Bargmann, 1997], e.g., some taste and 
putative pheromone receptors [Hoon et al., 1999]. A detailed description about mGluRs will 
be given in Section 1.4. The calcium-sensing receptor (CaSR) is an ion-sensing GPCR that is 
allosterically regulated by extracellular calcium and different aromatic amino acids, e.g., L-
phenylalanine and L-tyrosine [Conigrave et al., 2000; Kobilka, 2000]. GABAB is involved in 
the presynaptic inhibition of transmitter release and mediates the slow synaptic inhibition by 
increasing the potassium conductance responsible for long-lasting inhibitory postsynaptic 
potentials [Jones et al., 1998; Kaupmann et al., 1998]. 
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Figure 1.3-a. Schematic representation of a family 3 GPCR according to W. Spooren 
[Spooren et al., 2001]. 
 
3-GPCRs are characterized by an extracelluar domain (ECD), a HD consisting of seven 
transmembrane helices, which are linked by six alternating extracellular and intracellular 
loops and an intracellular domain (ICD), which contains the C-terminus and the G-protein 4 
interaction sites (Figure 1.3-a). They possess a typical but unique feature: A large 
extracellular ligand-binding domain (ECD) that shares some sequence similarities with 
bacterial periplasmic amino acid-binding proteins (PBPs) [O'Hara et al., 1993]. The ECD is 
characterized by a bilobate structure and adopts a closed conformation on agonist binding in 
the cleft that separates both lobes and is often called “Venus flytrap module” [Pin et al., 2003; 
Acher & Bertrand, 2005]. This stands in contrast to most other GPCRs, where natural ligand 
binding occurs in the HD [Wess, 1993]. The orthosteric binding sites of 3-GPCRs are well 
understood today, which is mainly due to the success in crystallizing the ECD of mGluR1 
with and without glutamate associated [Kunishima et al., 2000] as well as due to detailed 
mutation studies of both mGluRs [Pin et al., 1999], GABAB [Galvez et al., 2000] and CaSR
 
[Petrel et al., 2003]. In contrast, little is known about the 3D-structure and dynamics of the 
HD as well as the binding mode of allosteric modulators. However, in the past, there have 
been a lot of efforts in the identification of new allosteric modulators, especially in the mGluR 
area [Eastman et al., 2004; Wang et al., 2004; Poon et al., 2004; Zheng et al., 2005; Kohara et 
al., 2005; Bonnefous et al., 2005], just to name some. This is mainly due to the fact that 
ligands binding in the HD possess more drug-likeness than their analogues interacting with 
the orthosteric site. In particular the application of HTS technologies in pharmaceutical 
industry facilitated the discovery of agonists and antagonists binding exclusively in the HD of 
the receptor.  
 
1.3.1  The Transmembrane Region 
The precise knowledge of the 3D structure of a given target is a key concern in drug 
discovery since it facilitates a better understanding of ligand binding, which could be used for 
a rational design of novel ligands as prospective drug compounds [Cavasotto et al., 2003]. To 
gain an insight into the 3D-structure and binding sites of proteins the application of X-ray 
crystallography, electron microscopy and NMR are state of the art. However, the expression, 
purification and crystallization of membrane proteins remains a challenging process which 
impedes their structure elucidation [Becker et al., 2003; Stenkamp et al., 2002; Burley & 
Bonanno, 2002]. Therefore, only a high-resolution X-ray structure of an inactive state of 
bovine rhodopsin (bRho) and bacteriorhodopsin (BR) is available so far [Okada et al., 2000; 
Pebay-Peyroula et al., 1997]. In the past, particularly the X-ray structure of bRho has been 
applied as a template for building homology models of a given GPCR.  
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Figure 1.3.1-a. Homology model of the HD of CaSR according to A. Gutcaits [Noeske et al., 
2006]. Backbone residues potentially contributing to the ligand binding are depicted. 
 
All GPCRs bear a similar membrane topology. Seven transmembrane segments (H1–H7), 
predominantly helical, are linked together sequentially by extracellular (EC1, EC2 and EC3) 
and cytoplasmic loops (C1, C2 and C3) [Baldwin, 1993]. The transmembrane helices are 
tilted to varying degrees with respect to the putative plane of the membrane bilayer. Despite 
the common heptahelical architecture of their transmembrane regions, GPCRs are 
characterized by a relatively low sequence identity (less than 20%), especially when amino 
acid sequences of two GPCRs from different families are compared such as family 1 and 3. 
However, it has been demonstrated recently that the backbone of the bRho (family 1) appears 
to be a reasonable template for building a model of the HD of group I mGluRs and the CaSR 
(family 3) [Pin et al., 2003; Malherbe et al., 2003a; Miedlich et al., 2004; Hammerland et al., 
1999; Hawrot et al., 1998]. In case of GABAB-receptors their extraxcellular domain has been 
investigated in detail [Pin et al., 2003; Hawrot et al., 1998; Galvez et al., 1999; Bernard et al., 
2001] as well as the roles of receptor dimers in G-protein signaling and coupling efficacy 
[Galvez et al., 2001]. Still, no homology model of the transmembrane region of GABAB-
receptors has been published to date.  6 
Using the bRho template despite low sequence similarities is supported by the fact that the 
HD of mGluRs behaves like any other family 1 GPCR in terms of G protein coupling and 
regulation by various types of ligands [Goudet et al., 2004]. Like bRho, the HD of mGluRs 
constitutively couples to G-proteins and is negatively and positively regulated by ligands 
[Goudet et al., 2004]. Site-directed mutagenesis and molecular modeling performed a detailed 
analysis of the antagonist binding sites of mGluRs and the binding pocket was found to be 
equivalent to that of retinal in bRho [Malherbe et al., 2003a; Malherbe et al., 2003b; Pagano 
et al., 2000]. 
It has been shown recently that the application of homology models with the aim of 
performing a virtual screening for new allosteric binders requires special knowledge of the 
functional activity of the ligand which was used during the construction of the homology 
model [Bissantz 2003; Bissantz et al., 2003]. Since the X-ray structure of bRho corresponds 
to the ground state in which retinal is covalently bound [Palczewski et al., 2000] and since 
GPCRs are known to adopt different conformational states [Gether & Kobilka, 1998] the 
inactive state of the receptor resembles the “antagonist-bound” instead of the “agonist-bound” 
state  [Bissantz et al., 2003]. 
 
Table 1.3.1-a. Definitions of prominent ligand types according to the International Union of 
Pure and Applied Chemistry (IUPAC) [Wermuth et al., 1998]. 
Type Action 
Agonist  Endogenous substance / drug that can interact with a receptor and 
initiate a physiological or a pharmacological response characteristic of 
that receptor. 
Antagonist  Chemical entity that opposes the receptor-associated responses 
normally induced by another bioactive agent. 
Inverse Agonist  Drug which acts at the same receptor as that of an agonist, yet 
produces an opposite effect. Also called negative antagonists. 
Partial Agonist  Agonist, which is unable to induce full activation of a receptor 
population, regardless of the amount of drug applied. 
 
 
1.4  Metabotropic Glutamate Receptors  
The mGluR family comprises eight subtypes and several splice variants, which have been 
cloned and named mGluR1-8 according to the succession of the molecular cloning [Pin et al., 
2003; Conn & Pin, 1997]. These eight receptors can be further subdivided into three groups 
based on sequence homology, pharmacology and transduction mechanism: Group I (mGluR1 Introduction  7  
und mGluR5), Group II (mGluR2 and mGluR3) and Group III (mGluR4, mGluR6, mGluR7 
and mGluR8).  
Glutamate neurotransmission is primarily mediated by postsynaptic ligand-gated cation 
channels termed ionotropic glutamate receptors, which regulate membrane potential by 
opening sodium and calcium channels but it can also be mediated by metabotropic glutamate 
receptors. Glutamate receptors mediate excitatory transmission on the cellular surface through 
initial binding of glutamate [Nakanishi & Masu, 1994; Hollmann & Heinemann, 1994]. 
mGluRs are involved in the generation of excitatory and inhibitory synaptic potentials and 
synaptic and neuronal plasticity [Nakanishi et al., 1998]. In addition to glutamate, mGluRs are 
activated by ibotenate and quisqualate.  
Group I receptors (mGluR1 and mGluR5) for instance, are localized postsynaptically in the 
somatodendric membrane and coupled to the activation of phospholipase C (PLC) [Nakamura 
et al., 1994] and, thus, are considered to be stimulatory. In contrast, group II and group III 
receptors are often localized presynaptically. They are negatively coupled to cAMP (Gi/Go-
coupled receptors) and inhibit forskolin-induced increases of cAMP in brain slices and 
neuronal cultures [Prezéau et al., 1994; Bruno et al., 1995].  
Group I metabotropic glutamate receptors are positively coupled to PLC. PLC in turn 
enables the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2)  to diacylglycerol 
(DAG) and inositol trisphosphate (IP3). IP3 has several intracellular effects, e.g., stimulation 
of Ca
2+ release from intracellular stores. DAG remains in the membrane activating 
membrane-bound protein kinase (PKC), which phosphorylates ionotropic glutamate receptors. 
In contrast to mGlu5 receptors, which can be found in the cortex, mGlu1 receptors are 
localized in Purkinje cells in the cerebellum targeted to perisynaptic regions [Mateos et al., 
2000].  
Group I mGluRs have been proven to play an important role in numerous 
neurodegenerative, cognitive and psychiatric disorders [Spooren et al., 2003] (Section 1.4.1). 
This thesis is focused on the identification of non-competitive antagonists of this group 
especially of mGluR1. 
 
1.4.1  Implications of Group I mGluRs in CNS Diseases 
mGlu1 and -5 receptor activation influences NMDA responses and consequently cell 
excitability [Fitzjohn et al., 1996; Awad et al., 2001]. NMDA receptors (activated via the 
neurotransmitter glutamate) are associated with ischemic brain damage, thus mGluRs are 
assumed to affect the treatment of neurodegenerative disorders like stroke, Alzheimer and 8 
Parkinson disease (AD/PD) and epilepsy. To evaluate the influence of mGluR1 to stroke, the 
mGluR1 antagonists BAY36-7620 and EMQMCM, an analogue of R214127 (Figure 1.4.2-a), 
were tested in animal mid cerebral artery occlusion (MCAO) models. Both displayed 
neuroprotection and the latter also reduced total infarct volume [De Vry et al., 2001; Lesage 
et al., 2002]. In this context, the mGluR5 antagonist MPEP showed neuroprotective effects in 
a NMDA-induced toxicity model [Bruno et al., 2000]. 
Likewise, the pathogenesis of AD and PD is connected with excitotoxicity. It has been 
reported that stimulation of mGluR1 causes significant increase in β–amyloid formation 
[Nitsch et al., 1998] and plays a pivotal role in regulating locomotor activity via dopaminergic 
neurotransmission [Rouse et al., 2000], which in turn is disordered in PD. Moreover, 
excitation in neurons of the sub thalamic nucleus, induced by the stimulation of mGluR1 and 
mGluR5 can be completely inhibited by MPEP [Awad et al., 2001]. 
Glutamate is involved in epileptogenesis [Meldrum & Chapman, 1999]. Orthosteric group I 
mGluR agonists like ACPD, DHPG and CHPG induce limbic seizures in rats and mice 
[Tizzano et al., 1993; Camon et al., 1998; Chapman et al., 2000] due to increased glutamate 
release whereas allosteric antagonists like LY367385 showed anticonvulsant activity 
[Chapman et al., 1999]. 
Hypofunction of the glutamatergic system was postulated to be involved in schizophrenia. 
Thus, receptors modulating the glutamate activity have, at least theoretically, antipsychotic 
potential. Prepulse inhibition (PPI) of acoustic startle response is an experimental model to 
assess symptoms connected to schizophrenia (e.g., sensorimotor gating deficits). mGlu1 
agonists like DHPG and ACPD are known to disrupt PPI whereas the mGlu1 antagonist 
MCPG reversed these effects [Grauer & Marquis, 1999]. MTEP, but not EMQMCM, 
enhanced disruption of PPI induced by the NMDA antagonist (+)MK-801, demonstrating that 
blockade of mGluR1 and mGluR5 evokes different effects on behavior induced by NMDA 
receptor antagonists [Pietraszek et al., 2005]. The mGlu5 receptor antagonist MPEP exhibited 
no effect on the acoustic startle response at anxiolytic doses or above [Spooren et al., 2000].  
mGlu1 receptor ligands modulate synaptic plasticity [Manahan-Vaughan et al., 1999] in 
terms of disruption of long-term potentiation. Antagonists like BAY36-7620 and LY367385 
have proven to disrupt learning and memory formation [Manahan-Vaughan & Schuetz, 2002] 
whereas agonists like ACPD enhanced memory formation in the passive avoidance test 
[Riedel et al., 1996]. In mice, selective mGlu1 receptor blockade with a R214127 analogue 
impaired spatial acquisition processes, irrespective of spatial load, as well as spatial 
reacquisition performed in water maze [Steckler et al., 2004]. Introduction  9  
Finally, mGlu1 receptor ligands have shown considerable impact on pain, which is 
reviewed by Lesage [Lesage, 2004]. Agonists like DHPG induced nociceptive behavior in rats 
[Fisher & Coderre, 1998]. In contrast, antagonists like BAY36-7620 reduced thermal 
hyperalgesia in a rat model of neuropathic pain [De Vry, 2002]. 
Summarized, ligands mediating the effects of group I mGlu receptors have considerable 
impact on the treatment of CNS disorders. Especially modulators binding to the allosteric site 
seem to be promising since they do not directly affect endogenous ligands binding to the 
orthosteric site. 
 
1.4.2  Allosteric Modulators of Group I Metabotropic Glutamate Receptors 
Within the past years, a substantial number of potent allosteric inhibitors and potentiators of 
mGluRs has been identified (Figure 1.4.2-a and 1.4.2-b). Their binding sites have been 
determined to reside exclusively within the HD, far away from the othosteric site in the ECDs 
of the receptor [Litschig et al., 1999; Carroll et al., 2001; Knoflach et al., 2001; Schaffhauser 
et al., 2003; Lavreysen et al., 2003]. In contrast to the orthosteric binding site of mGluRs 
which is well conserved during evolution, there was no selective pressure to maintain 
allosteric binding sites. Therefore, most allosteric modulators appear as structurally diverse 
ligands and several of them bear a high selectivity for a given receptor subtype. Via site-
directed mutagenesis, specific residues responsible for the subtype selectivities of several 
ligands have been identified which also enables a characterization of their binding site in the 
HD [Litschig et al., 1999; Knoflach et al., 2001; Schaffhauser et al., 2003]. 
Several structurally diverse and highly potent mGluR1 antagonists have been reported 
[Knoflach et al., 2001; Lavreysen et al., 2003]. Among those, CPCCOEt (Figure 1.4.2-a) was 
one of the first subtype selective non-competitive mGluR1 antagonists with low micro molar 
affinity (hmGluR1b) [Litschig et al., 1999; Hermans et al., 1998]. Further mGluR1 
antagonists such as R214127, EM-TBPC, LY456066, DCTT and YM-298198 have detected 
novel scaffolds and shown highest affinities down to the sub-nano molar level (Figure 1.4.2-a) 
[Mabire et al., 2005, Li et al., 2002; Malherbe et al., 2003a; Zheng et al., 2005; Kohara et al., 
2005]. Binding of EM-TBPC to mGluR1 was reported to involve Val-757 and Thr-815. The 
latter residue is also involved in CPCCOEt binding whereas conversion of Ala-818 did not 
affect EM-TBPC binding [Malherbe et al., 2003a; Litschig et al., 1999; Knoflach et al., 
2001]. Based on a homology model, Malherbe et al. suggested that the aromatic ring of EM-
TBPC interacts with the cluster of aromatic residues formed from Trp-798, Phe-801 and Tyr-
805, thereby blocking the movement of the TM6 helix, which is crucial for receptor activation 10 
[Malherbe et al., 2003a]. Interestingly, they found that radio labeled EM-TBPC showed high 
affinity for rat mGluR1 (rmGluR1) but only low affinity for human mGluR1 (hmGluR1) and 
none for mGluR5. Val-757 was identified as the critical residue for the binding selectivity of 
EM-TBPC at the rat versus human mGlu1 receptor since all other mGlu receptors bear 
leucine at this position. It is worthy of note that the absence of one additional methyl group 
(valine versus leucine) already leads to a considerable decrease in affinity of EM-TBPC for 
hmGluR1 and the observed selectivity of this ligand for rmGluR1. Since CPCCOEt and 
BAY36-7620 were shown to displace binding of radio-labeled R214127 to mGluR1a it was 
suggested that most of the mGluR1 antagonists share the same binding pocket involving TM 
5-7. 
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Figure 1.4.2-a. Chemical structures of known negative allosteric modulators of the mGlu1 
and mGlu5 receptor. 
 
The first compounds that selectively bind to the allosteric site of mGluR5 were SIB-1757 
and SIB-1893 [Varney et al., 1999]. However, both of which revealed only moderate potency. 
Briefly thereafter, a novel class of mGlu5 receptor antagonists emerged: The pyridine 
derivative MPEP was the first mGluR5 antagonist that was found to bind to mGluR5 with 
nano molar affinity [Gasparini et al., 1999] followed by the structural analogue MTEP, a 
thiazole derivative [Cosford et al., 2003a]. At the beginning, most of the allosteric mGluR5 12 
antagonists revealed an MPEP-like structure and only recently, new antagonists with different 
scaffolds (e.g., compounds Merck1 and Merck2) have been reported [Bonnefous et al., 2005; 
Eastman et al., 2004; Wang et al., 2004; Poon et al., 2004]. In the past, mainly MPEP was 
investigated for the characterization of mGluR5 and crucial determinants of the subtype 
selectivities of MPEP have been identified in TM3 and TM7 [Goudet et al., 2004; Pagano et 
al., 2000; Litschig et al., 1999]. In two recent studies, several additional residues in TM5 and 
TM6 of mGluR5 have been demonstrated to contribute to the binding of MPEP. It has been 
shown that MPEP and the mGluR1 antagonist CPCCOEt bind to overlapping binding pockets 
in the TM region of mGluR1 and mGluR5, respectively, but interact with different non-
conserved residues [Pagano et al., 2000]. Their models suggest that the pyridine ring of 
MPEP occupies the same space between TM7 and TM3 as the benzene ring of CPCCOEt. 
However, other parts of these antagonists do not overlap and imply interactions with different 
TM helices. Recently, a similarity between the critical residues in the TM6 region involved in 
MPEP-binding site with those of EM-TBPC was described pointing to a common mechanism 
of inhibition shared by both antagonists [Malherbe et al., 2003b].  
A considerable number of positive modulators of group I mGluRs exists based on different 
structural motives (Figure 1.4.2-b). It was suggested that these enhancers bind to and stabilize 
the activated receptor states [Malherbe et al., 2003a; Knoflach et al., 2001; Gasparini et al., 
2002]. Knoflach et al. have described a novel class of ligands Ro 67-7476, Ro 01-6128, and 
Ro 67-4853 acting as positive allosteric modulators of the mGlu1 receptor. A detailed 
mutational analysis revealed that in particular Val-757 in the TM5 of the receptor is 
responsible for the enhancing effect of both Ro 01-6128 and Ro 67-7476 [Knoflach et al., 
2001]. Interestingly, Ro 01-6128 and the structurally different Ro 67-7476 bear only high 
affinity for rat mGluR1 whereas Ro 67-4853, structurally similar to Ro 01-6128, exhibits 
activity at both h/rmGluR1 and rmGluR5 suggesting a different binding mode for this 
compound. Moreover, Ro 01-6128 closely resembles a recently found selective, non-
competitive agonist of the mGlu7 receptor [Mitsukawa et al., 2005]. Further critical amino 
acids are located in TM3 and TM5 of mGluR1, at homologous residues where MPEP interacts 
with the mGluR5 receptor, e.g., close to the inverse agonist binding site [Knoflach et al., 
2001; Pagano et al., 2000]. It has been shown that the position of valine (Val-757) is critical 
not only for the enhancing effect of positive allosteric modulation of rat mGlu1 [Knoflach et 
al., 2001] but also for negative modulation (MPEP, EM-TBPC) [Malherbe et al., 2003a; 
Malherbe et al., 2003b]. Therefore, even though Ro 67-7476, EM-TBPC, and MPEP belong 
to different chemical series, this result indicated that this amino acid occupies a strategic Introduction  13  
position to gate the effect of positive and negative allosteric modulation [Malherbe et al., 
2003b; Cosford et al., 2003a]. 
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Figure 1.4.2-b. Chemical structures of known positive and neutral allosteric modulators of 
the mGlu1 and mGlu5 receptor. 
 
Furthermore, allosteric inhibitors of mGluR1 or mGluR5 signaling, such as PHCCC, SIB-
1893 and MPEP, have shown to be weak allosteric potentiators of mGluR4 signaling [Maj et 
al., 2003; Marino et al., 2003; Mathiesen et al., 2003] and a series of benzaldazine analogues 
(Figure 1.4.1-b) has exhibited everything from allosteric potentiation to allosteric inhibition to 
neutral cooperativity on mGluR5 signaling [O´Brien et al., 2003]. Recently, allosteric 
potentiators of the mGlu5 receptor have been described [Kinney et al., 2005]. Most 
interesting examples include DFB [O´Brien et al., 2003] and CPPHA. Although both 
potentiators increase the affinity for glutamate, only DFB partially displaces allosteric 
antagonists such as the radio labeled MPEP-derivative [3H]-3-methoxy-5-(pyridin-2-
ylethynyl)pyridine [O´Brien et al., 2003; Cosford et al., 2003b]. Therefore, it was proposed 
that CPPHA binds to a different binding site within the HD. Since DFB shares a similar 
binding pocket with mGluR5 antagonists, a series of DFB analogues was designed where a 
transition from positive (DFB) via silent to negative modulation was achieved [O´Brien et al., 
2003]. The crucial substituent that determines the mechanism of action were found to be the 
3-fluoro-phenyl-groups of DFB. Substitution of both groups by a chloro-substituents (DCB) 14 
resulted in a “silent” or neutral agonist without functional activity whereas substitution with a 
dimethoxy-group (DMeOB) yielded the respective allosteric antagonist. All these ligands 
were found to compete with each other as well as with the radio labeled antagonist and 
MPEP-derivative [³H]methoxy-PEPy pointing to the same binding pocket [O´Brien et al., 
2003].  
 
The identification of novel ligands selectively interacting with a group I mGlu receptor 
subtype via the allosteric site was one goal of this thesis. In general two major strategies exist 
which are commonly pursued by pharmaceutical companies: High throughput screening 
(HTS) and virtual screening (Section 1.5).  
 
1.5 Virtual  Screening 
Pharmaceutical research in chemical industry aims at discovering novel ligands that 
potently and selectively affect a given target of interest. This initial investigation can be 
assumed as a first step on a long way from a hit to a drug (Section 1.1). Two major strategies 
addressing this phase emerged within the second half of the last century: HTS and virtual 
screening. HTS and its technical extension ultra-HTS provide a common way to detect a first 
hit via a “blind-screening” and they allow for scanning hundreds of thousands of compounds 
using an appropriate assay system with highly sensitive detection devices in order to limit the 
occurrence of false positives and false negatives [Bajorath, 2002]. Large amounts of 
compounds are tested quickly within a relatively short period of time. However, this screening 
technique is combined with several inherent disadvantages. Although handling with small 
volume fluids lots of wasted laboratory material result from HTS. Noteworthy are the low hit 
rates significantly ranging below 1% and the relatively high costs of establishing and 
maintaining HTS assays. The common single point determination of a compound, regularly 
employed to speed up the throughput is inherently associated with an increase of false 
positives and, even worse, false negatives. High throughput automatically leads to high 
volumes of data being recorded during the screening process. Methods to efficiently retrieve, 
manipulate and analyze biological and chemical data (“data mining”) to determine the best 
series to follow up have been reviewed elsewhere [Böcker et al., 2004].  
The HTS-approach based upon manifold pharmacological experiments can be rationalized 
by means of computational methods [Agrafiotis et al., 2002; Bajorath, 2002]. Several 
techniques exist attempting to virtually retrieve potential hits from the synthetically feasible Introduction  15  
chemical space and they are named virtual screening methods [Böhm & Schneider, 2000]. 
The idea of these “intelligent” approaches is to drastically reduce the amount of compounds 
prior to experiments, thus saving money, time and waste. This strategy is particularly pursued 
by small pharmaceutical companies in order to circumvent HTS campaigns, but also large 
companies trust on the advantages of virtual screening methods. Consequently, 
pharmaceutical companies rely on virtually screening commercial compound libraries, hence 
retrieving potential hits and assembling activity-enriched subsets to achieve higher hit rates 
than HTS approaches. It must be emphasized that virtual screening techniques require 
structural information about the receptor and/or its ligands. If no such knowledge is available 
HTS becomes essential. 
Some virtual screening techniques like pharmacophore (Section 1.5.1) and topological 
searches (Section 1.5.2) will be introduced here as well as other related methods of data 
reduction and data visualization (Section 1.5.3 and 1.5.4). Finally, methods that are not within 
the scope of this thesis will be presented (Section 1.5.5). Combined with subsequent screening 
assays of limited (i.e., medium to low) throughput virtual screening techniques avoid many of 
the issues (vide supra) connected with HTS.  
These techniques have in common that they describe approaches to prioritize molecules 
from (commercial) compound libraries, hence producing activity-enriched subsets of 
compounds that can then be tested for some desired properties [Xu & Agrafiotis, 2002]. Such 
databases may contain already synthesized compounds as well as synthetically accessible 
virtual molecules.  
Often hierarchical approaches are applied starting with filters, which step wise reduce the 
number of molecules to be tested. Starting from simple filters that remove molecules not 
obeying common criteria of drug-likeness, e.g., the “Rule of Five” [Lipinski et al., 1997] or 
molecules bearing reactive and/or toxic groups, the initial database becomes considerably 
reduced. Subsequent methods, e.g., based on several similarity searches (Section 1.5.2) 
[Willett et al., 1998] or 3D pharmacophore searches, for instance, (Section 1.5.1) further 
minimize the molecular subset of interest. Docking experiments which sample conformations 
of small molecules into a protein-binding site describe one of the last possible step. 
Automated docking is time consuming and requires detailed information about the structure 
of the protein. Thus, they are often disfavored as primary virtual screening tools [Bissantz et 
al., 2005, Evers et al., 2005]. Nevertheless, docking is frequently applied as far as sufficient 
computing capacity is available. 16 
Complexity and target specificity increase from filter to filter in this hierarchy whereas the 
number of molecules (not necessarily) drastically decreases. Eventually, the remaining few 
molecules can be characterized in pharmacological experiments. Apart from docking methods 
which are named structure-based approaches, methods like pharmacophore or similartity 
searches belong to the ligand-based approaches since they are solely based on information 
derived from ligands affecting a particular target. In general, the latter approaches are 
applicable to prescreen databases and in particular, e.g., for investigations lacking information 
about the architecture of the target.  
Success or failure of ligand-based approaches depends on the availability of (ideally but not 
necessarily) potent and selective ligands serving as a starting point whereas structure-based 
approaches rely on precise receptor information as well as the choice of a docking method 
combined with an appropriate scoring function [Warren et al., 2005]. Nevertheless, the 
suitability of docking experiments based on homology models has also been discussed 
[Bissantz et al., 2003b, Hillisch et al., 2004].  
Even though HTS and virtual screening (here: mainly ligand-based virtual screening 
methods like clustering or similarity searches) pursue different approaches in finding novel 
ligands it should be stressed that the drug discovery process benefit from combining both 
[Stahura & Bajorath, 2004]. 
 
1.5.1  The Pharmacophore Hypothesis 
Many investigations and applications of 3D-SAR analyses are based on pharmacophore 
hypotheses. The term “Pharmakophor” was introduced by Paul Ehrlich in 1909, nearly a 
century ago, to describe the molecular structure or pattern, which “carries” (phoros) the 
biological activity of a drug (pharmacon) [Ehrlich, 1909]. According to Lemont Kier 
“pharmacophore” is derived from “chromophore”, which denotes the associated conjugation 
length that impart a particular color to a chromophoric molecule [Kier, 1971]; likewise, 
combination of structural features impart a certain bioactivity to a molecule. The International 
Union of Pure and Applied Chemistry (IUPAC) recently stated that a pharmacophore is the 
ensemble of steric and electronic features that is necessary to ensure the optimal 
supramolecular interactions with a specific biological target structure and to trigger (or to 
block) its biological response [Wermuth et al., 1998]. 
Pharmacophore hypotheses are generally applied to propose certain properties (features) of 
structurally diverse ligands that are required to affect a macromolecular target when the three-
dimensional architecture of this binding site is not known. Often, they display common 3D-Introduction  17  
patterns based upon distances (often also planes) and angles between particular features of the 
ligands and the complementary points of these features in the binding site of the 
macromolecule. Instead of this classical geometric definition a spherical coordinate system 
has been proposed recently where geometric parameters are put together and each 
pharmacophore point is, thus, described alone in spherical reference coordinates [Guérin et 
al., 2006].  
Ligands can interact with amino acids of a given target via hydrogen-bonding  (H-bond 
donor/acceptor), hydrophobic (dispersive) interactions, aromatic π-π stacking, cation-π 
interactions or electrostatic properties (partial charges). As different atoms may have similar 
properties (e.g., O and S in carbonyl or thiocarbonyl groups) different atoms of potential 
ligands can affect a particular target in the same way. Consequently, structurally diverse 
molecules may bind to a receptor in the same manner as long as they provide a similar 
ensemble of features. An ideal pharmacophore model should specify not only information 
about these interactions; accurate descriptions of hydrogen-bond vectors pointing from the H-
bond donor or acceptor centers towards the virtual receptor (spherical caps) complete a 
pharmacophore hypothesis [Guérin et al., 2006]. 
A careful selection of appropriate ligands considered in a pharmacophore model and a 
reasonable alignment of these molecules form a crucial step in setting up a hypothesis. 
Potential difficulties for this approach might arise from scaffolds showing different binding 
modes. Even a single ligand may adopt different binding modes. Occasionally, molecules 
bind to the target in a way distinct to the pharmacophore hypothesis´ prediction. 
Molecules, virtually retrieved from databases, can be tested for their activity or affinity 
towards a given target. They, in turn, may give a hint about the reliability of a pharmacophore 
hypothesis, i.e., they allow for refining an existing model. However, a hypothesis remains as 
long a model as the crystal structure of the receptor is unknown. This representation of the 
receptor helps to confirm or disprove the correctness of the model. It has, however, been 
evidenced that side chains or even backbone movements can occur when different ligands 
bind to a given target structure (“induced fit”), which impairs automated rigid docking [Birch 
et al., 2002]. Detailed informations about the advantages of automated docking in fast 
screening and molecular dynamics (MD) simulations suitable to explore the binding of a few 
selected hit candidates can be found elsewhere [Alonso et al., 2006]. 
Pharmacophore hypotheses, based on the alignment of ligands, have been adressed to 
several aspects in drug discovery, namely to search queries for virtual screening of databases 
[Sheridan  et al., 1989; Kuntz, 1992], to target structures of de novo design [Tschinke & 18 
Cohen, 1993; Waszkowycz et al., 1994; Lloyd et al., 2004] and molecular-graphics-aided 
molecular design [Glen et al., 1995] and, eventually, to many 3D-QSAR analyses [Cha et al., 
2003; Zhu et al., 2005] (Section 1.5.5). 
 
1.5.2 Similarity  Searching 
Similarity searching denotes techniques to pair-wise compare a set of molecules. These 
methods enable scientists to virtually screen a database for compounds that resemble the 
query molecule. The underlying idea of this concept is the “similarity principle”, which was 
explicitly stated some years ago: Structurally similar molecules should exhibit similar 
physicochemical and biological properties [Johnson & Maggiora, 1990].  
Similar to molecular docking which comprises (i) suitable docking methods and (ii) scoring 
functions, similarity searches in general consist of (i) descriptors appropriately encoding the 
molecules and (ii) similarity functions. Substructure similarity can be defined based upon 
exact chemical fragments - e.g., MACCS keys [MDL Information System] – or pairs and 
triplets [Carhart et al., 1985; Good & Kuntz, 1995; Schneider et al., 1999;]. Since similarity 
searching is not restricted to a common core it allows for detecting molecules with a topology 
distinct from the structure of the compound the search is based on (“scaffold hopping”) 
[Schneider et al., 1999]. A general benefit of similarity searches in contrast, e.g., to 3D-
pharmacophore searches or automated docking is the high computation rate as it only 
compares descriptors. 
This approach has considerable influence on the drug discovery path medicinal chemists 
pursue. Once a substructure is known to be associated with certain desirable activities or 
affinities, other molecules bearing the same fragment can be detected and assayed for that 
profile [Barnard, 1993]. Manually searching for compounds with the same substructure was 
time-consuming and has become more and more ineffective due to the increasing number of 
experimentally determined hits. 
The characteristics of substructure searching have led to the development of similarity 
searching [Downs & Willett, 1995]. Similarity searching needs representations of the 
molecules that are effective (i.e., representations that can differentiate between different 
molecules) and efficient (quick to calculate) [Willett et al., 1998]. These representations or 
molecular descriptors in turn can be compared using suitable numerical measures or 
coefficients. Some coefficients are measures of the distance (e.g., Hamming distance, 
Euclidean distance), or dissimilarity between objects (0 value for identical objects), while Introduction  19  
others directly measure similarity (most commonly 1 for identical objects) [Willett et al., 
1998]. 
One of the most prominent similarity indices is the Jaccard coefficient also known as the 
Tanimoto coefficient [Jaccard, 1901], which compares binary descriptors of molecules and 
can be formulated as follows: 
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where χA is the number of bits set to 1 in the bit string vector coding for compound A, and χB 
is the number of bits set to 1 in the bit string vector coding for compound B. Tanimoto 
coefficient values range from 0 to 1. In general, a similarity score larger than 0.85 is assumed 
to reveal molecules with similar biological activity [Matter, 1997]. Recent findings showed 
that biological similarity is not so strong: At ≥ 0.85 Tanimoto similarity in Daylight 
fingerprints [Daylight], only 30% of compounds similar to an active were themselves active 
[Martin et al., 2002]. The enrichment factor ef provides a simple way to quantitatively express 
the ability of a method to retrieve an activity-enriched subset from a library [Xu & Agrafiotis, 
2002]: 
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where Dsub is a virtually retrieved subset of molecules from the complete library Dall. This 
subset contains a certain amount Asub of bioactive molecules, whereas Aall denotes the total 
amount of bioactive compounds within the library. An ef of 1 describes an activity-enriched 
subset with a random distribution of active compounds. Values above 1 correspond to 
successful searches. 
 
Since similarity searching relies on the comparison of descriptor vectors rather than on the 
computationally more demanding alignment of two molecules, it allows for rapidly retrieving 
a set of candidates from a large library [Willett et al., 1998]. Therefore, two pivotal aspects 
need to be considered when performing a similarity search [Schneider & So, 2003]: 20 
 
1.  The chosen molecular descriptors must appropriately cover the structural features 
that are connected to the corresponding SAR. 
2.  There must exist a strong correlation between varieties in molecular descriptions 
and varieties in biological function provided by the applied similarity measure. 
 
Molecular similarity is employed for many objectives in virtual screening: Design of 
diverse libraries, discovery of novel scaffolds and as support for establishing SAR [Glen & 
Adams, 2006]. Several techniques have been proposed and evaluated like fingerprint searches 
[Whittle  et al., 2004], two-dimensional atom environment searches [Bender et al., 2004] 
topological pharmacophore searches [Schneider & Nettekoven, 2003], feature tree searches 
[Rarey & Dixon, 1998], simple, yet effective substructure analyses [Gillet et al., 1998] and, 
recently, 2D property descriptor value range-derived fingerprints (PDR-FP) [Eckert & 
Bajorath, 2006], just to name a few. 
 
1.5.3  Feature Extraction Methods 
Molecular compounds can be described by a large number of attributes or features like 
topological indices, molecular field parameters, etc. leading to multidimensional data 
representations. Feature extraction describes approaches to transform such a set of raw data 
into a new coordinate system, generally from a high-dimensional into a low-dimensional 
(most commonly 2D and 3D) space by removing irrelevant features. Several linear and non-
linear data reduction techniques have been proposed that might help to describe the shape of 
the original data distribution. Some information-theoretic functions have been compared and 
combined with classifiers to assess the effectiveness of the selection methods [Liu, 2004]. The 
probably most prominent statistical feature extraction method with widespread applications is 
the principal component analysis (PCA) [Lugger et al., 1998; Otto, 1999], which conducts a 
linear data projection from a multi-dimensional data matrix to a low-dimensional space by 
means of a projection matrix resulting in a score matrix. The score matrix in turn comprises 
rows (e.g., molecules) and columns (principal components). Figure 1.5.3-a gives an example 
how such a data distribution is visualized. Axes in the new coordinate system denote “factors” 
or “latent variables”. 
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Figure 1.5.3-a. Linear mapping of a set of two-dimensional data by two principal 
components. Abscissa (χ1) and ordinate (χ2) span the coordinate system. The perpendicular 
score vectors s1 and s2 were calculated according to the maximal convergence criterion. 
 
Since multidimensional data of SAR often do not follow a linear distribution [Agrafiotis & 
Lobanov, 2000], the linear reduction can produce misleading relationships between individual 
data points [Devillers, 1995]. Therefore, also non-linear data projection methods, namely 
SOMs [Zupan & Gasteiger, 1999] and non-linear PCA based upon NIPALS algorithms or 
encoder networks [Livingstone, 1996] found their way to applications like machine learning, 
artificial intelligence and parallel processing. These methods are unsupervised procedures 
(Section 1.5.4) and can be employed as a first step of data analysis. Encoder networks or 
ReNDeR (reversible non-linear dimension reduction) networks [Livingstone, 1996] reduce 
the input patterns to an arbitrary number of neurons, forming the parameter layer (i.e., the 
coordinates or “factors” of the low-dimensional map), followed by transferring the 
information to the output layer. Thus, the input layer is reproduced at the output layer via a 
simple internal representation. The number of input neurons and accordingly of output 
neurons depends on the amount of data vectors to be used. Assumed that there exist no hidden 
layers and hence the neurons have a linear transfer function the number of factors (output 
vectors) is identical to the amount of principal components. Here, non-linear mapping is 
facilitated by non-linear activities of the neurons forming the hidden layers. 
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Figure 1.5.3-b. Architecture of a typical encoder network. Empty circles denote input 
neurons (“fan out units”) and output neurons, respectively. Lines represent weights. Filled 
circles are hidden layers with sigmoidal or linear activity. Grey circles display the parameter 
layer. 
 
An integrating tool for data projection and 3D visualization termed ChemSpaceShuttle has 
been reported [Givehchi et al., 2003]. It performs non-linear data reduction based upon 
encoder networks and the NIPALS algorithm and served within this thesis as a method to 
manually select potential virtual hits from a large subset (Section 4.4). 
 
1.5.4 Kohonen-Maps 
Artificial neural networks (ANN) are straightforward statistical methods to construct linear 
or nonlinear correlations of features (e.g., descriptors) that classify molecule patterns [Katz et 
al., 1992; Schneider & Wrede, 1998]. They exhibit a relationship between features and 
observed data [Zupan & Gasteiger, 1999]. 
ANN can be divided into supervised neural networks (SNN) and unsupervised neural 
networks (UNN). In contrast to unsupervised neural networks supervised neural networks 
require not only a set of molecules but also the knowledge of target values or class-
membership (active/inactive). Nonlinear modeling of QSAR, classification, pattern 
recognition, data compression, etc. are the main applications for SNN (e.g., multilayer feed 
forward networks, encoder networks) whereas UNN (e.g., Kohonen- or Hopfield-networks) 
can be used for clustering, visualization and methods similar to those employed for SNN 
without the prior knowledge of pharmacological molecular activities [Schneider & Wrede, 
1998]. 
SOMs or Kohonen-networks constitute a special type of unsupervised neural networks and 
have been employed for a variety of tasks in chemistry and chemical biology ever since 
[Zupan & Gasteiger, 1999], predominantly for clustering, topology preserving projections and Introduction  23  
feature extraction [Schneider & So, 2003]. Each neuron or “receptive field” denotes a cluster 
of molecules as a result of the nonlinear mapping procedure where the Kohonen algorithm is 
applied (Section 3.2.2) [Kohonen, 1982]. The molecules of a particular neuron have a similar 
distribution of features and they can be represented by the molecule, which is in closest 
vicinity to the centroid of the corresponding neuron. 
Kohonen has introduced the concept of self-organizing topological feature maps which can 
be arranged as a map, most often either in a one-dimensional array or a two-dimensional 
plane of neurons [Kohonen, 1982]. The toroidal wrapping of an array (to a circle) and a map 
(to a torus) circumvents potential boundary problems associated with a planar topology. 
Kohonen-maps are single layer networks and their neurons are located in a defined topology, 
meaning that each of them has a defined number of neighboring neurons. Maps are visualized 
by circles or by columns and rows forming squares (Figure 1.5.4-a). Each neuron has either 
four (squares) or six (hexagons) neighbors. 
 
 
Figure 1.5.4-a. Visualization of neurons in the Kohonen network according to Zupan and 
Gasteiger [Zupan & Gasteiger, 1999]. Neurons can either be drawn as small boxes of several 
layers forming columns and rows (A) or as circles (B). Black arrows coming from the left (A) 
or above (B) represent the arbitrary number of input, the other arrows denote the output 
vectors. 
 24 
1.5.5 Other  Classification  Methods 
Until now only those virtual screening techniques applied within this thesis were presented. 
There exists a bunch of other methods that allow, e.g., for classifying molecule entries of 
large compound libraries into potentially active and inactive members. Some of the most 
prominent tools with widespread application in the field of computational chemistry and 
biology will be introduced here. 
The naïve Bayesian method is a straightforward classification technique, which is mainly 
used for HTS data analysis to distinguish between “active” and “inactive” compounds. It is 
based on the Bayes rule for conditional probability and imparts the assumptions that 
descriptors in the reference set are equally important and independent from each other. 
Multiplying individual probabilities results in combined probability. This classifier can be 
used for virtual screening [Bender et al., 2005] or to predict molecule properties like ADME 
[Klon et al., 2006]. 
Support vector machines (SVM) belong to the supervised learning methods [Vapnik, 1998]. 
They provide a machine-learning algorithm that basically projects input vectors to a very 
high-dimensional feature space and constructs an optimal hyper plane, which best separates 
data points into two classes. The mapping is described by a kernel function, which performs 
either linear or non-linear classifications [Boser et al., 1992]. In a retrospective study SVM 
have proven to yield comparable or better results than supervised ANN if employed for 
drug/nondrug classification [Byvatov et al., 2003]. Prospective virtual screening for ligands 
affecting dopamine D2/3-receptors
  benefits from the advantages of SVM [Byvatov et al., 
2005]. 
Decision tree learning describes a tree-shaped graph of decisions comprising nodes (or 
leaves) and branches where nodes represent decisions and branches denote conjunctions of 
these features [Breiman et al., 1984]. Starting from a root node an object or situation has to 
undergo an arbitrary number of decisions of attributed tests resulting regularly in yes or no. 
Decision trees provide attractive classifiers due to their high execution rate. However, they 
cannot expand to unlimited complexity as they will loose accuracy. Random forest classifiers, 
in turn, grow multiple trees in random subspaces and avoid a loss of accuracy caused by 
overwhelming decision patterns [Ho, 1995]. Decision trees and random forests are commonly 
employed for classifying and prioritizing compounds for testing [Muegge et al., 2001; Svetnik 
et al., 2003]. 
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In a recent study a set of seven classification methods was employed to divide databases 
into active and inactive compounds for five different targets [Plewczynski et al., 2005]. The 
applicability of each method for each target was assessed by means of enrichment factor, 
precision and recall of all positives that have been retrieved. It turned out that random forests, 
artificial neural networks and support vector machines lead to high enrichments of actives, 
whereas random forests are successful in reducing the number of false positives (precision). 
 
1.6  Quantitative Structure Activity Relationship 
The concept of the quantitative structure activity relationship (QSAR) model is a classical 
example of ligand-based approaches where the physicochemical together with 
pharmacological and structural properties of ligands play an important role in terms of 
predicting bioactivity data. This field has been explored more than forty years ago [Hansch & 
Fujita, 1964]. QSAR methods try to exhibit correlations between structural informations of a 
set of molecules and their bioactivity data in order to give predictions for new molecules 
regarding these data. Compounds to be included in QSAR studies most often display related 
structures differing only in the type of substituents being attached to the common core. Free-
Wilson analysis denotes an early 2D-QSAR method [Free & Wilson, 1964]. It is a regression 
technique using the presence or absence of substituents or groups as the only molecule 
descriptors in correlations with biological activity [Kubinyi, 1993]. This crude method has 
some pitfalls: (i) In contrast to Hansch analysis and more recent methods it lacks the influence 
of electrostatic properties and (ii) the properties of new substituents – even if they resemble 
already existing substituents (e.g., methyl vs. ethyl) – can not be predicted by this method. 
Setting up a QSAR model is a multi-stage process. The first step is to select appropriate 
descriptors, i.e., descriptors, which best describes a set of molecules for a given task. The 
variety of descriptors is manifold. 1D descriptors (e.g., MW) are normally constitutive 
descriptors giving no hint about the chemical structure. 2D descriptors comprise structure key 
descriptors, e.g., the UNITY fingerprints [Tripos], Daylight fingerprints [Daylight] and other 
fragment fingerprints, which are, however, preferably used for similarity searching than for 
QSAR. They can be calculated from the connection table representation and, therefore, they 
are not dependent on the conformation of a molecule and are most suitable for large database 
studies. 3D descriptors are derived from the three-dimensional conformation of a molecule; 
they characterize molecules according to their molecular volume, several surface areas and 
molecular interaction fields [Van Aalten et al., 1996; Lin et al., 2000]. More recent 3D-QSAR 26 
descriptors used for CoMFA (alignment dependent) [Cramer et al., 1988] and CoMSIA 
studies [Klebe et al., 1994] account for encoded combinations of steric, electrostatic and 
hydrophobic properties (Section 3.2.4).  
The next step comprises feature selection, which describes the step where certain attributes 
are chosen that are assumed to be relevant to generate reasonable correlations between 
descriptors and biological data. The final step in constructing a QSAR model is to formulate a 
mathematical relationship and to determine the model parameters. Linear methods like 
multiple linear regression (MLR) and partial least squares (PLS) are commonly used methods 
[Fernandez et al., 2006; Sirois et al., 2005]. PLS, like PCA, uses latent variables for the 
molecule descriptors and the biological responses, from which a linear model is derived. 
Cross-validation is necessary to avoid overfitting of the data and to evaluate the quality of 
prediction. In contrast, self-organizing maps and encoder networks provide ways of non-linear 
correlation methods. Once a model is built it has to be validated, meaning the prediction 
accuracy has to be estimated. Leave-one-out (LOO), leave-group-out (LGO) and 
bootstrapping are the most common techniques [Topliss & Edwards, 1979; Diaconis & Efron, 
1983, Cramer et al., 1988b]. 
QSAR studies aim at investigating the binding modes of certain structural classes of 
molecules affecting a given target as this way was pursued within this thesis. They do not 
belong to the virtual screening techniques as neither databases will be searched nor will novel 
scaffolds be found. Predictions can be done only upon existing molecule patterns. In general, 
they are suitable for activity or affinity optimization projects for molecules representing the 
same scaffold. 
 
1.7  Scope of this Thesis 
One aim of this thesis was to identify new scaffolds for compounds that allosterically 
inhibit group I metabotropic glutamate receptors (mGluRs), in particular mGluR1. Computer 
assisted virtual screening can be applied either based on knowledge about the receptor’s 
architecture (structure-based) or a set of bioactive reference ligands (ligand-based) [Böhm & 
Schneider, 2000]. We planned to pursue the latter approach since the precise structure of the 
heptahelical domain of group I mGluRs is still unknown. The idea within the scope of this 
thesis was to employ various virtual screening methods for the given task and to evaluate their 
effectiveness. However, before initiating such ligand based searches, as much information as 
feasible about already existing agents has to be gathered and exploited to increase the Introduction  27  
probability of success, which was another goal of this thesis. In this context we planned to 
compile a reference data collection comprising mGluR1 and mGluR5 allosteric inhibitors. 
The chemical structures including bioactivity data of the reference compounds should be 
obtained from literature and patents. Based upon a small selection of highly potent and 
selective mGluR1 antagonists a pharmacophore hypothesis for mGluR1 should be established 
thereafter providing an initial insight into common features and structural requirements for 
receptor inactivation by these ligands.  
The computer-assisted methods to be used within this thesis include similarity searching 
with the CATS atom-pair descriptor, 3D pharmacophore query searches as well as molecule 
clustering and mapping onto a plane by self-organizing maps (SOM) or into a 3D space by 
non-linear principal component analysis. These approaches denote ways to detect structurally 
new ligands, which is termed “scaffold hopping” [Schneider et al., 1999]. Virtual hits should 
be ordered from commercial vendors and screened in-house for the desired affinity and 
activity at the receptor.  
To realize this pharmacological screening, binding assays addressing allosteric sites of 
mGluR1 and mGluR5 must be developed, which was also a goal of this thesis. Comparable 
binding assays for non-competitive modulators of group I mGluRs have not been reported to 
the best of our knowledge. Compounds ordered from vendors have to be tested on these 
assays afterwards. Since it was our strategy to avoid HTS, binding assays to be developed 
herein should facilitate limited throughputs. Compounds to be found by virtual screening 
campaigns providing novel core structures with significant potency should help to 
continuously refine the existing pharmacophore hypothesis and, thus, to propose binding 
orientations for potentially new compounds as well as for representatives of an earlier 
published chemical series of quinolines [Mabire et al., 2005]. Another aim was to obtain 
information about structural features important for the inhibitory potential of these quinolines, 
which should be realized by 3D QSAR studies.  
If any virtual screening campaign turned out to detect a set of molecules with inhibitory 
activity at mGluR1, promising representatives shall be chemically modified to optimize their 
pharmacological properties (that is increase of affinity and inhibitory activity at mGluR1). 
Furthermore, we also planned to established selectivity profiles for representative mGluR1 
and mGluR5 antagonists. A virtual screening concept should allow to predict cross activities 
for these types of ligands. 
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1.8 Initial  Hypotheses 
Initially, we hypothesized that binding assays for allosteric mGluR1 and mGluR5 
antagonists on a 96-well plate format could be established starting from an already running 
NMDAR binding assay on 24-well plates (Section 2.2, Section 2.3). 
Following, hypotheses for the identification of new scaffolds of negative allosteric mGluR1 
modulators were formulated. We postulated that a pharmacophore model based upon a 
selection of potent and selective non-competitive mGluR1 antagonists should be capable of 
retrieving an activity-enriched subset of a vendor compound library (Section 4.2). 
We further hypothesized that reference molecules employed for the pharmacophore model 
could also serve as reference compounds for similarity searching and that the CATS 
descriptor [Schneider et al., 1999] would best describe topological similarities (Section 4.3). 
The application of a tool performing non-linear principal component analyses 
(ChemSpaceShuttle) should narrow down a large set of compounds characterized by a 
multidimensional space so that a small subset of the initial database could be retrieved for 
further experimental testing (Section 4.4). 
According to our hypothesis the CATS descriptor should be applicable to adequately 
encode molecules for clustering by means of self-organizing maps (SOM). SOM should 
enable a discrimination between all available non-competitive mGluR1 and mGluR5 
antagonists. Moreover, the SOMs employed in this project should be capable of detecting 
hidden relationships between a large set of structural diverse reference (mGluR1) and test 
molecules (Section 4.5). 
Some hypotheses were proposed after first results of the scaffold identification were 
obtained. Since clustering of reference and test compounds according to the SOM algorithm 
led to promising results regarding molecule distribution and visualization (Section 4.5.1), we 
were tempted to speculate that this method should also facilitate the prediction of cross-
activities for reference compounds (Section 5.2). 
We also hypothesized that a meaningful CoMFA model could be derived from a recently 
published set of quinoline derivatives acting as non-competitive mGluR1 antagonists [Mabire 
et al., 2005] (Section 5.1). The conclusions drawn from this QSAR model in turn should 
improve our understanding about the orientation of quinolines in the mGluR1 binding site.  
A hit optimization project was launched for coumarines (Section 5.3). All side chains of this 
chemotype should systematically be modified. The idea was to generate a set of structural 
analogues large enough to derive comprehensive SAR data. We postulated that these data Introduction  29  
might simplify considerations about the hypothetical ligand orientation at the recognition site 
of mGluR1 (Section 5.4). 30 
2 Assay  Development 
We wished to identify ligands binding to group I mGluRs. To this means, it was necessary 
to characterize not only whether they bind to the allosteric binding site of the given receptor 
but also what functional consequences this binding evokes. The question arises: Does ligand 
interaction with the receptor cause an activation or blockade of the intracellular signal cascade 
(here: Ca
2+-mobilization from intracellular Ca
2+-stores). Binding assays address the first issue 
whereas functional assays address the latter one. Summarized, together they are indispensable 
tools to pharmacologically characterize new ligands. We wished to avoid HTS due to 
disadvantages like high costs and low hit rates (Section 1.5), and rather developed binding 
and functional assays characterized by high data content and moderate throughput. Combined 
with the virtual screening campaigns that will be introduced in later this strategy proved to be 
suitable for our hit-finding process. Once established, the assays allowed us to verify or 
falsify predictions which were based upon the results of virtual screenings (Chapter 4). More 
precisely, the presumed potency of “virtual hits” found by virtual screening campaigns had to 
be supported by data from real experiments. 
Functional and binding assays for targeting mGlu1 and –5 receptors were already developed 
in-house. However, the existing binding assays were relatively cumbersome to handle and 
were associated with a low throughput of test compounds. Consequently, the first step of the 
practical work was to establish new binding assays for both receptor subtypes. More detailed, 
one goal was to convert the read out formats of mGluR1 and mGluR5 binding assays based 
on a 12-well millipore system to a state of the art 96-well plate format, hence facilitating the 
performance of binding experiments with an increased number of compounds whilst saving 
materials and time. 
 
Note: For the sake of clarity most experiments that failed were not mentioned within this 
chapter. Only a few of them have explicitly been included in case they could give helpful 
hints for further assay development processes. Furthermore, it must be stressed that affinity 
values were given as IC50-values and not as Ki-values. The Kd-value of the radioligand, which 
is necessary to calculate the Ki-value from the IC50-value (Section 3.1.11), is specific for a 
particular binding assay / radioligand and was indeed determined by binding saturation 
experiments [McKinney, 1998] during the assay development process (Section 2.5). 
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to have only a modest effect on the difference between Ki and IC50. Furthermore, for SAR, 
relative differences are more important, and these are the same for both IC50 and Ki.  
Eventually, it should also be emphasized that all results calculated from the luminescence 
reader MicroBeta
®Trilux (e.g., IC50, percent of inhibition, etc.) were based on raw data given 
as counts per minute (CPM) and not as disintegrations per minute (DPM). We are well aware 
that DPMs denote the more precise values since they are bias corrected (i.e., they only 
consider flashlights caused by radioactive decays). However, the procedure for determining 
this ratio between flashlights triggered by decays or by any other influences (“quenching”) 
cannot be performed for the present assay conditions. 
 
2.1  Membrane Quality - Preliminary Tests 
Preliminary binding tests were necessary to evaluate several basic parameters like the 
choice of an appropriate membrane / protein concentration and suitable screening plates. They 
were performed with cortical rat membranes expressing NMDA-receptors using [³H]-(+)MK-
801 as a radioligand, since this assay is well characterized in house (using the millipore 
system), robust, exhibits low non-specific binding values and is easy to perform, e.g., long 
incubation times at room temperature.  
 
2.1.1  Characterization of NMDA receptors within the membrane 
In a pilot experiment only positive (“bound”) and negative (“non-specific”) controls were 
tested on various screening plates at different membrane concentrations. Positive control 
describes a status where the radiotracer can interact with the membrane without being 
displaced by any competitor. In contrast, the negative control denotes that status where the 
radioligand should be totally displaced from the binding site with a highly potent competitor. 
The competitor or “cold displacer” is generally the unlabeled compound or, where possible, a 
closely related, potent and specific analogue in roughly several thousand-fold higher 
concentrations. In general, a background negative control of less than 20% of the full signal is 
assumed to be adequate for screening purposes. 
The reaction volumes of positive and negative controls (containing a radioligand 
concentration of 5nM, a membrane-suspension of 0.2/0.4/0.6 mg/ml, glycine/glutamate at a 
concentration of 10µM to facilitate channel access of the radioligand and 10µM (+)MK-801 
as cold displacer) were either incubated on a regular 96-well plate (transparent plastic plate 32 
with flat-bottom wells) [Greiner Bio-One GmbH] and afterwards transferred for filtration to 
an opaque 96-well plate with glass fiber filters at the bottom of each well (“multiscreen 
plate”) [Millipore GmbH] or directly incubated on a “multiscreen plate”. Incubation was 
terminated after two hours by rapid vacuum filtration of the reaction volume through the 
filters using a vacuum manifold. The filters were rinsed four times with 150 µl ice-cold Tris-
buffer (50mM, pH 7.5). After washing scintillation cocktail Ultima-Gold
TM [Perkin Elmer 
Life Sciences] (40 µl / well) was added to the filter and the plates were incubated for another 
16 hours. Then radioactivity was measured in a MicroBeta
®Trilux [Perkin Elmer Life 
Sciences]. 
For the first plate (incubated on an opaque 96-well plate) a good signal-to-background ratio 
was only obtained at 0.60 mg/ml membrane concentration (11.4% non-specific). For the 
second plate (incubated on a multiscreen plate) there was no signal over background for any 
protein concentration, leading to the assumption that the reaction volume should preferably be 
incubated on a regular 96-well plate prior to transferring to a multiscreen plate. 
 
NH2 NH2
N NH
HCl HCl
HCl
Memantine Neramexane MK-801 PCP
Figure 2.1.1-a. Chemical structures of known NMDA receptor antagonists. 
 
In a subsequent experiment, the influence of varying protein concentrations on the IC50-
value was evaluated by means of conducting full concentration response curves (CRC) for 
(+)MK-801 (Figure 2.1.1-a) at two different membrane concentrations. Since membrane 
concentrations of 0.20 mg/ml or 0.40 mg/ml were previously found to be too low for 
sufficiently high signals, membrane concentrations of 0.60 mg/ml and 0.80 mg/ml were used 
(Figure 2.1.1-b). A good signal-to-background ratio (12-13% background) was obtained for 
both whereas the absolute counts were dependent on membrane concentration (1715 CPM for 
0.60 mg/ml vs. 1914 CPM for 0.80 mg/ml, data not shown). 
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Figure 2.1.1-b. Concentration response curves for (+)MK-801 displacing [³H]-(+)MK-801 at 
two different concentrations of membrane. The unlabeled ligand revealed a calculated IC50-
value of 9.9 nM (lower membrane concentration) and 18.0 nM (higher membrane 
concentration), respectively. 
 
The affinity values of (+)MK-801 obtained for this experiment correspond well with those 
given in literature (Kd-value of the radioligand 16.5nM) [Foster & Wong, 1987], which 
demonstrated that the binding assay was successfully performed giving reliable results. 
Moreover, the significantly increased CPM values for the higher membrane concentration 
(~12%) showed that no binding saturation was reached at least for the experiment with the 
lower membrane concentration since DPM values and also CPM values could linearly 
correlate with the radioactive emission of a sample. 
To confirm the robustness of the assay the experiment was repeated twice with a 
sufficiently high membrane concentration (0.80 mg protein per ml) by means of conducting 
CRCs for other NMDA antagonists namely Phencyclidine (PCP), Memantine and 
Neramexane (Figure 2.1.1-a, Figure 2.1.1-c). Other parameters like incubation time and 
temperature (2 hrs, room temperature), plate format and washing process remained 
unchanged. 
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Figure 2.1.1-c. Concentration response curves for Memantine (IC50-value: 2.82µM; SEM: 
0.33), Neramexane (3.68µM; 0.31) and PCP (0.229µM; 0.023) displacing [³H]-(+)MK-801 
from the NMDAR binding site. Results represent the mean values of two independent 
experiments performed in quadruplicate. 
 
Both experiments were successfully carried out and reliable results for all reference 
compounds were obtained when comparing the IC50-values to Ki-values published in literature 
(Memantine 0.69µM, Neramexane 0.68µM and PCP 0.04µM) [Bresink et al., 1995; Parsons 
et al., 2000]. Satisfying signal-to-background ratios were achieved for all ligands (9-12% 
background, data not shown). 
 
2.1.2 Conclusions 
The NMDAR binding assay is simple to perform and facilitated the transfer of general 
binding assay procedures to a new system. All parameters applied herein served as initial 
parameters for setting up binding experiments for mGluR1 and –5, respectively.  
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2.2  Development of a Binding Assay for mGluR1 
First, a binding assay with increased throughput to detect allosteric mGluR1 modulators 
was developed. 
 
2.2.1 Experiments 
The same conditions as for the NMDAR binding assay were applied for an initial mGluR1 
binding assay (membrane conc. 0.80 mg/ml, incubation time 2hrs at room temperature). 
Radio labeled (+)MK-801 was replaced with [³H]-EMQMCM, which is a high-affinity ligand 
at the allosteric site of the mGlu1 receptor [Mabire et al., 2005] and a structural analog to the 
quinoline R214127 [Lavreysen et al., 2003]. The concentration of radioligand was changed 
from 5nM to 1nM because of its potent binding affinity. R193845 (30µM), which is also an 
analog of R214127 served as cold displacer (Figure 2.2-a). To evaluate the validity of the 
assay the affinities of three already known non-competitive mGluR1 antagonists that served 
as reference compounds, R193845, NPS 2390 and the propenone AMMPP [Mabire et al., 
2005; Van Wagenen et al., 2000; Parsons et al., 2006], were determined by full CRCs (Figure 
2.2.1-a, Figure 2.2.1-b). EMQMCM served also as a reference compound in several mGluR1 
experiments and was frequently used within this thesis. 
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Figure 2.2.1-a. Chemical structures of known non-competitive mGluR1 antagonists that were 
used during assay development. 36 
A surprisingly high signal-to-background ratio was achieved with a mean background of 
5% (data not shown). In this context, relatively high absolute values of above 2500 CPM were 
obtained giving a hint that either the protein concentration or the incubation time could be 
reduced. However, the obtained IC50-value of NPS 2390 was more than 100-fold weaker than 
reported in literature (Kd-value 1.4nM) [Lavreysen et al., 2003]. Here, an IC50-value of 
259nM for NPS 2390 [Van Wagenen et al., 2000] and 120nM for R193845 was obtained 
(Figure 2.2.1-b). The considerable deviation between experimentally obtained affinity for 
NPS 2390 and the affinity given in literature was probably caused by slight precipitation, 
which was observed while diluting the stock solution (compound dissolved in pure DMSO) 
with an excess of buffer. As demonstrated by the error bars, the raw data of AMMPP (IC50-
value: 497nM) also showed strong variation. This was probably also due to poor solubility. 
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Figure 2.2.1-b. Concentration response curves for R193845 (IC50-value: 0120µM; SEM: 
0.017), NPS 2390 (0.259µM; 0.038) and AMMPP (0.497µM; 0.116) displacing [³H]-
EMQMCM from the rmGluR1 binding site. Experiment was performed in quadruplicate. 
Error bars denote SEM. 
 
The less than optimal concentration response curves indicate that the assay was not yet 
suitable for screening. For the next experiment the settings were slightly changed in terms of Assay Development  37  
the incubation time, which was shortened to one hour. To avoid solubility problems connected 
with the compounds tested before, concentration response curves were conducted for two 
other allosteric mGlu1 receptor modulators namely LY456066 [Li et al., 2002] and the 
propenone AQP [Parsons et al., 2006] (Figure 2.2.1-c). However, AQP turned out to be 
poorly soluble when the stock solution was diluted with buffer to the desired concentrations. 
This is confirmed by the corresponding CRC where data points deviate considerably from the 
fitted curve. Moreover, LY456066 elicited more than ten-fold weaker binding compared with 
literature values (IC50-value 142nM vs. Kd-value 9.3nM). 
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Figure 2.2.1-c. Concentration response curves for LY456066 (IC50-value: 0.142µM; SEM: 
0.041) and AQP (0.159µM; 0.036) displacing [³H]-EMQMCM from the rmGluR1 binding 
site. Experiment was performed in quadruplicate. Error bars denote SEM. 
 
At this stage, the binding assay was still not optimized since it lacked reliable results for 
well-known mGluR1 antagonists, i.e., results that were consistent with those reported in 
literature. As the poor solubility of some test compounds seems to be a major pitfall of the 
incorrect affinity values it was decided to add DMSO as solvent with a final concentration of 
5%. The procedure is detailed in Section 2.4.  
In this context another binding experiment was performed (Figure 2.2.1-d) determining the 
potency of EMQMCM, a potent allosteric mGluR1 antagonist [Mabire et al., 2005]. The 38 
previous assay parameters remained unchanged except for the addition of 5% DMSO (final 
concentration) to increase the solubility of the compounds to be tested. The experiment was 
repeated twice and the resulting affinity values were consistent with activity data published by 
Mabire et al. (binding 3.4nM vs. functional 3nM). This clearly demonstrates that reliable 
results can be produced allowing for screening test compounds thereafter. 
The final assay procedure is given in the experimental part (Section 3.1.3). 
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Figure 2.2.1-d. Concentration response curves for EMQMCM (IC50-value: 3.4nM; SEM: 0.6) 
displacing [³H]-EMQMCM from the rmGluR1-binding site. Results are mean values of three 
independent experiment conducted in quadruplicate. Error bars indicate SEM. 
 
Finally, to validate the robustness of the present binding assay for future screening an 
experiment was performed to define the Z´-factor [Zhang et al., 1999]. This simple statistical 
parameter can be calculated using only control data without the need for test compounds. It is 
normally employed to assess the overall assay quality of an HTS assay taking the data 
variation of the assay signal into account (i.e., the Z´-factor gives a hint whether a compound 
should preferably tested in singlet or duplicate, etc.). The following equation is applied: 
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where σc+ is the SD of the positive control, σc- the SD of the negative control and µc+ and µc- 
denote the mean values of positive and negative control, respectively. A Z´-value above 0.5 is 
assumed to give reliable results and a value of 1 would indicate an ideal assay. 
 
Positive (bound) and negative (non-specific) control values were measured on a 96-well 
plate according to the regular assay protocol (Section 3.1.3). Odd column numbers (1, 3, etc.) 
were used for positive control samples and even column numbers for negative control 
samples. The result was a Z´-factor of 0.61 for the total plate which is in accordance with a 
required value of ≥ 0.50. It was decided to keep the previously defined settings (each 
concentration or control assayed in quadruplicate). 
 
2.2.2 Conclusions 
Several experiments were carried out one after the other and the results of the previous 
experiment were taken into account in order to improve the performance of the next test. This 
allowed iterative improvements in the assay procedure to satisfy all criteria necessary for a 
mGluR1 binding assay with limited throughput. It has been demonstrated that the preliminary 
NMDA binding assay experiments (Section 2.1) served as a useful basis for the development 
of mGluR binding assays. However, the assay procedure had to be modified to fulfill mGluR1 
specific assay requirements. Finally, the optimized experimental procedure was successfully 
tested in terms of robustness of the system by means of determining the Z´-factor. 
 
2.3  Development of a Binding Assay for mGluR5 
A binding assay for mGluR1 was successfully established based upon the NMDAR binding 
assay. Likewise, a binding assay for allosteric mGluR5 antagonists was developed, which is 
described in the following section. 
 
2.3.1 Experiments 
The assay parameters for an initial mGluR5 binding assay were taken directly from the 
preliminary experiments of section 2.1. The first test was carried out on a regular 96-well 40 
plate at room temperature and [³H]-MPEP (5nM) served as the radioligand for rat cortical 
membrane (0.80 mg/ml). The test ligand MTEP (Figure 2.3.1-a) was applied in various 
concentrations to give a full concentration response curve. Membrane suspension and test 
ligand as well as positive and negative controls were prepared on the 96-well plate and the 
reaction was initialized by the addition of radioligand. After two hours the regular process 
was continued (transfer to multiscreen plate, wash steps, scintillation-cocktail addition and 
second incubation). Since no discrimination between positive (bound) and negative (non-
specific) values could be made for this experiment (data not shown) it clearly failed. These 
results demonstrated that the experimental procedure of the NMDA binding assay could not 
directly be used for the mGluR5 binding assay. 
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Figure 2.3.1-a. Chemical structures of known non-competitive mGluR5 antagonists that were 
used during the assay development. 
 
Consequently, the experiment was repeated while slightly changing the settings. First, the 
reaction was started by addition of membrane and not by addition of the radiotracer, second, 
the incubation time was reduced to one hour and performed under cooled conditions (1°C, 
ice), as temperature was presumed to influence the reaction, and finally the rinse process was 
extended to four steps of ice cold buffer (150µl). CRCs were conducted for the potent 
allosteric mGlu5 receptor antagonists MPEP and MTEP (Figure 2.3.1-a, Figure 2.3.1-b). 
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Figure 2.3.1-b. Concentration response curves for the antagonists MPEP (IC50: 0.0074µM) 
and MTEP (0.0156µM) displacing [³H]-MPEP from the allosteric binding site of the mGlu5 
receptor. 
 
The experiment revealed somewhat too potent IC50-values for both compounds [Anderson 
et al., 2002] and the background in relation to the total signal was too high (40% and 47%, 
respectively). Therefore, the opaque 96-well plate was replaced by a transparent 96-well plate 
and the experiment was repeated for MPEP, MTEP and additionally M-MPEP (Figure 2.3.1-
a, Figure 2.3.1-c). 
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Figure 2.3.1-c. Concentration response curves for the antagonists MPEP (IC50: 0.0138µM), 
MTEP (0.0252µM) and M-MPEP (0.0072µM) displacing [³H]-MPEP from the allosteric 
binding site of mGluR5. 
 
The background signal was further reduced (MPEP / MTEP / M-MPEP: 30 / 45 / 31%) and 
the  IC50-values calculated from the concentration response curves displayed much better 
accordance with the values given in the literature (MPEP: 15nM; MTEP: 30nM; M-MPEP: 
3.6nM) [Anderson et al., 2002; Gasparini et al., 2001]. 
Apart from the background signal, which is still somewhat too high, the mGluR5 binding 
assay with labeled MPEP as the radiotracer produced reliable results. For screening the 
cooling conditions were further optimized (blue ice was replaced with dry ice maintaining a 
mean temperature of 1-2°C in each well). Eventually, background values of roughly 15% 
from total signal were obtained when test compounds were screened (data not shown). 
 
2.3.2 Conclusions 
Like in Section 2.2 the NMDAR binding assay procedure served as a starting point for 
setting up the present assay in order to speed up the optimization process. “Trouble-shooting” 
was done by iterative changing of assay parameters. The fact that incubation of compounds Assay Development  43  
with membrane had to be conducted under cooled conditions considerably hampered the 
developmental process. This was attributed to an assumed rapid dissociation of bound ligand 
from the receptor (see also Section 2.6). Apart from the cooled conditions both, mGluR1 and 
mGluR5 binding assays were performed in the same way. 
The final assay procedure is given in the experimental part (Section 3.1.4). 
 
2.4  The Influence of DMSO 
The molecules that were retrieved from commercial compound libraries by virtual 
screening methods are assumed to bind to the allosteric site of group I mGluRs in particular of 
mGluR1. Since the allosteric binding site is embedded in the hydrophobic transmembrane 
region (Section 1.3.1) ligands interacting with the binding pocket elicit predominantly poor 
aqueous solubility.  
Hence, this led to a pitfall, which became especially apparent within the hit optimization 
procedure: higher affinity often correlated with higher lipophilicity. The binding assays 
initially used were solely conducted in aqueous solutions meaning that all constituents were 
dissolved in pure Tris-buffer. As some reference compounds (EMQMCM, NPS 2390 and 
AMMPP) used for CRCs during the assay development process were poorly soluble in buffer, 
their testing was hampered by precipitation problems especially at high concentrations 
(Section 2.2.1). Likewise, when test compounds were screened substance precipitations 
occurred for many molecules, in particular during the preparation of dilution series for CRCs. 
Consequently, a considerable percentage of all test structures was not suited for testing under 
the conditions used. It turned out that nearly all solids showed acceptable solubility in the 
organic solvent dimethyl sulfoxide (DMSO). The relatively polar solvent DMSO, in turn, can 
be diluted with buffer in any ratio. Tris-buffer containing up to 5% DMSO was capable of 
solving nearly all test compounds even at relatively high concentrations. 
 
2.4.1 Experiments 
First, the influence of two DMSO concentrations was investigated for the mGluR1 binding 
assay. Figure 2.4.1-a clearly demonstrates the significant signal reduction caused by DMSO: 
While 1% DMSO displayed little influence on control values 5% DMSO led to approx. 20% 
signal reduction. Higher DMSO concentrations were not tested. The ratio between positive 
and negative control remained unchanged for both DMSO concentrations (<10%). 44 
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Figure 2.4.1-a. Bar chart representing the influence of DMSO as solvent in the mGluR1 
binding assay on positive (bound) and negative (non-specific) control values. 
 
To further evaluate the influence of DMSO on ligand affinity concentration response curves 
were performed for some standards. A selection is given in Figure 2.4.1-b demonstrating that 
there is little (if any) influence of DMSO on the affinity towards the allosteric binding site. 
The  IC50-value for EMQMCM, which is well soluble in both DMSO and water, was 
11nM/12nM (with 1% and 5% DMSO, respectively) and 6nM without DMSO; the affinity of 
R193845, an analogue of EMQMCM, did not change at all (233nM/235nM vs. 218nM 
without DMSO). Only the affinity of NPS 2390 was significantly reduced from 210nM to 
311nM at 5% DMSO (271nM without DMSO, data not shown). However, as the IC50-value 
calculated in aqueous solution lay between the values determined in the presence of DMSO 
one could assume that the values calculated in this experiment showed a typical error of 
measurement. Assay Development  45  
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Figure 2.4.1-b. 3-concentration CRCs for three allosteric mGluR1 antagonists at two 
different DMSO concentrations performed in quadruplicate. Calculated IC50-values in the 
presence of 1% and 5% DMSO: EMQMCM 11nM (SEM: 0.6nM) vs. 12nM (0.3nM), 
R193845 233nM (24.3nM) vs. 235nM (7.7nM), NPS 2390 211nM (9.1nM) vs. 311nM 
(6.4nM). 
 
2.4.2 Conclusions 
Summarized, DMSO up to 5% final concentration had no influence on the interaction of 
ligands binding to the allosteric site of mGluRs. In contrast to living cells, which are sensitive 
even to low DMSO concentrations (< 0.5%) membranes are relatively insensitive to DMSO at 
the concentrations applied. 
 
2.5 Scatchard  Analysis 
Binding saturation experiments (Scatchard analyses) describe a method to directly 
determine the true potency of a radioligand for its binding site under the conditions used 
[McKinney, 1998]. Here, a radio labeled ligand is tested in various concentrations but at a 
fixed protein level. Only positive (total binding) and negative controls (non-specific binding) 
are measured. Based upon the results of Scatchard analyses the Kd-value of a given 46 
radioligand can be determined. This value in turn is indispensable to calculate Ki-values for 
test compounds according to the Cheng-Prussoff Equation (Section 3.1.11). It must be 
emphasized that Kd-values resulting from such saturation experiments are specific for a 
particular assay. Consequently, changing any fundamental parameters which probably 
influence the binding behavior of ligands towards receptors (e.g., protein concentration and 
temperature) necessarily means that the Kd-value becomes invalid and has to be 
experimentally determined again.  
Saturation experiments were performed for both types of tissue: the cerebellar and cortical 
rat membranes containing mGluR1 and mGluR5, respectively. Thus, the procedure of 
Scatchard analyses followed the assay protocols of the corresponding binding assays of 
mGluR1 and mGluR5 for later compound screening (Section 3.1.3 and 3.1.4). 
 
2.5.1  Saturation Experiments on Cerebellar Membranes 
For saturation experiment at the allosteric binding site of mGluR1 the binding behavior of 
the potent and highly selective non-competitive antagonist [³H]-EMQMCM was investigated. 
Experiments were carried out according to the established binding assay protocol (Table 
2.5.2-a). The practical work was performed by Sabine Denk, a technical assistant at Merz. 
 
Table 2.5.1-a. Assay protocol giving the parameters for mGluR1 binding saturation 
experiments. 
Parameter Setting 
Radiotracer  [³H]-EMQMCM (0.36nM – 100nM) 
Cold displacer  EMQMCM (10µM) 
Protein  Rat cerebellum (0.80 mg/ml) 
Total volume  250µl/well 
Detection volume  150µl/well 
1
st Incubation  60 min. (room temperature, shaker) 
2
nd Incubation  16 hours (room temperature, dark) 
Buffer  Tris-HCl 50mM, pH 7.5 
Detecting device  Microbeta TriLux® 
 
Positive and negative controls were tested at twelve different concentrations of radioligand 
starting with 0.36nM up to a three hundred-fold higher concentration (Figure 2.5.1-a). Assay Development  47  
Specific binding was calculated by subtracting negative control from positive control at each 
concentration. 
The signal-to-background ratio was exceptionally good over a wide range of radiotracer 
concentrations with the best ratio at 15nM [³H]-EMQMCM. However, with increasing 
radioligand concentrations the ratio steadily degrades since the background values (non-
specific) linearly increase whereas the total signal asymptotically approaches a certain 
threshold (i.e., the binding saturation). 
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Figure 2.5.1-a. Saturation curve of [³H]-EMQMCM binding in rat cortical membranes. 
Results represent mean values of three independent experiments performed in quadruplicate. 
Error bars indicate SEM. 
 
Analysis of [³H]-EMQMCM binding to rat cortical membranes revealed a single binding 
site that was of high affinity and saturable (Figure 2.5.1-b). The Kd-value of [³H]-EMQMCM 
is equal to the slope of the regression line. Bmax in turn is the intercept of this line of best fit 
with the abscissa. However, to determine the receptor capacity (Bmax) of cerebellar 
membranes it was first necessary to calculate which amount of ligand is specifically bound to 
the membranes (i.e., ideally the receptors) per given protein concentration (abscissa in Figure 48 
2.5.1-b) resulting in a certain signal. Therefore, the total signal of various amounts of 
radioligand has been measured (data not shown) to determine this amount. 
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Figure 2.5.1-b. Scatchard plot of [³H]-EMQMCM binding in rat cerebellar membranes. The 
binding site has a capacity of 0.59 pmol/mg protein with high affinity of the ligand (Kd-value: 
13.1nM). Results represent mean values (and SEM) of three independent experiments 
performed in quadruplicate. 
 
The assay specific Kd-values determined in this section for [³H]-EMQMCM and in the 
following section for [³H]-MPEP were implemented in Equation 3.1.11-e [Cheng & Prussoff, 
1973] to calculate Ki-values for further compound screening. 
 
2.5.2 Saturation  Experiments on Cortical Membranes 
For saturation experiments at the allosteric binding site of mGluR5 the binding of [³H]-
MPEP was investigated. Experiments were carried out according to the established binding 
assay protocol (Table 2.5.2-a). 
 
Table 2.5.2-a. Assay protocol giving the parameters for mGluR5 binding saturation 
experiments. 
Parameter Setting 
Radiotracer  [³H]-MPEP (0.4nM – 40nM) 
Cold displacer  MPEP (10µM) 
Protein  Rat cortex (0.80 mg/ml) Assay Development  49  
Total volume  250µl/well 
Detection volume  150µl/well 
1
st Incubation  70 min. (cooled conditions, shaker) 
2
nd Incubation  16 hours (room temperature, dark) 
Buffer  Tris-HCl 50mM, pH 7.5 
Detecting device  Microbeta TriLux® 
 
Positive and negative controls were tested at twelve different concentrations of radioligand 
starting with 0.4nM up to a hundred-fold higher concentration (Figure 2.5.2-a). Likewise, 
specific binding was calculated by subtracting negative control from positive control at each 
concentration. Here, the saturation curve displays a poor signal-to-background ratio exhibiting 
~30% of background only at radiotracer concentrations of up to 2nM. At higher 
concentrations the background increases dramatically. 
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Figure 2.5.2-a. Saturation curve of [³H]-MPEP binding in rat cortical membranes. Results 
represent mean values of three independent experiments performed in quadruplicate. Error 
bars indicate SEM. 
 
Likewise [³H]-EMQMCM binding (Figure 2.5.1-b), analysis of [³H]-MPEP binding in 
cortical rat brain membranes revealed a single binding site that was saturable and of high 50 
affinity (Figure 2.5.2-b). The Kd-value of [³H]-EMQMCM is equal to the slope of the 
regression line. Bmax in turn is the intercept of this line of best fit with the abscissa. To 
determine the receptor capacity (Bmax) of cerebellar membranes it was first necessary to 
calculate which amount of ligand is specifically bound to the membranes (i.e., ideally the 
receptors) per given protein concentration (abscissa in Figure 2.5.2-b) resulting in a certain 
signal. Therefore, the total signal of various amounts of radioligand has been measured (data 
not shown) to determine this amount. 
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Figure 2.5.2-b. Scatchard plot of [³H]-MPEP binding in rat cortical membranes. The binding 
site has a capacity of 0.82 pmol/mg protein with high affinity of the ligand (Kd-value: 
12.9nM). Results represent mean values (and SEM) of three independent experiments 
performed in quadruplicate. 
 
2.5.3 Conclusions 
Both radioligands, [³H]-EMQMCM and [³H]-MPEP, showed properties that exhibit similar 
binding behaviors at their corresponding binding pockets. They bind with high affinity to their 
saturable binding sites (mGluR1 vs. mGluR5; Kd: 13.1nM vs. 12.9nM), which have similar 
binding capacities (Bmax: 0.59 vs. 0.82 pmol/mg protein). Regarding the scatchard plots, there 
seems to be only one site in the HD of each receptor to which the radioligand binds. Assay Development  51  
The ratio between total binding and specific binding significantly differs between the 
mGluR1 and mGluR5 scatchard experiments (Figures 2.5.1-a and 2.5.2-a). Regarding 
mGluR1 we observed a relatively good ratio for all [³H]-EMQMCM concentrations (Figure 
2.5.1-a) ranging between 49% and close to 100% for specific binding. Contrary to these 
results, the ratio between total and specific bound ligand for [³H]-MPEP concentrations was 
worse where specific bound ligand ranged between 25% and 70% of total binding (i.e., 30% – 
75% background). The reason for poor specific binding of the radioligand to the allosteric 
mGluR5 receptor site is probably the fast dissociation rate of MPEP-like ligands from the 
mGluR5 binding pocket, which occurs even at low temperature and is shown in the following 
chapter.  
 
2.6 Kinetic  Experiments 
The kinetics of ligand (agonistic or antagonistic) actions observed in vitro can yield 
valuable information about ligand-receptor interactions [Kenakin, 1987]. Kinetic experiments 
allow for determining the actual association and dissociation constant for a given ligand. 
In contrast to the mGluR1 binding assay, the mGluR5 binding experiments revealed 
considerably higher background levels (~5% vs. >15% background from total bound). Several 
assay settings were changed until it became apparent that the assay had to be performed under 
optimized cooled conditions in order to minimize background bias to an acceptable level 
(Section 2.3). Hence, the conclusion drawn was that the unfavorable signal-to-background 
ratio was caused by the temperature (i.e., the fast dissociation kinetics from specific sites). 
Within this section the binding kinetic for [³H]-M-MPEP, an analogue of [³H]-MPEP, was 
investigated. It was hypothesized that association and dissociation kinetics of the radioligand 
were fast, even at a cold temperature close to the freezing point of water. Especially a rapid 
offset kinetic where the bound radioligand becomes rapidly displaced by another potent cold 
ligand could lead to the assumption that the radiotracer binds relatively weak to the binding 
site though it shows high equilibrium affinity towards the receptor. This in turn may give a 
hint that even the duration of the rinse step could have a large impact on the signal-to-
background ratio since even the buffer could probably wash out the bound radioligand to a 
certain degree. 
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2.6.1  On-set and Off-set Studies on Cortical Membranes 
Association and dissociation kinetic experiments were carried out according to the 
corresponding protocols given in the experimental part (Section 3.1.9 and 3.1.10). Two 
different concentrations of radiotracer were used in order to determine which amount of radio 
labeled ligand leads to sufficiently high signals.  
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Figure 2.6.1-a. Association time course curve for [³H]-M-MPEP binding to rat cortical 
membranes. Association kinetcs were measured at different incubation times and at room 
temperature. The experiment was performed in quadruplicate. Error bars represent SEM. 
 
Although the total binding values corresponding to the higher radioligand concentration 
(1nM) are roughly twice as high as those of the lower concentration, they cover an absolute 
range which is only slightly increased in relation to the values of 0.5nM [³H]-M-MPEP (~300 
CPM  vs. ~200 CPM). Samples with higher radioligand concentration would considerably 
deviate from a fitted curve. For 1nM ligand concentration, around 70% of the maximal 
binding was achieved within one minute. This fast onset kinetic indicates a potent ligand. Assay Development  53  
In fact, the time course curve clearly demonstrates that association of [³H]-M-MPEP to 
membranes was extremely fast since maximal binding was reached within ten minutes of 
incubation, irrespective of the radioligand concentration. 
 
Also dissociation of [³H]-M-MPEP showed fast kinetics at room temperature (Figure 2.6.1-
b). The reaction seems to be finished after one minute of interaction between the proteins and 
the cold displacer, i.e., the radioligand that was bound to the membrane was displaced by an 
excessively high amount of unlabeled ligand within a few seconds.  
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Figure 2.6.1-b. Dissociation time course curve for [³H]-M-MPEP binding to rat cerebellar 
membranes. Dissociation kinetics were measured after different incubation times of cold 
displacer (M-MPEP, 10µM) and at room temperature. Experiment was performed in 
quadruplicate. Error bars represent SEM. 
 
It must be stressed that the dissociation experiment was also carried out at room 
temperature. The kinetics will be slower under cooled conditions. There were two reasons for 
performing kinetic experiments at room temperature: (i) To directly compare on-set and off-
set experiments both have to be performed under the same conditions and (ii) conduction at 54 
cooled temperatures would have led to extensive technical problems for which we could find 
no solution with our laboratory conditions – one would need a cool room. 
 
2.6.2 Conclusions 
The observation that the mGluR5 radiotracer [³H]-M-MPEP follows a fast association and 
dissociation kinetic at room temperature has considerable impact on cold displacement in 
mGluR5 binding assays: Assuming that MPEP and its structural analogue M-MPEP behave in 
the same manner at their binding site, one may conclude that the fast dissociation kinetics are 
the reason for the failure of attempted cold displacement experiments when conducted at 
room temperature. If the radioligand is indeed only loosely bound to the membrane (at least at 
room temperature) then it might perhaps be easy to remove it from the receptor binding site 
during the rinse steps. This in turn can account for the poor signal to background ratio. To 
overcome this problem, the mGluR5 binding assay for compound screening must be 
performed under cooled conditions to obtain an acceptable signal-to-background ratio (15%).  Methods  55  
3 Methods 
3.1 Experimental  Details 
Note: Some of the following experimental procedures and methods (indicated by an asterisk 
in the headline) were not performed by the author of the thesis. They have been included for 
completeness of the scientific results. 
 
3.1.1  Preparation of Solutions  
Each compound was delivered as powder and was dissolved in pure DMSO and shaken for 
two hours on a shaker “RM5 Assistant” [Karl Hecht GmbH] to give a 10 mM stock-solution. 
Insoluble compounds were assumed to be inactive. The final concentration of DMSO in the 
assay was 5% (binding) and 0.5% (functional), respectively. The influence of DMSO on the 
membranes and cells was evaluated previously and turned out to be negligibly low at the 
concentrations used. Full concentration-response curves were performed using seven different 
concentrations (binding) or five different concentrations (functional), respectively with a log 3 
concentration progression. For these curves, serial dilutions of the stock solutions were made 
in pure DMSO before dilution in buffer to obtain the desired final concentration. This assured 
that, even for poorly soluble compounds, at least the lower concentrations tested really 
contained the required concentration of compound. 
 
3.1.2 Membrane  Preparation 
Male Sprague Dawly Rats (approx. 200-250g) were anaesthetized and decapitated. 
Cerebelli (forebrains for cortex preparation) were removed and homogenized (Ultra Turrax, 8 
strokes, 600 rpm) in 0.32M Sucrose. The suspension was centrifuged at 1,500g for 4 min. 
using a Sorvall Discovery 90 SE ultracentrifuge [Kendro Laboratory Products]. Supernatant 
was removed and centrifuged at 20,800g for 20 min. The resulting pellet was resuspended in 
ice-cold distilled water and centrifuged at 7,600g for another 20 min. Supernatant and loosely 
associated flocculent membrane material (buffy coat) were removed by gentle trituration of 
the pellet and centrifuged at 75,000g for 20 min. Supernatant was discarded and the 
membrane pellet was resuspended by sonication in Tris-Buffer (5mM, pH 7.4) and afterwards 
centrifuged at 75,000g for 20 min. The last step was repeated twice and membranes were 
resuspended in Tris-Buffer (50mM, pH 7.5). 56 
The concentration of protein was determined by the Lowry protein assay with bovine serum 
albumin as a standard [Lowry et al., 1951]. Membranes were stored frozen at –24°C, thawed 
on the day of the assay and washed once again at 75,000g for 20 min. All centrifugation steps 
were carried out at 4°C. 
 
3.1.3 [³H]-EMQMCM Binding Assay 
Binding assays were performed at room temperature in quadruplicate in a 96-well format 
using fixed concentrations of test compound (10µM). On a MS2 mini-shaker [IKA Werke 
GmbH] rotating with ~600 rpm the assay was incubated for 1h in the presence of 1nM [
3H]-
EMQMCM (23.9 Ci/mmol) and membranes (0.8 mg/ml) and non-specific binding was 
estimated using 30µM (3-Ethyl-2-methyl-quinolin-6-yl)-(4-hydroxy-cyclohexyl)-methanone 
[Asinex Ltd.]. Directly after transferring the reaction volume onto a 96-well multiscreen plate 
with glass fiber filter 0.22µm [Millipore GmbH] binding was terminated by rapid filtration 
using a multiscreen vacuum manifold [Millipore GmbH]. Afterwards, filters were washed 
three times with ice-cold assay-buffer and Ultima-Gold
TM MV Scintillation Cocktail [Perkin 
Elmer Life Sciences] was added. After 14h – 16h, radioactivity was counted in a 
MicroBeta
®Trilux [Perkin Elmer Life Sciences]. 
 
3.1.4 [³H]-MPEP-Binding Assay 
Binding assays were performed under cooled conditions (4°C) in quadruplicate in a 96-well 
format using fixed concentrations of test compound (10µM). On a MS2 mini-shaker [IKA 
Werke GmbH] rotating with ~600 rpm the assay was incubated for 1h in the presence of 5nM 
[
3H]-MPEP (50.2 Ci/mmol, Tocris) and membranes (0.8 mg/ml) and non-specific binding was 
estimated using 10µM MPEP. Directly after transferring the reaction volume onto a 96-well 
multiscreen plate with glass fiber filter 0.22µm [Millipore GmbH] binding was terminated by 
rapid filtration using a multiscreen vacuum manifold [Millipore GmbH]. Afterwards, filters 
were washed three times with ice-cold assay-buffer and Ultima-Gold
TM MV Scintillation 
Cocktail [Perkin Elmer Life Sciences] was added. After 14h – 16h radioactivity was counted 
in a MicroBeta
®Trilux [Perkin Elmer Life Sciences].  
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3.1.5  Preparation of Cerebellar Granule-cells* 
Cerebellar cortici were obtained from P8 postnatal Sprague Dawley rats, mechanically 
disrupted into small pieces with forceps and then transferred to Ca
2+- and Mg
2+-free Hank's 
buffered salt solution (HBSS-CMF) on ice. After three washes in HBSS-CMF, the tissue 
pieces were incubated at 37°C for 8 minutes in the presence of 0.25% trypsin / 0.05% DNase. 
The enzymatic reaction was stopped with 0.016% DNase / 0.1% ovomucoid before 
centrifugation at 800 rpm for 5 minutes. The supernatant was replaced twice with 
NaHCO3/HEPES-buffered basal Eagle medium (BEM) plus 20mM KCl. Cells were 
mechanically dissociated in 2 ml of BEM by trituration through three Pasteur pipettes of 
successively decreasing tip diameter and then filtered through a 48 µm gauge filter. Cells 
were plated at a density of 150,000 cells in 50 µl in each well of poly-L-Lysin pre-coated 96-
well plates [BD Biosciences]. The cells were nourished with BEM supplemented with 10% 
fetal calf serum, 2 mM glutamine [Biochrom AG], 20 mM KCl and gentamycin [Biochrom 
AG] and incubated at 36°C with 5% CO2 at 95% humidity. After 24 hours cytosine-ß-D-
arabinofuranoside (AraC, 10µM) was added to the medium. 
 
3.1.6 IP3-Assay with [³H]-myo-Inositol* 
After 6 DIV the culture medium was replaced completely with inositol free DMEM [MP 
Biomedicals] containing [³H]-myo-inositol [Perkin Elmer Life Sciences] at a final 
concentration of 0.5 µCi / 100 µl / well and incubated for a further 48 hours. The culture 
medium in each well was replaced with 100 µL Locke´s buffer (plus 20 mM LiCl, pH 7.4) 
and incubated for 15 min at 37°C. Locke´s buffer was replaced with agonists / antagonists / 
putative mGluR1 ligands in Locke´s buffer and incubated for 45 min. These solutions were 
then replaced with 100 µL 0.1 M HCl in each well and incubated for a further 10 mins on ice 
in order to lyse the cells. The 96-well plates can be frozen at -20°C at this stage until further 
analysis. 
Home made resin exchange columns were prepared as follows. Empty Bio-Spin 
Chromatography columns [Biorad Laboratories] were plugged with filter paper before filling 
with 1.1-1.3 ml of resin (AG1-X8 Biorad, 140-14444) suspended in 0.1M formic acid (24 g 
resin per 50 ml acid). The formic acid was allowed to run out before sealing the syringe tips 
and filling with 200-300 µL of 0.1M formic acid before storage at 4°C. 
On the day of assay, columns were washed with 1 ml of 0.1M formic acid followed by 1 ml 
of distilled water. Then the contents of each assay well were added to one column and washed 58 
with 1 ml distilled water followed by 1 ml of 5mM Sodium tetra borate / 60mM sodium 
formate. Thereafter, the retained radioactive inositol phosphates were eluted with 2 x 1ml of 
1M ammonium formate / 0.1M formic acid into 24-well visiplates. Scintillation liquid (1.2 ml 
UltimaFlow AF [Perkin Elmer Life Sciences] was added to each well, the plate sealed and 
vortexed before radioactivity was determined by conventional liquid scintillation counting 
(MicroBeta
®Trilux) [Perkin Elmer Life Sciences]. Unless otherwise stated, all reagents were 
obtained from Sigma-Aldrich [Sigma-Aldrich Chemie GmbH]. 
 
3.1.7  Preparation of and Cultivation of Rat Cortical Astrocytes* 
Astrocytes were prepared mechanically from cortices of newborn Sprague Dawley rats as 
described earlier [Booher & Sensenbrenner, 1972]. The tissue was disintegrated with a nylon 
filter (20x20 cm; pore size 80 µm) and carefully triturated. The cell suspension was seeded in 
a T 225 flask and cultivated in DMEM containing 10% fetal calf serum, 2mM glutamine and 
50 µg/ml gentamycin at 37°C in 5% CO
2 and 95% humidity for 7 days with a medium change 
at day 2. After 7 days in culture, cells were shaken overnight [Miller et al., 1993] to remove 
oligodendrocytes. The next day astrocytes were washed, trypsinized and seeded into 96-well 
plates coated with Poly-L-Lysin at a density of 40.000 cells / well. One day after trypsination, 
the medium was switched to serum free chemical defined DMEM (ADM) containing 1x G5-
supplement, 50 µg/ml heparan sulfate, and 1.5 µg/ml fibronectin. 
 
3.1.8  Calcium FLIPR Studies* 
Cultured astrocytes expressed mGluR5 receptors as shown by immunostaining. The 
increase of intracellular calcium after stimulation with the mGluR5 agonist DHPG or L-
quisqualate was measured using the fluorometric imaging plate reader (FLIPR) and the Ca-
Kit. Prior to addition of agonist or antagonist the medium was aspirated and cells were loaded 
for 2 h at RT with 150 µL of loading buffer consisting of a calcium-sensitive dye 
reconstituted in NaCl (123mM), KCl (5.4mM), MgCl2 (0.8 mM), CaCl2 (1.8mM), D-glucose 
(15mM), and HEPES (20mM), pH 7.3. Subsequently, plates were transferred to FLIPR to 
detect calcium increase with the addition of DHPG (300µM) or L-quisqualate (100nM) 
measured as relative fluorescence units (RFU). If antagonists were tested, these compounds 
were pre-incubated for 10 min at room temperature before addition of the respective agonist. 
The fluorescence signal increase after addition of agonist reflects the increase of intracellular 
calcium. Inconsistencies in the amount of cells per well were normalized by using the spatial Methods  59  
uniformity correction of the FLIPR software. The mean of replicated temporal data (n=5) was 
calculated and used for graphical representation. For the evaluation of the pharmacology, the 
calcium changes in response to different concentrations of agonist or antagonist were 
determined using a maximum minus minimum (MaxMin) or an area under the curve (AUC) 
calculation. All responses (CPM- or RFU-values) were determined as percentage of control (= 
maximum response at 50 nM CBC). 
 
3.1.9 Association Kinetic Studies 
Solutions containing assay-buffer (Tris-HCl 50mM, pH 7.5), radioligand ([³H]-M-MPEP 
0.5nM and 1nM) and cold displacer (M-MPEP 10µM) for negative control values were 
prepared on a regular 96-well plate and transferred to a 96-well multiscreen plate with 
moistened glass fiber filter 0.22µm [Millipore GmbH]. Incubation was started by the non-
synchronous addition of a suspension containing rat cortical membranes (0.24 mg/ml) for 
incubations lasting 1, 2, 3, 4, 5, 7, 10, 15, 20 and 30 min., respectively, at room temperature. 
Then incubation was terminated by synchronous, rapid filtration using a multiscreen vacuum 
manifold [Millipore GmbH]. Afterwards, filters were washed three times with ice-cold assay-
buffer and Ultima-Gold
TM MV Scintillation Cocktail [Perkin Elmer Life Sciences] was added. 
After 14h – 16h radioactivity was counted in a MicroBeta
®Trilux [Perkin Elmer Life 
Sciences]. 
 
3.1.10 Dissociation Kinetic Studies 
Suspensions of rat cortical membranes were incubated on a regular 96-well plate for one 
hour in the presence of assay-buffer (Tris-HCl 50mM, pH 7.5) and different radioligand 
concentrations ([³H]-M-MPEP 0.5nM and 1nM). After addition of cold displacer (M-MPEP 
10µM) reaction volumes were incubated for 1, 2, 3, 4, 5, 7, 10, 15, 20 and 30 min., 
respectively. Reaction was stopped by transferring solutions to a 96-well multiscreen plate 
with moistened glass fiber filter 0.22µm [Millipore GmbH] and rapidly removing the 
solutions using a multiscreen vacuum manifold [Millipore GmbH]. Afterwards, filters were 
washed three times with ice-cold assay-buffer and Ultima-Gold
TM MV Scintillation Cocktail 
[Perkin Elmer Life Sciences] was added. After 14h – 16h radioactivity was counted in a 
MicroBeta
®Trilux [Perkin Elmer Life Sciences]. 
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3.1.11 Estimation of IC50-values  
To estimate the IC50-value of each compound without assaying the compound solution in a 
full dose-response-curve the result of the assay for each compound (% of Control) had to be 
inserted into a two-parameter equation. 
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% 100
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= ,                  (Eq. 3.1.11-a) 
 
where s is the slope factor (= 1), x is the final concentration of the compound to be tested 
(µM) in the assay and y denotes the result of the experiment for the compound to be tested (% 
of Control). This applies for both, functional and binding assays. If s is assumed to be 1 
Equation 3.1.11-a can be reformulated as follows: 
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Full concentration response curves (7-10 concentrations, depending on assay conditions) 
have been conducted for SAR studies to determine precise activity or affinity values whereas 
calculations based upon two-concentration CRCs (1µM and 10µM) were carried out for 
regular screens. 
 
 
Figure 3.1.11-a. Full concentration response curve of a test ligand in a radioactive binding 
assay.  Methods  61  
 
Results of binding experiment are normally given as Ki, a value that depends on the 
radioligand´s properties. K i-values were calculated from the IC50-values by the Cheng-
Prussoff Equation [Cheng & Prussoff, 1973]: 
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where L corresponds to the radioligand concentration and Kd to its dissociation constant in a 
particular assay. 
 
3.1.12 Muscarinic Acetylcholine Receptor Assay* 
The increase of intracellular calcium after stimulation with carbachol was measured using 
the fluorometric imaging plate reader (FLIPR) and the Ca-Kit [both Molecular Devices]. Cells 
were seeded in black 96 well plates with clear bottom [CoStar] at a density of 60,000 
cells/well and incubated in Ham’s F12 medium for one night. Prior to addition of agonist or 
antagonist the medium was aspirated and cells were loaded for 1h at 37°C with 150 µL of 
loading buffer consisting of Ca-sensitive dye [Molecular Devices] reconstituted in HBSS, 
MgCl2 (0.8 mM), CaCl2 (1.8 mM), probenecid  (2.5 mM), and HEPES (20 mM), pH 7.3. 
Subsequently, plates were transferred to FLIPR to detect calcium increase with the addition of 
CBC (50 nM final concentration) measured as relative fluorescence units (RFU). If antagonists 
were tested, these compounds were pre-incubated for 20 min at RT before addition of CBC. 
The fluorescence signal increase after addition of agonist reflects the increase of 
intracellular calcium. Inconsistencies in the amount of cells per well were normalised by 
using the spatial uniformity correction of the FLIPR software. The mean of replicated 
temporal data (n=5) was calculated and used for graphical representation. For the evaluation 
of the pharmacology, the calcium changes in response to different concentrations of agonist or 
antagonist were determined using a maximum minus minimum (MaxMin) or an area under 
the curve (AUC) calculation. All responses (CPM- or RFU-values) were determined as 
percentage of control (= maximum response at 50 nM CBC). 
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3.1.13 Dopamine D2short- and D3-Receptor Binding Assay* 
Membrane preparations of CHO-cells stably expressing human D2short- and D3-receptors 
were used for displacement studies [Hayes et al., 1992; Sokoloff et al., 1992]. [³H]-Spiperone 
(0.2 nM) served as a radioligand and non-specific binding was determined in the presence of 
BP 897 (10 µM). Stock solutions (10 mM) of test compounds were prepared with pure 
DMSO. They were diluted to give final concentration ranges either from 1 µM to 1 mM or 
from 10 nM to 10 µM, depending on the test compound’s affinity. The assay was incubated 
for 2 h at RT and terminated by rapid filtration through PerkinElmer GF/B glass fibre filters 
[Perkin Elmer Life Sciences] coated with 0.3% polyethylenimine [Sigma-Aldrich Chemie 
GmbH] using an Inotech cell harvester (Inotech AG, Dottikon, Switzerland). Radioactivity 
was counted using a PerkinElmer MicroBeta
®Trilux scintillation counter [Perkin Elmer Life 
Sciences]. For all compounds two independent experiments were performed in triplicates. 
Competition binding data were analyzed by GraphPad Prism 3.02 [GraphPad Software, Inc.], 
using non-linear least squares fit. Ki values were calculated from the IC50 values according to 
Cheng-Prussoff (Equation 3.1.11-c). 
 
3.1.14 Histamine H1-Receptor Binding Assay* 
Membrane preparations of CHO-cells stably expressing human H1-receptors were used for 
displacement studies [Smit et al., 1996]. [Pyridinyl-5-³H]-pyrilamine (1 nM) served as a 
radioligand and non-specific binding was determined in the presence of chlorphenamine 
hydrogenmaleate (10 µM). Stock solutions (10 mM) of test compounds were prepared with 
pure DMSO. They were diluted to give final concentration ranges from 1 µM to 1 mM. The 
assay was incubated for 2 h at RT and terminated by rapid filtration through PerkinElmer 
GF/B glass fiber filters [Perkin Elmer Life Sciences] coated with 0.3% polyethylenimine 
using an Inotech cell harvester. Radioactivity was counted using a PerkinElmer 
MicroBeta
®Trilux scintillation counter [Perkin Elmer Life Sciences]. For all compounds two 
independent experiments were performed in triplicates. Competition binding data were 
analyzed by GraphPad Prism 3.02 [GraphPad Software, Inc.], using non-linear least squares 
fit. Ki values were calculated from the IC50 values according to Cheng-Prusoff (Equation 
3.1.11-c). Methods  63  
3.2 Computational  Methods 
3.2.1  CATS 2D Similarity Search 
CATS (Chemically Advanced Template Search) enables a topological pharmacophore 
search applicable for virtual screening procedures. The CATS descriptor denotes a topological 
atom-pair descriptor and has been reported earlier [Schneider et al., 1999]. Since it is based 
on the two-dimensional structure of a molecule it circumvents problems derived from 
conformational flexibility. Topological information of a molecule is encoded with the CATS 
descriptor by the following procedure: Assigning each atom (i.e., a node of the molecular 
graph) to one of the following generalized atom types: hydrogen-bond donor (D), hydrogen-
bond acceptor (A), positively charged (P), negatively charged (N) or lipophilic (L) (Figure 
3.2.1-a). Atoms which do not belong to one of the five mentioned potential pharmacophore 
point groups are not taken into account. Atom pairs denote the shortest distance connecting 
two nodes. The frequency of all 15 possible atom pairs of CATS types (DD, DA, etc.) is 
determined and the resulting histogram is divided by the number of non-hydrogen atoms in 
the molecule to get a scaled vector [Fechner et al., 2003].  
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Figure 3.2.1-a. Schematic conversion of a two-dimensional molecular representation into a 
molecular graph with assigned generalized atom types. 
 
The CATS-similarity is defined by the degree as to which the topological pharmacophore 
descriptors of  two molecules A and B match and is expressed by the euclidian distance 
measure D (A,B) (Equation 3.2.1-a): 
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where v
A and v
B denote the correlation-vectors derived from molecules A and B. 
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To obtain a final ranked list the compounds were sorted by increasing order according to 
the CATS-dissimilarity - that is the distance given as Tanimoto coefficient - of the test 
compound towards the reference compound within the individual lists that resulted from the 
similarity searches.  
 
3.2.2 Self-Organizing  Maps 
For the studies presented within this thesis two-dimensional Kohonen-maps with a toroidal 
topology were used and visualized as squares consisting of either 100 or 225 neurons. 
The SOM training process is comparable to vector quantization, where the network weight 
vectors move towards the centers of data distribution [Nasrabadi & King, 1988]. During the 
SOM training input patterns χ (here: descriptor vectors) are compared to all neurons w of the 
output layer (“fan-out” units). The neuron vector displaying the highest similarity to a 
particular input vector gets activated (“winner neuron”) while the other neurons remain 
inactive. For SOM training the Kohonen-algorithm was applied: 
 
1.  Initialize a map M to contain N=N1*N2 neurons ci with the reference vectors 
wci ∈R
n randomly chosen according to p(χ) from the input patterns. Initialize 
the connections to form a rectangular N1*N2 grid and the time parameter t = 0. 
2.  Generate randomly an input signal χ according to p(χ). 
3.  Determine the “winner neuron” according to the vector distance between the 
training patterns χ and the neurons w. 
4.  Adapt each neuron r to p(χ) according to 
 
) ( ) ( r rs r w h t w − = ∆ χ ε .       (Eq.  3.2.2-a) 
The Gaussian neighborhood function around the winner neuron s is 
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where the Hamming distance d1 defines the distance between two neurons and 
σ is the standard deviation. The time dependent standard deviation can be 
calculated by: 
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and the time dependent learning rate by: 
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ε .       (Eq.  3.2.2-d) 
    
5.  Increase time parameter t = t +1. 
6. If  t<tmax continue with 2., otherwise abort. 
 
The training of SOMs was computed with som_create using 10x10 (100) and 15x15 (225) 
neurons, tmax = 60,000, σinitial = 1 and εinitial = 6. Visualization was performed with som-show 
(software by Schneider, unpublished). 
 
3.2.3 Principal  Component  Analysis 
For definitions of the matrices used for ChemSpaceShuttle (CSS) the reader is referred to 
the original literature [Givehchi et al., 2003]. Data projections for this particular study have 
been done by the NIPALS algorithm and encoder networks, implemented in CSS. The input 
vectors were projected to the space covered by the first three eigenvectors calculated with the 
NIPALS algorithm: 
 
1.  Normalize the data set (unit variance scaling and mean entering). 
2.  Set the array of the of the score matrix  i s  to the first column 
→
1 x  of the input 
vector matrix  X  (each row of this matrix denotes a different compound and 
each column a different matrix). 
3.   Calculate: 
 
  
→
→
→
=
T step
i
T
i
i s
l
l 3 ,        (Eq.  3.2.3-a) 
 66 
 where  T means transpose. 
4.    Normalize the vector 
→
i l  to the length 1: 
    
→
→
→
=
i
i
i
l
l
l .        (Eq.  3.2.3-b) 
 
5.   Calculate: 
 
2
5
→
→
→
⋅ =
i
i step
i
l
l
X s .       (Eq.  3.2.3-c) 
 
6.   Compare 
→
5 step
i s  from step 5 to 
→
3 step
i s  from step 3 ; if the sum of squared 
residual is smaller than 10
-10 then go to step 7, else go to step 3 and calculate 
→
i l  
again. 
7.    Calculate the residual R :  R  =  X - 
→ →
T
i i l s  and set  X  = R . If i = p or R<10
-10 
then stop the calculation, else go to step 3. 
 
After i loops the composition of the X-matrix will be obtained, i.e.,  X  = 
T l s 1 1  + 
T l s 2 2  + …. 
+ 
T
i il s . 
 
Data projection performed by encoder networks can be divided into two procedures. In the 
first step the input vectors are supplied to the input and output layer (Figure 3.2.3-a). The 
input data can reasonably be described by the values of the neurons forming the parameter 
(i.e., hidden) layer only if the network weights are optimized. Therefore, CSS applies a (1,λ) 
evolution strategy representing an adaptive stochastic search method [Bäck & Schwefel, 
1993; Schneider & Wrede, 1998]. Here, Kruskal´s STRESS serves as a goodness-of-fit 
measure [Kruskal, 1964]:  
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,       (Eq.  3.2.3-d) 
 
where  d
t
ij denotes the Euclidean distance between the 3D-vectors i and j, and d
o
ij is the 
Euclidean distance between the original descriptor vectors i and j.  
Input vectors Input vectors
 
Figure 3.2.3-a. Architecture of an encoder network in the training mode implemented in CSS. 
Decriptor (input) vectors supply both, the input and output layers (empty circles) with original 
data. 
 
Once a previously defined STRESS value is reached, the training mode is completed. Now 
the optimized net enables the transformation of the high-dimensional to low-dimensional data 
(Figure 3.2.3-b) from the input layer to the parameter layer leaving out the output layer. The 
three neurons of the parameter layer represent the final vectors in the 3D-plot.  
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Figure 3.2.3-b. Architecture of an encoder network in the projection mode implemented in 
CSS. The output values of the three central neurons (grey circles) can be visualized by 
representing a 3D-plot. 
 
3.2.4  Comparative Molecular Field Analysis 
The CoMFA method has been detailed nearly two decades ago [Cramer et al., 1988]. A set 
of chemically similar molecules (optimal number of structures: 20-50) has to be flexibly 
aligned in a proper way according to structural pharmacophore features (e.g., H-bond 
donor/acceptor, etc.). These molecules should bear a consistent core structure differing only in 
type and position of substituents. Setting up a reasonable alignment is a pivotal step since the 
predictive capability of a CoMFA model strongly depends on the alignment. 
In the next step the aligned structures have to be embedded into a three-dimensional 
rectangular grid with sufficient space to encompass all molecules. Each lattice point 
represents a positively charged carbon atom with sp³ properties, which measures the steric 
interaction energy (Lennard-Jones potential) and the electrostatic energy (Coulomb potential) 
for all atoms of each molecule. To minimize domination by large steric and electrostatic 
energies, all energies that exceed a previously defined threshold value are set to this cutoff 
value. These energy calculations produce an extraordinary large amount of data resulting in 
by far more columns than rows. To extract a stable QSAR from such an unproportioned data 
table the partial least-squares (PLS) method was employed [Wold, 1966; Lindberg et al., 
1983]. The columns are not auto scaled since the units of all columns are the same (kcal/mol). 
Cross-validation evaluates a model by how well it predicts data points, not used for the Methods  69  
calculation. Noteworthy, activities of molecules that extend into regions not covered by the 
training set cannot be predicted, which pertains to all QSAR methods. 
CoMFA models have been established using the QSAR tool implemented in the Sybyl 7.1 
software package [Tripos Inc.]: 
Initially, the EMQMCM-data collection (Section 3.2.6) was loaded in Sybyl 7.1 as sd-file. 
Activity data have been added by means of pIC50-values. 3D structures of ligands were 
generated using CONCORD. The structure energy minimization was performed for CoMFA 
using the Tripos molecular force field [Clark et al., 1989] and Gasteiger-Hückel charges. 
Steric and electrostatic interactions were calculated with same force field using a distance 
dependent dielectric constant at all intersections in an evenly spaced 2.0Ǻ grid. The cutoff 
was set to 30 kcal/mol. To create an initial model, the dataset was divided into a training and a 
test set as follows: all molecules were sorted in ascending order with respect to their internal 
ID. The first nine entries constituted the test set and the remaining 30 entries the training set. 
Regression analysis was performed using the full cross-validated PLS method (leave one out). 
Based on the training set the final model was calculated using the optimum number of 
components to that yielding the highest q² (cross-validated). Optimum number does not 
necessarily mean the number of components yielding the highest q²(cv): According to the 
“parsimony-principle” an increase of q²(cv) values of less than 5% for the use of an additional 
component was used as a stop criterion [Thibaut et al., 1993]. For improved statistical 
significance of the results ten new models were established by randomly dividing the total 
dataset into two subsets of nearly equivalent size (20 molecules training set, 19 molecules test 
set). 
Several parameters reflect the quality of a given model and indicate how well it fits existing 
data. PRESS and q² have been proposed for cross-validation to give good estimates of the real 
prediction of a model : 
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=
− =
N
i
i obs i pred y y PRESS
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2
, , ,   (Eq.  3.2.4-a) 
 
where N is the number of objects and y denotes the target parameter in the activity data. Based 
upon this equation q² can be calculated as follows:   
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To validate the derived CoMFA models, activity data of the external test sets were 
predicted using the models derived from the training set. The predictive abilities of the 
training sets were expressed by q²(cv) whereas the predictive ability of the test sets were 
expressed by the analogous r²pred using the formula 
 
SD
PRESS SD
rpred
−
=
2 ,     (Equation  3.2.4-c) 
 
where  SD denotes the sum of squared deviations between the activity of the test set 
compounds and the mean activity of the training set compounds, and PRESS is the sum of 
squared deviations between the observed and the predicted activity of the test set molecules.  
 
All-placement search (APS) and all-orientation search (AOS) describe techniques which 
optimize the field sampling routine in the CoMFA approach [Wang et al., 1998]. They allow 
for assessing the statistical relevance of a given model. Since steric and electrostatic 
interactions are distance dependent there exists a strong influence of the relative orientation of 
the alignment against the probe grid [Böhm et al., 1999]. Starting from an arbitrary 
orientation APS and AOS provide a way to stepwise translate the molecular aggregate within 
the lattice and to detect a specific orientation leading to the highest q² and consequently the 
most valid CoMFA model.  
The corresponding spl-scripts and shell scripts obtained from the authors were implemented 
in Sybyl 7.1. For APS the whole grid was systematically translated in 0.1Ǻ-steps against the 
molecular aggregate. This process was performed in all three dimensions of the coordinate 
system and finished after 2.0Ǻ since in this case the grid had overlapped the original one. 
Therefore, 20x20x20=8000 placements were obtained. In contrast, AOS allowed for rotating 
the molecular aggregate in the grid around the x-, y- and z-axis. The stepwise rotation was 
divided into increments of 20° resulting in 18x18x18=5832 orientations. 
 
3.2.5 Homology  Modeling 
Note: The homology model of the transmembrane region of the mGlu1 receptor presented 
in this thesis has not been built by the author. It was solely developed by Steffen Renner, a 
former postdoctoral student at Merz. 
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The mGluR1 receptor was modeled based on the template of bovine rhodopsin (PDB code 
1l9h). An alignment of the transmembrane region of the rat mGluR1 sequence to the 
transmembrane region of bovine rhodopsin was adapted from previously published mutational 
studies on mGluR1 and other related class C GPCRs: 
Based on the effect of mutations in the transmembrane region on binding of the mGluR1 
negative allosteric modulator EM-TBPC an alignment for mGluR1 to bovine rhodopsin was 
proposed [Malherbe et al., 2003a]. Alignments for transmembrane helices for which 
mutations affected the binding of EM-TBPC (3, 5, 6, and 7) were adopted directly. These 
alignments were consistent with mutational data for mGluR5 for the binding of M-MPEP 
[Pagano et al., 2000] and MPEP [Malherbe et al., 2003b]. The only reported mutation in a 
family 3 GPCR for transmembrane helix 2 (TM2), that was found to influence the binding of 
an allosteric modulator, was found in the calcium sensing receptor [Miedlich et al., 2004]. 
Thus, the alignment of TM2 was overtaken from this study and converted into the mGluR1 
sequence. The alignment of TM1 was used from Malherbe et al. [Malherbe et al., 2003a]. For 
TM4 a more reasonable alignment was found for the model of the calcium sensing receptor 
[Miedlich et al., 2004], where two neighboring prolines at the C-terminal end of TM4 were 
aligned with two prolines in the C-terminus of the rhodopsin TM4. Since these two prolines 
were conserved in mGluR1 and in other family 3 GPCRs this alignment was used. The final 
alignment is given in the following Figure. 
 
 
TM1 
>bopsd       38 SMLAAYMFLLIMLGFPINFLTLYVTVQ 
>rmGluR1    590 DIESIIAIAFSCLGILVTLFVTLIFVL 
Consensus/80%   sbbthbhbhb.hLGb.lsbbshblhVb 
 
TM2 
>bopsd       71 PLNYILLNLAVADLFMVFGGFTTTLY 
>rmGluR1    625 SSSRELCYIILAGIFLGYVCPFTLIA 
Consensus/80%   s.sbbLh.lhlAslFbsass.hThlh 
 
TM3 
>bopsd      108 TGCNLEGFFATLGGEIALWSLVVLAIERYVVVC 
>rmGluR1    655 TSCYLQRLLVGLSSAMCYSALVTKTNRIARILA 
Consensus/80%   TtC.Lp.bbssLtt.bsb.tLVsbs.cbh.lls 
 
TM4 
>bopsd      150 ENHAIMGVAFTWVMALACAAPPLV 
>rmGluR1    709 IASILISVQLTLVVTLIIMEPPMP 
Consensus/80%   bsphlbtV.bTbVhsLhhh.PPbs 
 
EL2 
>bopsd      178 YIPE    185 CSCG 
>rmGluR1    736 YPSI    744 LICN 
Consensus/80%   Y.sb......h.Cs 
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TM5 
>bopsd      205 IYMFVVHFIIPLIVIFFCYGQLVFTV 
>rmGluR1    750 NLGVVAPVGYNGLLIMSCTYYAFKTR 
Consensus/80%   .bhhVs.hhbshllIb.ChhbhhbT. 
 
TM6 
>bopsd      249 EVTRMVIIMVIAFLICWLPYAGVAFY 
>rmGluR1    782 NEAKYIAFTMYTTCIIWLAFVPIYFG 
Consensus/80%   p.s+blhbhhbshhIhWLsasslhFh 
 
TM7 
>bopsd      288 MTIPAFFAKTSAVYNPVIYIMMN 
>rmGluR1    811 KIITTCFAVSLSVTVALGCMFTP 
Consensus/80%   bhIsshFA.*.tVhsslhhbbhs 
 
Figure 3.2.5-a: Alignment of transmembrane helices and EL2 of rat mGluR1 to the bovine 
rhodopsin structural template. Consensus symbols other than residue letters are: - = negative, 
* = ser/thr, | = aliphatic, + = positive, t = tiny, a = aromatic, c = charged, s = small, p = polar, 
b = big, h = hydrophobic. Identical residues are highlighted in grey. Similar amino acids are 
colored according to the following scheme: red = negative, cyan = S/T, grey highlighted 
yellow = aliphatic, dark blue = positive, light green = tiny, dark blue highlighted yellow = 
aromatic, pink = charged, dark green = small, light blue = polar, light blue highlighted yellow 
= big, black highlighted yellow = hydrophobic. 
 
For the initial model of mGluR1 the HOMER server (version 1.3) [Tosatto, 2005] was used. 
HOMER was successful for the transmembrane regions, however, most of the modeled loops 
were not closed, i.e., they were only connected to a single helix instead of connecting two 
helices. Thus the torsion angles of the loop residues were refined manually to enable the 
connection of the helices. The loops were minimized with the Tripos force field (max. 500 
steps Powell with Simplex initiation) within Sybyl 7.1 [Tripos Inc.]. The extracellular loop 2 
(EL2) in direct contact with the inverse agonist in bovine rhodopsin was modeled by taking 
the backbone coordinates of the conserved disulfide bridge and neighboring residues (Figure 
3.2.5-a). In class C GPCRs the linker from the disulfide Cys in EL2 to TM5 is much shorter 
compared to bovine rhodopsin. To enable a connection between TM5 and EL2, TM5 was 
moved towards the center of the seven helices until the residues were sufficiently near to each 
other to be connected. The structure was minimized, and irresolvable side chain clashes were 
solved by using different rotamers. Ligands were placed manually into the receptor, based on 
the position of 11-cis-retinal in bovine rhodopsin, and subsequently minimized with the 
Tripos force field. Residue numberings are used according to the scheme proposed by 
Malherbe [Malherbe et al., 2003b]. 
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3.2.6 Datasets 
Four different datasets were employed for the present studies: The EMQMCM-data 
collection has been compiled based on a series of quinoline-derivatives [Mabire et al., 2005] 
and was used for the QSAR studies. Initially, it contained 49 compounds bearing the same 
core structure including precise activity data for the rmGlu1 receptor. Ten molecules have 
been removed from the dataset either lacking precise bioactivity values or being structurally 
distinct from the other molecules (that is their residues point into spatial regions not covered 
by other molecules; consequently, they would falsify the QSAR models).  
The Asinex Gold Collection provided by Asinex [Asinex Ltd.] was used in sd-format for 
virtual screening purposes. This external compound library is continuously being updated and 
we applied the versions of February 2003 (194,598 entries) and October 2003 (201,304 
entries). Apart from the 2D-chemical structures they include predicted Lipinski rule properties 
[Lipinski et al., 1997]. Both versions contain many compounds violating these rules, as it was 
exemplified for the latter version (October 2003). The database was filtered for drug-likeness 
according to the following cut-offs [Lipinski et al., 1997]: five or less H-bond donor atoms, 
10 or less H-bond acceptor atoms, MW < 500 and SlogP < 5. 156,112 structures (77.55%) 
fulfilled these criteria but 45,192 (22.45%) failed. 
The COBRA 3.12 database was solely used for developing SOMs. This collection (5,376 
molecules) was compiled from scientific literature and is a set of bioactive reference 
compounds affecting a large number of different targets like proteases, kinases, GPCRs and 
ion channels [Schneider & Schneider, 2003]. The COBRA compounds have mean values of 
MW and logP which are within the limits proposed by Lipinski`s rule of five (MW<500 and 
logP<5) [Lipinski et al., 1997]. 
The mGluR-data collection comprises 357 positive and negative allosteric modulators of 
mGluR1 and mGluR5 and was manually compiled from literature. It served as reference 
molecule dataset for all campaigns in this thesis (detailed description in Section 4.1) 74 
4 Scaffold  Identification 
A goal of this thesis was to improve the understanding of function and ligand binding in the 
transmembrane region (HD) of group I metabotropic glutamate receptors (mGluR) and in 
particular of subtype 1. The identification of ligands acting as allosteric modulators and 
providing novel core structures (i.e., “scaffolds”) was one of the two main rationales of this 
thesis since these ligands may facilitate further insight into the binding mode at the allosteric 
binding site (e.g., knowledge about structural requirements for (i) potent and selective binding 
and (ii) inactivation of receptor function). The precise architecture of the HD of group I 
mGluRs is still unexplored; yet some hypotheses have been published [Belenikin et al., 2003; 
Malherbe et al., 2003a/b]. Therefore, a structure-based approach for the detection of novel 
ligands remains inherently difficult so we pursued a ligand-based approach. Several methods 
of virtual screening have been employed (Section 1.5). In the following chapter we describe 
their application and evaluate their suitability for the given research objective. The whole hit 
finding procedure describes a sensible alternative to simple compound screening pursued by 
HTS. 
 
4.1 Data  Consolidation 
The elucidation of novel hits for mGlu1 receptor via virtual screening requires the 
collection of ligands affecting mGluR1. More precisely, before applying several virtual 
screening methods the need of compiling a data collection of reference molecules providing 
as much structural information as possible arose. Homology models of the transmembrane 
region of the mGlu1 receptor have been reported [Belenikin et al., 2003; Malherbe et al., 
2003a] but they remain only hypotheses as long as the crystal structure is not known. Thus, 
we pursued the ligand-based approach. Such approaches aiming at detecting novel ligands for 
a given target regarding the chemical core structure need at least one known bioactive 
molecule as a starting point. This requirement was fulfilled for both, mGluR1 and mGluR5 
(Section 1.4.2). Since success or failure of performing virtual screening procedures and 
setting up a valid pharmacophore hypothesis strongly depends on the reference dataset, 
compounds to be included in such a library have to be carefully selected concerning the 
subtype selectivity and the correct chemical structure. 
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4.1.1  Assembling a Data collection  
A collection of reference molecules in the following referred to as mGluR-data collection 
has been compiled. This library comprises in total 357 ligands acting at the allosteric sites of 
the mGlu1 and mGlu5 receptor (Table 4.1.1, Table 7.1-a), which have been solely collected 
from scientific literature and patents published until August 2003. Though this dataset has 
been continuously updated by adding recently published molecules, a copy of the original 
compilation was saved for the purpose of retrospective analyses. Each entry is described by 
the chemical structure of the molecule and its activity and, if available, affinity data. 
However, it must be stressed that the functional assays that were performed to determine the 
activities differ to some extent between different research groups, mainly concerning the 
tissue (e.g., membranes or cell lines) and the detecting devices. Consequently, the relative 
potency at the same receptor could not strictly be compared for molecules from different 
publications or patents. During the hit finding process such differences were not crucial since 
no SAR studies were performed where precise activity values are generally required. 
Therefore, at this stage it was sufficient to discriminate mainly between “potent” (< 1 µM cut-
off) and “highly potent” (< 100 nM cut-off) compounds. 
 
Table 4.1.1-a. Distribution of the mGluR-compounds in the mGluR-data collection regarding 
the receptor subtype and interaction mode. 
Target Molecules 
Negative allosteric modulators of mGluR1  212 
Positive allosteric modulators of mGluR1  19 
Negative allosteric modulators of mGluR5  125 
Positive allosteric modulators of mGluR5  1 
 
 
4.2 Pharmacophore  Model 
To initiate a hit finding process it seemed reasonable to create a flexible overlay of known 
allosteric mGluR1 antagonists. Such an alignment describes the template for establishing a 
pharmacophore model. A pharmacophore model in turn can be interpreted as a visualized 
pharmacophore hypothesis. It displays a set of structural features, which preferably several 
ligands have in common and is related to the ligand`s recognition at the target site (Section 
1.5.1).  76 
The underlying idea of starting a hit identification process in this way has several reasons: 
(i) Some of the ligand-based screening approaches rely on a three-dimensional 
pharmacophore model or at least on certain molecules used for that model. (ii) It was helpful 
to get a first impression of common structural features of ligands bearing different core 
structures and of their potentially pivotal interaction points. In general, initial knowledge of 
relevant pharmacophore features obtained, e.g., by collecting reference molecules as starting 
point for virtual screening and postulating a hypothesis is inevitable to correctly interpret 
screening results. In particular, visually revising a set of retrieved virtual hits in order to sort 
out potentially non-relevant molecules is only feasible when the medicinal chemist is 
provided with sufficient information about already known ligands (meaning structural 
requirements, that is features being crucial for binding to the receptor). 
 
4.2.1  Molecules from the Reference Data collection 
The pharmacophore hypothesis presented herein is based on a set of six reference 
molecules. They were selected from the mGluR-data collection as they were corresponding to 
the following requirements: 
-  Ligands known as allosteric antagonists of mGluR1 
-  Ligands being structural diverse to each other 
-  Ligands revealing high activity (< 100 nM cut-off) at mGluR1. 
 
In total, six compounds were selected fulfilling these criteria (Figure 4.2.1-a). This number 
was assumed to be sufficient since a proper pharmacophore model should comprise as few 
molecules as necessary providing as much structural information as possible. 
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R-01 (7nM)                                                  R-02 (3nM)                              R-03 (3nM)
R-04 (5nM)                                                  R-05 (5nM)                              R-06 (45nM)  
Figure 4.2.1-a. Chemical structures including functional activity at mGluR1 of reference 
molecules  R-01-R-06 selected from the mGluR-data collection and used for the 
pharmacophore model. Molecules R-01 and R-03 closely resemble R214127, molecules R-05 
and R-06 are EM-TBPC analogues. R-02 is identical to R193548 and R-04 is identical to 
NPS 2390 (both Figure 2.2.1-a). 
 
Molecules R-01-R-03 present an almost identical scaffold, since it has proven in the past to 
be advantageous to use at least two molecules providing the same scaffold as starting point to 
perform a flexible overlay (Section 4.2.2). In this context, similarities of the reference 
molecules according to MACCS keys are given in Table 4.2.1-a. Molecules R-05 and R-06 
display the highest degree of structural similarity, whereas similarity between R-02 – R-03 is 
less pronounced. Overall, the similarity index is below 0.8, which is usually considered as an 
indication of different chemotypes [Matter, 1997; Martin et al., 2002].  
 
Table 4.2.1-a. Similarities of the six mGluR-data collection representatives. Values denote 
Tanimoto coefficient of MACCS similarity. 
Number 
MACCS 
Similarity 
to R-01 
MACCS 
Similarity 
to R-02 
MACCS 
Similarity 
to R-03 
MACCS 
Similarity 
to R-04 
MACCS 
Similarity 
to R-05 
MACCS 
Similarity 
to R-06 
R-01  1  0.457 0.614 0.442 0.258 0.304 
R-02  0.457  1  0.674 0.316 0.292 0.346 
R-03  0.614 0.674  1  0.318 0.275 0.345 
R-04  0.442 0.313 0.318  1  0.362 0.380 
R-05  0.258 0.292 0.275 0.362  1  0.765 
R-06  0.304 0.346 0.345 0.380 0.765  1 
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4.2.2 Creating  the  Pharmacophore Model 
After generating 3D structures for all molecules using a favored force field for small 
compounds (MMFF94) [Halgren, 1996], molecules R-01 and R-02 were superimposed in a 
flexible manner using the Flexible Alignment tool included in the MOE software package 
Version 2003.02 [Chemical Computing Group] according to the following settings (Iteration 
limit: 200 attempts; Failure limit: 20 configurations in a row; Energy Cutoff: 10.0 energy 
value plus the minimum generated value; Configuration limit: 1000 alignment configurations; 
Alpha: 2.5; Gradient Test: 0.01; RMSD Tolerance: 0.5Å; Maximum steps: 500 energy 
minimization steps; Similarity Terms: H-bond Donor/Acceptor (1/1), Aromaticity (3), 
Acid/Base (1), Hydrophobe (1), Polar Hydrogens (1), Volume (3)) . Several orientations have 
been calculated including their corresponding energy values. One orientation with a low 
energy value and a reasonable overlay (i.e., the most complete overlay with respect to the core 
structures) was manually selected and both molecules were kept in a fixed position relative to 
each other for further alignments. In the next step, molecule R-03 was superimposed onto this 
orientation and a sensible overlay was saved and fixed for the next alignment procedure. 
Eventually, the remaining three structures were aligned one after the other on this orientation 
resulting in a final alignment for allosteric mGluR1 antagonists (Figure 4.2.2-a). Alignment 
settings remained unchanged throughout the whole process. 
 
 
Figure 4.2.2-a. Flexible alignment of reference compounds R-01-R-06 (hydrogen atoms not 
shown). 
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A pharmacophore hypothesis was established based upon this flexible overlay using the 
Pharmacophore Query Editor of the MOE software. This tool displays certain chemical 
properties (H-bond donor/acceptor, etc.) of non-hydrogen atoms of each molecule to be 
edited, which are here referred to as annotation points (a complete list is given in the 
Appendix, Table 7.2-a). A pharmacophore scheme defines how each ligand in the database to 
be searched is annotated. Depending on the selected pharmacophore scheme, lipophilic or 
aromatic properties of ring systems, for instance, can be displayed either for each carbon atom 
of the corresponding ring (Planar-Polarity-Charge-Hydrophobicity; PPCH-type) or by one 
annotation point for the whole ring located in its center (Polarity-Charge-Hydrophobicity; 
PCH-type). For this model the default PCH-type was employed. Here, annotation points of 
the same label, which occur in all reference molecules at nearly the same spatial position were 
presumed to be important, for instance item F2:Acc in the lower left part of Figure 4.2.2-b. 
Query features were then assigned to these important annotation points (Figure 4.2.2-b). 
 
F1: Acc
F2: Acc F3: Aro
F4: Aro|Hyd
F5: Aro
F6: Hyd
F1: Acc
F2: Acc F3: Aro
F4: Aro|Hyd
F5: Aro
F6: Hyd
 
Figure 4.2.2-b. Preliminary pharmacophore hypothesis and underlying reference alignment 
for non-competitive antagonists of the mGlu1 receptor (H-atoms were hidden for more 
clarity). Small and solid balls in various colors according to their properties indicate the 
automatically proposed annotation points. Light blue spheres denote manually allocated query 
features for H-bond acceptors, light green spheres represent aromatic features and dark green 
spheres show hydrophobic query features. For details see text. 
 
A query feature denotes a point in space with a radius-like tolerance on spatial proximity 
and an associated expression. Expression and radius of each query feature were manually 
edited as follows: The expression corresponds to the annotation points found here (e.g., query 80 
feature  F4:Aro|Hyd in Figure 4.2.2-b denotes a region where aromatic and hydrophobic 
labeled annotation points were found). The diameter of each tolerance radius was chosen 
sufficiently large to cover identical annotation points of every molecule in that region.  
Constraints and partial matches (both are options within the Pharmacophore Query Editor) 
have not been applied to the initial pharmacophore model. A constraint groups query features 
that tie the required presence of one feature to the presence of another feature. A partial match 
in turn allows a certain degree of violations within a constraint (e.g., a constraint of three 
query features combined with a partial match of at least one query feature means that at least 
one of these three queries must be matched irrespective which of them).  
The preliminary pharmacophore hypothesis contains six query features assumed to play an 
important role (Figure 4.2.2-b). Excluded volumes, which denote spheres that must not 
contain any non-hydrogen atom of a ligand to be aligned have not been allocated. 
 
4.2.3 Validation 
Prior to performing a pharmacophore search on an external compound library the 
preliminary model had to be assessed for its validity. Therefore, a set of ten 3D-conformations 
was calculated for each molecule of the mGluR-data collection using MOE Conformation 
Input (10 conformations, no input filters (physicochemical properties) but default Constraints; 
MM Settings (default): Stochastic Search Strain Limit: 7, Superpose RMSD Test: 0.15, 
Refinement Conformation Limit: 300, Stochastic Search Failure Limit: 30, Stochastic Search 
Iteration Limit: 500, Energy Minimization Iteration Limit: 200, Energy Minimization 
Gradient Test: 0.01).  
The mGluR-data collection was then virtually screened by employing the preliminary 
model and the aim was to retrieve as many of the 212 non-competitive mGluR1 antagonists as 
possible and as few other data collection members as possible. In general, an automatic 
pharmacophore search can be described as follows: When a new ligand is aligned with the 
query set, its ligand annotation points will match the given query feature only if the points lie 
within the specified radius of the query feature and if its set of attached labels satisfies the 
expression associated with the feature. 
After a first pharmacophore search of the mGluR-data collection certain settings of the 
query set were slightly changed in order to optimize the screening results. This was an 
iterative process where only one parameter was manually modified in each step. However, no 
crucial modifications have been done like removing or adding essential query features. 
Mainly, the radius-like tolerance of a query feature was enlarged or reduced.  Scaffold Identification 
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Visual inspections of the first pharmacophore search results revealed that many mGluR1 
antagonists being members of the mGluR-data collection failed to match the query set since 
their structures did not satisfy all query features allocated to the pharmacophore model. To 
circumvent this pitfall initially all query features were tied together to one constraint and a 
partial match was introduced. During the iterative validation process one or two query 
features were alternately removed from the constraint or incorporated into it and the partial 
match restriction was changed accordingly.  
 
Table 4.2.3-a. Distribution of the mGluR-data collection and the mGluR1-enriched subset 
after the pharmacophore search. 
Target  mGluR-data collection Retrieved subset
Negative allosteric modulators of mGluR1 212  69 
Positive allosteric modulators of mGluR1  19  5 
Negative allosteric modulators of mGluR5 125  2 
Positive allosteric modulators of mGluR5  1  - 
 
The validation process was terminated after roughly ten steps when no further enrichment 
in the subset of correctly retrieved mGluR1-reference compounds was yielded (Table 4.2.3-a). 
The results illustrate a successful performed search, which is confirmed by an enrichment-
factor ef of 1.53 (Equation 1.5.2-b). Interestingly, a fourth of all positive mGluR1 modulators 
has also been extracted, whereas less than 2% of all mGluR5 antagonists matched the 
pharmacophore model’s queries. Only a third of all target compounds (69 of 212) has been 
correctly classified, which impairs the model to a certain extent as it does not retrieve all 
chemotypes of the reference molecules. This is caused by the fact that only a small selection 
of the many different scaffolds of mGluR1 antagonists was considered in the molecule 
alignment. The integration of additional scaffolds would most likely have led to an impaired 
molecule alignment (less overlay) and consequently to a less precise pharmacophore model. 
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Figure 4.2.3-a. Final pharmacophore hypothesis and underlying reference alignment for non-
competitive antagonists of the mGlu1 receptor (H-atoms not shown). Light blue spheres 
denote query features for H-bond acceptors, light green spheres represent aromatic features 
and dark green spheres show hydrophobic query features. 
 
The final hypothesis still contained the initial six query features that were assumed to best 
describe the properties of potential allosteric mGluR1 modulators (Figure 4.2.3-a, Table 
4.2.3-b). Eventually, query features F1, F2, F3 and F5 were tied together in a way that at least 
three of them had to be matched by a newly aligned ligand (i.e., queries F4 and F6 had to be 
satisfied by all means). 
 
Table 4.2.3-b. Collection of all relevant features for the final pharmacophore hypothesis. 
Code Feature  Description  Radius [Å]
F1 Acc  H-bond  acceptor  0.9 
F2 Acc  H-bond  acceptor  1.0 
F3 Aro  aromatic  system  1.0 
F4 Aro|Hyd  either  aromatic or hydrophobic system  1.2 
F5 Aro  aromatic  system  1.1 
F6 Hyd  hydrophobic  residue  1.2 
C1  Constraint  matching at least three features of F1, F2, F3, F5   - 
 
Based upon iterative validation steps the crude, preliminary pharmacophore hypothesis was 
refined leading to an improved final pharmacophore model: The manually compiled mGluR-
data collection served as reference dataset comprising “active” (negative mGluR1 
antagonists) and “inactive” (others) members for retrospective analyses. However, we did not Scaffold Identification 
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perform retrospective virtual screenings on a large dataset of many thousand “inactive” 
members spiked with some “actives”. The reason can be found in a drawback associated with 
datasets containing numerous “inactive” (better: negative) compounds: We know that 
“inactive” members of our mGluR-data collection are definitely inactive mGluR1 antagonists, 
which has been experimentally proven (according to literature). In contrast, the tremendous 
number of “negative” members of large datasets is usually randomly selected from even 
larger databases but not tested on the target of interest. 
 
4.2.4 Conclusions 
The proposed final pharmacophore hypothesis for non-competitive mGluR1 antagonists 
(Figure 4.2.3-a) was capable of selectively retrieving allosteric mGluR1 modulators of the 
mGluR-data collection during a validation step of retrospective screening. This hypothesis 
was established to recover negative mGluR1 modulators listed in the reference collection 
(32.5% of them have been correctly identified), yet it also identified five of nineteen positive 
mGluR1 modulators (~26%) from the reference mGluR-dataset.  
  
4.3  Virtual Screening by CATS Similarity Search  
A topological pharmacophore search based upon an atom-pair descriptor and the Euclidian 
distance measure is provided by CATS [Schneider et al., 1999]. It allows for rapidly 
screening even largest compound libraries with a speed nearly comparable to simple 
substructure searches. The notable advantage of CATS and related molecule descriptors is, 
however, that molecules might be retrieved or designed bearing core structures unlike the 
structures of the reference molecules [Schneider et al., 1999; Nærum et al., 2002]. Here, the 
rationale was to retrieve molecules from the Asinex Gold Collection February 2003 [Asinex 
Ltd.] that are similar - according to the CATS atom-pair descriptor - to a set of six reference 
compounds. In this study we employed as reference compounds the same six molecules that 
were used for setting up the pharmacophore model for mGluR1 antagonists (Figure 4.2.1-a).  
 
4.3.1  Reference Compounds and Test Compounds 
Test compounds as well as reference compounds were encoded with the CATS atom-pair 
descriptor (Section 3.2.1) as follows: 2D structures of test and reference molecules were saved 
as MDL MOL-file and all hydrogen atoms were removed using CLIFF software [Molecular 84 
Networks GmbH]. Distance (Euclidean metric) calculation was restricted to 10 (0 to 9 bonds) 
intervening bonds resulting in a 150-dimensional correlation vector representation for each 
molecule (10 bonds multiplied with 15 possible atom-pairs). This vector was scaled to relative 
counts (S2). 
Here, six separate similarity searches were carried out: Each reference compound served as 
query structure for one search process, and the remaining five molecules were merged with all 
compounds of the Asinex Gold Collection 2003 (Section 3.2.6). This database “spiking” was 
done to get an idea of the relevance of the obtained virtual hit lists [Schneider & Schneider, 
2004]. For each run the CATS-software was prompted to create a ranked list for the 100 most 
similar molecules (according to the CATS descriptor) of the “spiked” database. Hence, we 
obtained six top 100 ranking lists (Appendix, Section 7.3). The first five test compounds of 
each list as well as all test compounds, which occur in at least three top 100 scoring lists 
simultaneously, were purchased and their pharmacological profile (mGluR1 binding assay, 
mGluR1 functional assay) was characterized.  
 
4.3.2 Results  of  the CATS Similarity Searches and Discussion 
Regarding the first five test molecules of each list four molecules appeared twice in 
different top five scoring lists (6 lists multiplied with 5 entries leading to 30 test molecules 
minus 4 doubles: 26 selected compounds). Additionally, twelve test compounds appeared in 
three different scoring lists among the first hundred compounds. The fact that they occurred 
solely in the scoring lists of reference compounds R-01-R-03 can be explained by the degree 
of similarity of compounds R-01-R-03  according to MACCS keys and CATS similarity 
(Table 4.2.1-a, Figure 4.3.2-a), which consequently also applies for the members of their 
scoring lists. In accordance to this observations, reference compounds R-01, R-02 and R-03 
appeared among the top 100 scoring lists of each other (e.g., R-02 is ranked as number one 
and R-03 as number 58 among the first 100 entries for R-01´s similarity search; Appendix, 
Table 7.3-a).  
In total, 38 compounds were found in the Asinex Gold Collection and ordered, but only 23 
of them were delivered (Table 4.3.2-a). Compound C-23 has accidentally been ordered and 
delivered although it was retrieved only by the first and second CATS run (reference 
molecules  R-01 and R-02) among the top 100 molecules. A detailed overview about all 
ordered and delivered compounds of this study is given in the Appendix, Section 7.3. 
 The structural similarity between the seed compounds R-01-R-03 and the test compounds 
C-05, C-19 and in particular C-20 was confirmed by the similarity values (Table 4.3.2-a). Scaffold Identification 
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Visual inspection detected also similarity between R-04 and test compound C-08: Both 
molecules have similar scaffolds with two H-bond acceptors (nitrogens were replaced with 
oxygens), the same polar linker and hydrophobic moieties of comparable size (Figure 4.2.1-a, 
Table 4.3.2-a). The vast majority of test compounds is, however, structurally distinct from the 
reference compounds.  
 
Table 4.3.2-a. Retrieved (available) test compounds of the output of six separate CATS runs. 
The number of a CATS run corresponds to the reference compound’s ID this search was 
based on (e.g., for CATS run 1: R-01). Similarity Score indicates the Euclidean distance 
between reference and test molecule. Experiments were performed in quadruplicate (binding) 
or sextuplicate (fct.), respectively. 
CATS 
Run  Rank 
Similarity 
Score 
Chemical Structure Number Binding 
Ki [µM] 
Functional 
IC50 [µM] 
1 3  0.3986 
2 2  0.3671 
N
O
N C-01  >40 
7.9 
(± 2.5) 
1 4  0.4144  NC l
O
S
 
C-02  >40 
20.8 
(± 0.8) 
1 5  0.4279 
2 5  0.4031 
O
N O
 
C-03  >40 >40 
1 6  0.4279 
2 6  0.4031 
O
O O
 
C-04  >40 
18.9 
(± 3.0) 
3 1  0.2863 
O
O
O
 
C-05  >40 >40 
3 2  0.3369 
BO
O F
O
F C-06 
25.3  
(± 5.1) 
13.5 
(± 7.0) 
3 3  0.3470 
O OO
Cl
 
C-07 
0.75  
(± 0.05) 
0.36 
(± 0.03) 
4 2  0.3401  N
H
O
O
O
 
C-08  >40 >40 86 
4 3  0.3616 
N N
N
H
O
F
F
F
C-09  >40 >40 
5 1  0.7360 
N
N N
N
H
N N
OH
 
C-10  >40 >40 
5 3  0.8153 
N
N N O
N
H OH
 
C-11  >40 >40 
6 1  0.5254 
N N
OH
O
F
F
F
 
C-12  >40 
29.1 
(± 3.7) 
6 3  0.5640 
N N
N
OH  
C-13 
21.6  
(± 3.6) 
12.9 
(± 1.0) 
6 4  0.5804 
N N
OH
O
F
F
F
 
C-14  >40 >40 
1 75  0.5670 
2 54  0.5313 
3 91  0.4568 
N
O
O
 
 
C-15  >40 >40 
1 65  0.5511 
2 59  0.5364 
3 16  0.3886  S
O
O
O
 
C-16  33.8 
17.3 
(± 0.9) 
1 74  0.5666 
2 29  0.5014 
3 76  0.4505 
N O
O
 
C-17  >40 
20.9 
(± 1.6) 
1 100  0.5847 
2 66  0.5445 
3 40  0.4200 
N
O
O  
C-18  >40 >40 
1 8  0.4569 
2 8  0.4312 
3 38  0.4187 
O
O
F
 
C-19  >40 
23.8 
(± 3.3) 
1 24  0.5031 
2 10  0.4405 
3 46  0.4280 
O
O
F
 
C-20  >40 
17.2 
(± 4.7) Scaffold Identification 
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1 77  0.5684 
2 41  0.5114 
3 72  0.4495  O N
O
Cl
 
 
C-21  >40 
13.2 
(± 4.1) 
1 32  0.5196 
2 18  0.4763 
3 95  0.4570 
S
O
O  
 
C-22  >40 
11.1 
(± 3.0) 
1 38  0.5275 
2 99  0.5711 
O
O
N
F
C-23  9.3 >40 
 
The occurrrence of test molecules representing structurally distinct chemotypes (with 
respect to the reference molecules) might be explained due to the fact that non-hydrogen 
atoms of the molecules are classified into five generalized atom types for this study, meaning 
that molecules with the same atom types (e.g., H-bond donor) but not necessarily with the 
same atom (e.g., a hydroxyl group could be replaced with a thiol) within a given bond 
distance are assumed to be similar. Moreover, since the distance counted between two atom 
types solely depends on the absolute number intervening of bonds, the spatial distance could 
vary to some extent depending on the bond length, the bond angle and whether or not the 
bond is rotatable (Figure 4.3.2-a). 
O
N
O O O
N
Spatial distance: ~1.3 Å Spatial distance: ~5.0 Å
180°
 
Figure 4.3.2-a. Sketch of two hypothetical 3D-arrangements of a sample molecule (here: 3-
Pyridin-2-ylmethyl-pyran-2-one). In both orientations the bond distance between carbonyl-
oxygen and nitrogen (both H-bond acceptors) is five (CATS atom-pair: AA5). The calculated 
spatial distance between both features, however, increases from the left to the right molecule 
arrangement. 
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Consequently, a given test compound could resemble a particular seed compound regarding 
potentially important interacting points but the possible difference in the spatial orientation of 
these pharmacophore features could lead to a change or even a loss of binding affinity and 
functional activity. 
 
Affinity and activity of compounds C-01-C-23 has been characterized using mGluR1 
binding and functional assays. First, single concentration determinations were carried out in 
both assays in order to roughly classify a given compound as a high (Ki or IC50: < 1µM), 
medium (Ki or IC50: < 15µM), low active (Ki or IC50: 15 - 40µM) or inactive (Ki or IC50: > 
40µM) candidate rather than to reflect its precise activity value for structure activity 
relationships. The correlation between estimated IC50-values via a single point measurement 
and determined IC50-values for a certain concentration range were given in Section 3.1.11. In 
general, all test compounds showing baseline corrected values from >80% (~40µM) were 
assumed to be inactive (Section 3.1.11). Full CRCs were only recorded for those compounds 
displaying  IC50-values below 10µM due to limited solubility. Table 4.3.2-a reveals the 
antagonistic activity of all test compounds. Results are given as mean values of two 
independent experiments performed in quadruplicate (binding) or sextuplicate (functional), 
respectively. Asterisks denote values determined by full CRCs. In total, one compound was 
found to be “highly active” (IC50: < 1µM) and five compounds were “moderately active” with 
IC50-values between 1-15µM in functional assay (Figure 4.3.2-b). Furthermore, eight 
compounds revealed a low activity (IC50: 15 – 40µM) and nine compounds were inactive 
(IC50: > 40µM) leading to a total hit rate of approximately 26 % (IC50: < 15µM).  
It must be emphasized that such a small subset of virtual hits (here: 23 compounds) hardly 
allows for giving reliable (i.e., precise) information in terms of hit rates for a given task. This 
applies for all methods where only a limited number of test compounds was retrieved, ordered 
and assayed. 
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Figure 4.3.2-b. Graphical summary of the screening results (rmGluR1 functional assay) of 23 
hit compounds retrieved from the Asinex Gold Collection by the CATS similarity search. 
 
The test compounds elicited predominantly low activity at the receptor except for molecule 
C-07. In contrast, the six seed compounds that were used for the similarity search in this study 
are of extremely high potency (Figure 4.2.1-a). However, similarity searches aim at 
discovering new core structures (“scaffold-hopping”), which does not necessarily mean that 
these ligands perfectly fit into the binding pocket. New chemotypes can be structurally 
optimized afterwards. 
We focused on compound C-07 that was found to bind to the allosteric site of the mGlu1 
receptor with an IC50-value in the nano molar range and significantly inhibits DHPG-induced 
receptor activation (Figure 4.3.2-c). Moreover, compound C-07 seems to selectively interact 
with mGluR1 since no affinity towards mGluR5, the closest related subtype according to 
sequence similarity, was observed (Figure 4.3.2-d).  
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Figure 4.3.2-c. Compound C-07 is a non-competitive antagonist of the mGlu1 receptor. It 
displaces [³H]-EMQMCM binding to the allosteric mGluR1 site with an Ki-value of 0.753µM 
(A, SEM: 0.048) and inhibits DHPG-induced intracellular IP3-formation with an IC50-value of 
0.362µM (B, SEM: 0.031). Results are the mean values of two independent experiments 
performed in quadruplicate (binding) or sextuplicate (functional), respectively. 
 
 
 
Figure 4.3.2-d. Compound C-07 does not displace [³H]-MPEP (5nM) binding to the allosteric 
site of the mGlu5 receptor (A) nor does it significantly inhibit quisqualate induced 
intracellular Ca
2+ release in rat cortical astrocytes (B, for detailed experimental procedures see 
Section 3.1.4 and 3.1.8). Results are the mean values of two independent experiments 
conducted in duplicate (MPEP binding) or quintuplicate (Ca-flux). Error bars denote SEM.  
 
Apart from the promising pharmacological data the chemical structure of molecule C-07 is 
attractive since to the best of our knowledge no interaction with family 3 GPCRs has been 
reported for any coumarine-derivatives to date. The most prominent coumarine-derivatives 
phenprocoumon and warfarin are well known drugs acting as indirect anticoagulants due to 
interfering with the vitamin-K synthesis. They are used for the prophylaxis of thrombosis and Scaffold Identification 
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embolism in many disorders. The therapeutic potential of other coumarines like scoparone 
(reduces total cholesterol and triglycerides), osthole (causes hypotension in vivo, inhibits 
platelet aggregation in vivo) and cloricromene (reveals antithrombotic antiplatelet actions, 
causes vasodilatation) has been reviewed [Hoult & Paya, 1996]. Since some 3,4-
dimethylcoumarines like esuprone inhibit either monoamine oxidase type A or B the 
treatment of epilepsy by representatives of this chemical class has been discussed [Loscher et 
al., 1999]. Coumarine-derivatives were hereby introduced as potential drug candidates to the 
therapy of mental disorders connected with mGlu1 receptor interaction. 
 
4.3.3 Conclusions 
In this study we have performed similarity searches based on a topological pharmacophore 
descriptor for six reference compounds on a large and diverse database. A set of 23 test 
compounds showing high similarity towards the reference compounds was selected and 
assayed for affinity and functional activity at mGluR1. All compounds selectively interacted 
with mGluR1 as they did not evoke any response on the closely related subtype mGluR5. An 
overall hit rate of 26 % (activity < 15µM) demonstrated the applicability of this concept. One 
compound, structurally belonging to the chemical class of coumarines, exhibited binding 
affinity and functional activity at mGluR1 below 1µM. 
 
4.4  Data mining by ChemSpaceShuttle  
ChemSpaceShuttle (CSS) is an application that facilitates the reduction of a multi-
dimensional space to a 3D-representation [Givehchi et al., 2003] (Section 1.5.3, Section 
3.2.3). Noteworthy, this data mining application is not a SAR tool since the network training 
algorithm does not implement any biological data like activity or affinity. It allows for 
revealing hidden relationships within a large set of molecular data and gives an overview over 
the occupied and unoccupied chemical space. Thus, commercial databases can be analyzed 
with respect to their molecular distribution which in turn facilitates the design of activity-
enriched subsets. The rationale of CSS within this study was to select a few virtual hits from a 
potentially activity-enriched library (here referred to as “focused library”). This “cherry-
picking” procedure was part of a virtual screening campaign. 
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4.4.1  Compilation of a focused library 
The idea was to visualize not the total compound library but a single subset. Thus, a 
“focused library” was compiled by performing a pharmacophore search as follows: The 
complete Asinex Gold Collection February 2003 [Asinex Ltd.] was virtually screened with 
the final pharmacophore model for non-competitive mGlu1 receptor antagonists (Figure 
4.2.3-a). This searching process was carried out by running the Pharmacophore Search tool 
of the MOE software package Version 2003.02 [Chemical Computing Group]. The following 
settings were applied: Asinex database (single conformation for each molecule) was specified 
as input database. It was preprocessed to make searching faster: For each database entry an 
annotation field (pharmacophore scheme: PCH; Section 4.2.2) was automatically calculated. 
The refined pharmacophore model (Section 4.2.3) was specified as query set. The search tool 
was prompted to create a new output database, containing the same indication fields (e.g., 
molecule and ID) as the input database.  
The search resulted in a subset A of 3137 virtual hits, retrieved from a total number of 
194104 molecules out of the Asinex database. Next, subset A as well as the mGluR-data 
collection were characterized by two 2D-descriptors implemented in MOE, namely SlogP and 
Weight. According to the Gaussian-like distribution of the reference compounds of the 
mGluR-data collection (Figure 4.4.1-a), a range of descriptor values restricted by defined 
thresholds for both descriptors was set for all entries in subset A: 
 
Lipophilicity (SlogP):   lower threshold = 0, upper threshold = 6 
Molecular weight (Weight):  lower threshold = 230, upper threshold = 500 
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Figure 4.4.1-a. Distribution pattern for molecule weight and lipophilicity of the mGluR1-data 
collection (212 members). Values are binned into ranges of 10 unit size (MW) or 0.2 unit size 
(SlogP), respectively. Scaffold Identification 
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As it turned out that nearly all reference compounds exhibited values to be found within the 
proposed threshold ranges, subset A was narrowed down to the “focused library” by removing 
all test compounds eliciting values beyond the given parameter range (i.e., exceedingly high 
or low MW and poor lipophilicity) irrespective of the original distribution patterns of subset A 
(Figure 4.4.1-b). The bell-shaped distribution for the test compounds was shifted to the right if 
compared with the reference compounds. Approximately one third of all test compounds (926 
of 3137 or 29.5%) did not match the defined criteria, which is also demonstrated by the 
distribution patterns for test molecules (Figure 4.4.1-b). 
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Figure 4.4.1-b. Distribution pattern for molecule weight and lipophilicity of subset A (3137 
members). Dashed lines border the range for molecules of the “focused library”. Values are 
binned into ranges of 10 unit size (MW) or 0.25 unit size (SlogP), respectively. 
 
4.4.2  Processing the Data 
All molecules of the focused library (2211 members) as well as the “washed” mGluR-data 
collection (negative allosteric modulators of mGluR1 and –5; positive modulators were 
discarded; 337 members) were encoded with all 146 2D-descriptors provided by MOE. Non-
relevant descriptors (i.e., descriptors displaying the same value for all reference compounds) 
were removed resulting in 130 2D-descriptors. Potentially redundant descriptors have been 
retained. Reference compounds were classified as “R-1” or “R-5”, respectively and test 
compounds as “unknown” without changing the original ID number. After transforming both 
datasets into tab-separated text files, the mGluR-data collection was imported in 
ChemSpaceShuttle, a weight optimization was performed in the training mode and the three 
principal components were calculated and visualized in the projection mode (Figure 4.4.2-a). 
The scatter plot demonstrates that this method allows for discriminating between “R-1” and 
“R-5” compounds: “R-5” compounds form a sharply defined cluster pointing to the upper 94 
background. All members of this cluster belong to the same chemical class of modulators. In 
contrast, “R-1” compounds are predominantly located in the upper foreground apart from 
some widely distributed molecules in the lower front. However, both groups of modulators 
are not completely spatially separated as they partly overlap with each other. Especially the 
main cumulation of “R-1” compounds is spotted with several “R-5” molecules. 
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Figure 4.4.2-a. 3D-Plot displaying the distribution of reference compounds. Factors X, Y and 
Z represent the principal components calculated from the multidimensional space. 
 
In the next step, reference compounds were plotted together with all test members of the 
focused library (Figure 4.4.2-b). Compared to the reference compounds test molecules cover a 
large area where they are mainly located in one prolate cluster. However, they do not extend 
to all regions occupied by the reference compounds, which is most likely due to the limited 
number of subset members. Therefore, not the total space, which is covered by the reference 
molecules can be exploited for analysis (i.e., the distance dependent detection of test 
molecules, vide infra). 
 Scaffold Identification 
 
95  
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
-0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4
F
a
c
t
o
r
 
Z
Factor X
Factor Y
mGluR1-antagonists
mGluR5-antagonists
focused library compounds
 
Figure 4.4.2-b. 3D-Plot displaying the distribution of reference compounds and test 
compounds. Factors X, Y and Z represent the principal components calculated from the 
multidimensional space. 
 
Since these three-dimensional plots provide topology-preserved mappings, compounds 
which are close to each other on this grid are also assumed to be in close proximity in the 
original multidimensional space. Consequently, they are assumed to bear similar properties 
with respect to the descriptors they are encoded with. Therefore, a radius-like distance 
tolerance (marked distance) was applied for all “R-1” compounds to detect adjacent 
compounds within this certain range irrespective of their type (Figure 4.4.2-c). In some 
densely populated regions many compounds were detected by a single “R-1” compound. In 
contrast, some of the widespread reference molecules (in the lower right corner on Figure 
4.4.2-c) were not able to find any molecules within the defined distance. 96 
 
Figure 4.4.2-c. Original 3D-Plot visualized in CSS (display detail). White spots denote 
mGluR1 reference compounds, green spots are test compounds and other reference 
compounds. White lines represent the three axes spanning the coordinate system. Green lines 
represent the distance between the mGluR1 reference compounds and their neighbors within a 
marked distance in the 3D space. 
 
All molecules located within this radius were listed in a tab-separated text file and reference 
compounds labeled with “R-1” and “R-5” were removed. The remaining 46 test molecules 
were then sorted according to their distance to the corresponding reference compound and 30 
compounds displaying the lowest distance-value were selected. After visual revision, eighteen 
of those were ordered from the database vendor [Asinex Ltd.]. 
 
4.4.3  Results of the Neighborhood Search and Discussion 
Fifteen virtual hits have been delivered as solids and tested in-house for binding affinity and 
functional activity on mGluR1. The chemical structures and a list of all ordered and delivered 
compounds can be found in the appendix (Section 7.4). Summarized, no compound was found 
to be “highly active” (<1µM), three compounds were “moderately active” with IC50-values 
between 1-15µM in functional assay (Figure 4.4.3-a). Furthermore, two compounds revealed Scaffold Identification 
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a low activity (15 – 40µM) and ten compounds were inactive (>40µM) leading to a total hit 
rate of  20 % (cut off <15µM). 
 
Table 4.4.3-a. Overall result of in vitro pharmacological experiments for all test compounds. 
Results are the mean values of at least two independent experiments performed in 
quadruplicate (binding) or sextuplicate (functional), respectively. Asterisks denote values, 
which were determined by full CRCs. Compounds with IC50-values higher than 40µM were 
assumed to be inactive. SEM are given in parentheses. 
Number Binding  Ki [µM]  Functional IC50 [µM] 
P-01  >40 >40 
P-02  >40 >40 
P-03  >40 >40 
P-04  21.9 (± 4.0)  >40 
P-05  >40 >40 
P-06  *33.27 (± 5.34)  *1.11 (± 0.41) 
P-07  >40 >40 
P-08  >40 >40 
P-09  >40  25.7 (± 1.6) 
P-10  >40 >40 
P-11  >40  12.9 (± 0.4) 
P-12  >40 >40 
P-13  >40  25.1 (± 2.5) 
P-14  *13.05 (± 0.94)  7.4 (± 0.5) 
P-15  >40 >40 
 
Compound P-06 was found to be the most potent molecule among all compounds of this 
subset. It structurally resembles the prominent negative allosteric modulator LY456066 
(Figure 4.4.3-a, Figure 1.4.2-a). The remaining compounds display poor, if any, functional 
activity and binding affinity.  
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Figure 4.4.3-a. Graphical summary of the screening results (rmGluR1 functional assay) of 15 
hit compounds retrieved from the Asinex Gold Collection by the 3D-pharmacophore searches 
combined with non-linear PCA (performed by CSS). 
 
Regarding the scaffolds most of  the structures closely resemble either LY456066 or 
R214147. This could probably have several reasons: The previously performed 
pharmacophore search retrieved a subset mainly comprising molecules structurally related to 
R214147 since the underlying pharmacophore alignment predominantly contains R214147 
derivatives. Second, due to the fact that the majority of reference compounds belongs to either 
groups many test compounds have been found being located within a marked distance of 
those reference molecules. Based upon this, we assumed that the chosen descriptors encode 
molecules in a way that mainly structures bearing the same scaffold are adjacently located (in 
the high- and low-dimensional space) and not molecules with similar features but different 
scaffolds. 
The low hit rates might be caused due to the following facts: (i) The high number of 
reference compounds revealing weak activity, (ii) test compounds were ranked, selected and 
ordered according to their distance to any reference compound, not just to the potent reference 
molecules and (iii) the focused library serving as test compound collection contained 
molecules with less structural diversity than the complete Asinex database. This loss of 
diversity was most likely attributed to the pharmacophore search based on a model that has 
proven not to match all chemotypes of mGluR1 antagonists during validation (Section 4.2.3). Scaffold Identification 
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One can conclude in turn that this pharmacophore model ignores several potential hits from 
the Asinex database. 
Moreover, the total amount of compounds retrieved by the pharmacophore search and 
analyzed by CSS was probably too low. Initially, the pharmacophore search was employed to 
reduce the amount of test compounds and to apply a “focused library” to CSS. After 
analyzing the results of the CSS run and visualizing the plot we observed that for many 
reference compounds no test compounds were found within the defined distance (Figure 
4.4.2-b). The application of the whole Asinex database for data mining by CSS would have 
solved probably the issues of (i) a too specific data subset (regarding chemical diversity) and 
of (ii) a too small subset not covering the whole space provided by the reference compounds. 
Furthermore, ranking criteria solely considering highly potent reference molecules combined 
with an increased marked distance for neighborhood search would have presumably enhanced 
the chance of detecting more promising structures.  
 
4.4.4 Conclusions 
The strategy for identifying novel scaffolds presented in this section aimed at combining the 
advantages of two methods: (i) The design of a potentially activity-enriched subset from a 
large library by pharmacophore search and (ii) the retrieval of some “virtual hits” from this 
subset via a data mining tool suitable to reduce and visualize the data distribution. Since the 
focused library comprised too many compounds to manually select some of them for follow-
up (i.e., order and assay), it was decided to apply the “filter” presented in this section to 
minimize the subset. We recovered a set of 18 molecules from the focused library. This set 
was ordered and the delivered 15 compounds were tested on binding affinity and functional 
activity on mGluR1. One molecule revealed inhibitory activity of 1.1µM (Ki-value). 
 
4.5  Virtual Screening using Self-Organizing Maps  
SOMs or Kohonen-networks -- describing a certain type of unsupervised neural networks -- 
are predominantly applied for molecule clustering and topology preserving projections. They 
allow for designing focused libraries of ligands affecting a given target [Schneider & 
Nettekoven, 2003]. Consequently, they are understood more as an application to assist and 
support a given virtual screening campaign rather than as a virtual screening tool itself.  100 
Once again the Asinex Gold Collection February 2003 [Asinex Ltd.] was employed as 
source for retrieving molecules potentially interacting with the allosteric mGluR1 binding 
site, whereas the COBRA database [Schneider & Schneider, 2003] was used to unfold and 
train a SOM and the mGluR-data collection contained the necessary reference molecules. The 
CATS atom-pair descriptor was applied to encode all compounds for the network. The aim 
was to create and visualize 2D-distribution patterns for mGluR1 and mGluR5 antagonists, 
which should facilitate a clear discrimination between ligands of both subtypes. Based upon 
two-dimensional mappings of the Asinex database activity-enriched subsets should be 
retrieved from this database and tested afterwards for affinity and activity on the mGlu1 
receptor.  
 
4.5.1  Training the Maps 
The first step of this virtual screening procedure was the conversion of all molecules of the 
three different datasets into a 150-dimensional vector representation using the CATS 
topological pharmacophore descriptor. Thereafter, a SOM was developed based on the 
COBRA database that means the 150-dimensional space was mapped onto a plane by 
applying a slightly modified version of the Kohonen algorithm [Schneider & Schneider, 
2004]. Since the projection is topology-preserving, molecules, which are in close proximity 
on the two-dimensional projection, are also adjacently located in high-dimensional space 
(Section 1.5.3). Here, a SOM is composed of a grid of 100 (or 225) neurons, each of which 
containing molecules having certain pharmacophore features in common. The map was 
visualized according to the density value of each neuron meaning the number of molecules to 
be included in a certain neuron (Figure 4.5.1-a). As it can be seen, the molecular distribution 
is more or less consistent apart from some highly occupied clusters close to neurons with low 
density. Only 1% (2.7%) of all neurons is unoccupied demonstrating a successfully trained 
and unfolded SOM. 
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Figure 4.5.1-a. Self-organizing maps showing the distribution of the COBRA database 
molecules in CATS topological pharmacophore space according to the density values of the 
neurons. 
 
Since this study aimed at detecting novel and selective allosteric antagonists of the mGlu1 
receptor the selectivity aspect was firstly investigated, meaning the discrimination between 
molecules acting on mGluR1 and mGluR5. Here, the main question was whether it is possible 
to separate between non-competitive antagonists of mGluR1 and mGluR5. In this context, the 
mGluR dataset was projected onto the smaller SOM (10x10 grid) developed before. Then, the 
map was visualized according to the mGluR subtype selectivity of each compound (Figure 
4.5.1-b). One large mGluR1 cluster in the upper right corner and two mGluR5 cluster were 
found, one in the upper center and the other in the lower right corner. Only six neurons (6%) 
contain molecules of both subtypes. However, it should be stressed that this particular 
visualization gives no hint about the molecular density of the neurons. Yet, the map 
demonstrated that one could successfully discriminate between molecules of each receptor 
subtype. This result substantiates earlier findings that both the CATS descriptor and the SOM 
procedure are suited for clustering compounds according to their pharmacological activity 
[Anzali et al., 1996; Polanski & Walczak, 2000; Schneider & Nettekoven, 2003; Teckentrup 
et al., 2004; Xiao et al., 2005]. 
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Figure 4.5.1-b. Self-organizing map showing the selectivity of the mGluR data collection 
molecules in the CATS topological pharmacophore space according to discrimination 
between subtype 1 and 5. Dashed arrows point to mGluR5 clusters and the black arrow to the 
mGluR1 cluster. 
 
In the next step only the mGluR1 subset of the mGluR data collection was mapped onto the 
SOM that was trained by the COBRA database. The map was once again visualized according 
to the density value of each neuron (Figure 4.5.1-c). Considering that these SOMs have a 
toroidal “donut-like” shape in the three-dimensional space, both of them (10x10 and 15x15 
grid) reveal one large cluster, one smaller cluster and several “activity islands” distributed 
over the whole map. The large cluster comprises derivatives of R214127, EM-TBPC, 
CPCCOEt and LY456066 (Figure 1.4.2-a). Neurons 8/7 and 6/6, respectively displayed the 
highest density of reference compounds. These are structurally related to some extend in the 
topological pharmacophore space. This mapping was necessary to detect those areas in the 
Asinex database where test compounds can be found with pharmacophore properties similar 
to those of the mGluR1 reference compounds (Section 4.5.2). 
 Scaffold Identification 
 
103  
 
Figure 4.5.1-c. Self-organizing maps showing the distribution of the mGluR1 dataset 
molecules in the CATS topological pharmacophore space according to the density values of 
the neurons. 
 
4.5.2 Selection  of Virtual Hits   
Finally, the complete Asinex Gold Collection was projected onto the SOM that was trained 
with the COBRA database. The map was visualized according to the density value of each 
neuron (Figure 4.5.2-a). Apart from one densely populated “receptive field” (neuron) the 
molecules of the Asinex library were consistently distributed over the whole space that was 
provided by the trained SOM. Only three neurons (1.3%) of the larger grid were unoccupied. 
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Figure 4.5.2-a. Self-organizing maps showing the selectivity of the Asinex database 
molecules in the CATS topological pharmacophore space according to the density values of 
the neurons. 
 
Since we were interested in those Asinex test compounds that bear topological 
pharmacophore features similar to those of the mGluR-reference data collection we focused 
on neurons 8/7 and 6/6, respectively displaying the highest density of mGluR-reference 
compounds on the mGluR1 map (Figure 4.5.1-c). In general, molecules included in neurons 
8/7 and 6/6 of the Asinex map were assumed to be similar to molecules incorporated in 
neurons 8/7 and 6/6 of the mGluR1 map. Neuron 8/7 (10x10 grid) comprised 1864 cluster 
members whereas 6/6 (15x15) contained 749 cluster members. All molecules that were 
represented by both maps (10x10 and 15x15) – altogether 407 -  have been selected and 
ranked by ascending order according to their distance to the centroid of neuron 6/6 (15x15). 
We selected this neuron and not neuron 8/7 of the small grid (10x10) as the large map 
provides higher resolution. A total of 29 compounds from the first 50 compounds being in 
closest proximity to the centroid were ordered from Asinex (a detailed list of the 50 best 
ranked compounds is given in the appendix, Section 7.5). 28 of them were delivered and 
tested in binding and functional assays of mGluR1 (Table 4.5.2-a). 
 
 
 
 Scaffold Identification 
 
105  
Table 4.5.2-a. Overall results of in vitro pharmacological experiments for all test compounds. 
Results are the mean values of at least two independent experiments performed in 
quadruplicate (mGluR1 binding assay) or sextuplicate (mGluR1 functional assay), 
respectively. Asterisks denote values which were determined by full CRCs. Compounds with 
IC50-values above 40µM were assumed to be inactive. SEM are given in parentheses. 
Number  Binding Ki [µM]  Functional IC50 [µM] 
S-01  >40 >40 
S-02  >40 >40 
S-03  >40  23.9 (± 1.2) 
S-04  >40  22.5 (± 7.3) 
S-05  *9.18 (± 1.08)  *1,71 (± 0.15) 
S-06  >40  *8.49 (± 0.62) 
S-07  >40 >40 
S-08  *9.93 (± 1.25)  *0.74 (± 0.29) 
S-09  *17.23 (± 2.14)  *2.97 (± 0.40) 
S-10  >40  14.8 (± 3.5) 
S-11  >40  25.7 (± 4.9) 
S-12  >40 >40 
S-13  >40 >40 
S-14  >40 >40 
S-15  >40 >40 
S-16  >40  9.0 (± 2.2) 
S-17  >40 >40 
S-18  >40  23.9 (± 0.9) 
S-19  >40 30.0 
S-20  >40 >40 
S-21  >40 >40 
S-22  >40 >40 
S-23  >40 >40 
S-24  >40  28.4 (± 3.9) 
S-25  >40 >40 
S-26  >40 >40 
S-27  >40 >40 
S-28  *36.16 (± 2.60)  *10.63 (± 1.80) 
 
Full CRCs were only recorded for those compounds displaying IC50-values below 10µM 
due to their limited solubility. Regarding functional activity values nearly half of molecules S-106 
01-S-28 reveal at least low activity. We achieved a higher hit rate than standard HTS. One 
compound (3.6%) was classified as “highly active” (>1µM), six compounds (21.4%) were 
“moderately active” (1-15µM), six compounds revealed low activity (15-40µM) and for 
fifteen compounds (53.6%) we observed “no activity” (>40µM) leading to a total hit rate of 
approximately 46% (<15µM). Concerning binding affinity values the majority of the 
compounds displays no affinity towards the allosteric site of the mGlu1 receptor. Two 
compounds (7.1%) were of “moderate affinity” (1-15µM) and two compounds exhibited “low 
affinity” (15-40µM), whereas the remaining 24 compounds (85.7%) showed “no affinity” 
(>40µM) towards the binding site. 
 
 
Figure 4.5.2-b. Graphical summary of the screening results (rmGluR1 functional assay) of 28 
hit compounds selected from the Asinex Gold Collection visualized by self-organizing maps. 
 
A detailed pharmacological profile has been created for molecules S-05, S-06, S-08, S-09 
and S-28, the five most active compounds. Full dose-response curves have been carried out in 
order to precisely determine affinity and activity values. Possible interactions of these 
compounds with the closely related mGlu5 receptor were also in our focus in order to evaluate 
their selectivity: All active compounds displayed no interaction with the allosteric binding site 
of mGluR5 (Figure 4.5.2-c) indicating that we have found selective allosteric mGluR1 
modulators. These findings correspond well with the predictions that were made before: 
According to Figure 4.5.1-b there is only few overlap between compounds of both mGluR 
subtypes and molecules S-05,  S-06,  S-08,  S-09 and S-28  were located in areas with no 
mGluR5 reference compounds. Scaffold Identification 
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Figure 4.5.2-c.  A: Compounds S-05,  S-06,  S-08,  S-09 and S0-28 are non-competitive 
antagonist of the mGlu1 receptor. They inhibit DHPG-induced intracellular IP3-formation 
with  IC50-values of 1.706µM (SEM: 0.1508µM), 8.488µM (0.6187µM), 0.744µM 
(0.2676µM), 2.973µM (0.4046µM) and 10.633µM (SEM 1.7972), respectively. Results are 
the mean values of two independent experiments performed in sextuplicate. B: Compounds S-
05, S-06, S-08, S-09 and S0-28 (10µM) do not displace [³H]-MPEP, binding to the allosteric 
site of the mGlu5 receptor (MPEP: 10µM). Results are the mean values of two independent 
experiments conducted in duplicate. Error bars denote SEM. 
 
4.5.3 Discussion 
Despite the fact that most of the reference compounds used for this study exhibited high 
potency, the corresponding test compounds were structural similar and elicited predominantly 
low inhibitory activity at the mGlu1 receptor. This discrepancy regarding the activity values is 
not surprising since virtual screening techniques mainly detect structurally new molecules 
with low rather than high activity. Nevertheless, the five outstanding compounds, S-05, S-06, 
S-08,  S-09 and S-28,  interacted subtype-selectively with the mGlu1 receptor, hence 
confirming the applicability of this method. Apart from compounds representing various 
different core structures, nearly half of all retrieved molecules (11 structures of 28, ~40%) can 
be assigned to one of two different scaffolds. They belong either to the 2H-Chromen-2-one 
derivatives, which can also be interpreted as coumarine analogues, or the 2-Chloroquinoline 
derivatives (Figure 4.5.3-a).  
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Figure 4.5.3-a. The two chemotypes found within the 28 virtual hits as exemplified by S-07 
(left) and S-05 (right), respectively. Red bonds and atoms represent the common scaffold. 
 
The chemical structures of all 28 molecules are given in the appendix. One promising 
coumarine derivative has also been found by the CATS similarity search (Section 4.3). The 
fact that all training and test molecules used within the CATS similarity search and for the 
Kohonen maps have been encoded with the same descriptor could serve as a reasonable 
explanation. In contrast to the 2-Chloroquinolines that closely resemble the R214127-
analogues (quinolines), a strategy of further optimizing the coumarine derivatives has been 
pursued (Section 5.3). 
 
4.5.4 Conclusions 
The rationale of the present campaign was to reduce molecule clusters – encoded with the 
CATS descriptor - from a multidimensional space to a 2D-representation and, thus, to detect 
hidden relationships between molecules of several classes (e.g., test compounds and reference 
compounds). Since the selectivity aspect plays an important role for group I mGluRs it was 
also inevitable for further analysis to prove whether or not our method allows to discriminate 
between ligands affecting either receptor subtype 1 or subtype 5. 
The complete Asinex database was employed for this study, which is in contrast to the 
previous concept based on ChemSpaceShuttle, where we performed data reduction and 
visualization on a “focused library” (Section 4.3). Here, a subset of 28 test compounds - 
comprising only two different chemotypes - was selected and assayed for binding affinity and 
functional activity on mGluR1 and nearly a half of them (13) evoked inhibitory activity below 
15µM. 
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5 Scaffold  Optimization 
In chapter 4 the application of virtual screening concepts like similarity searching (Section 
4.3) and SOM-based clustering (Section 4.5) to identify novel structures affecting the mGlu1 
receptor were proposed. Chemical classes were detected so far not associated with family 3 
GPCRs. In particular, coumarine derivatives introduced in Section 4.3 seemed to provide the 
most promising scaffold. The following chapter contains procedures that aimed at exploiting 
the results of the screening campaigns in terms of optimizing the detected coumarine scaffold 
with respect to activity and investigating a potential binding mode for quinolines (e.g., 
EMQMCM, R193845) by comparative molecular field analyses (CoMFA). The conclusions 
drawn from a reliable CoMFA model improved the understanding of the binding mode of 
coumarines. Furthermore, we introduced a simple yet effective method to predict potential 
cross-activities for a set of group I allosteric mGluR antagonists. Compound selectivities were 
predicted by self-organizing maps. Since selectivity plays a crucial role for potential drugs 
this procedure also pertains to the hit optimization process. 
Based on the detection of C-07, a promising mGluR1 antagonist, a hit optimization project 
was started (Section 5.3). Structure-Activity Relationships for coumarines were investigated  
Eventually, the hypothesized binding mode of two prominent chemotypes of allosteric 
mGluR1 antagonists – coumarines and quinolines - was discussed by means of a homology 
model for the transmembrane region of mGluR1 (Section 5.2.2).  
 
5.1  QSAR Studies on Quinoline Derivatives 
Conventional structure-activity relationships (SAR) will be applied based upon a large data 
set of coumarine analogues to emphasize the impact of this novel class of non-competitive 
mGlu1 receptor antagonists (Section 5.3). Quantitative structure-activity relationships for a 
chemical classes of negative allosteric modulators on mGluR1 will be reported within this 
section: Computer assisted comparative molecular field analyses (CoMFA) were employed to 
quantitatively describe the influence of a certain structure on bioactivity values for the 
prominent class of quinoline derivatives [Mabire et al., 2005].  
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5.1.1 Statistical  Evaluation of a CoMFA Model  
The structure-activity relationship of the quinolines exemplified for the potent molecules 
EMQMCM and its derivatives is probably one of the best-evaluated SAR and it represents an 
ideal data set to quantitatively describe this relationship and to obtain further insights into the 
binding mode of this group of ligands. A detailed SAR study has been reported [Mabire et al., 
2005] and based upon molecular structures and functional activity values (rmGluR1) included 
therein, QSAR analyses were conducted. Coumarines, structurally not resembling the 
quinolines, were assumed to bind to the same cavity like the latter group since they were 
found to selectively displace EMQMCM from its binding site within the transmembrane 
region of mGluR1 (Section 4.3.2, Figures 4.3.2-b and 4.3.2-c). Considerations regarding the 
alignment of EMQMCM as quinoline and B-04 as coumarine relative to each other will also 
be proposed (Section 5.4.2). 
The above-mentioned study of Mabire and co-workers contains 49 quinoline derivatives 
with a common core structure differing only in the nature and position of the attached 
substituent at the core scaffold. Initially, a preselection of the structure dataset was done as 
follows: Five compounds were removed from the subset since they were lacking precise 
bioactivity data. Another five molecules were discarded as they exhibited structural 
inconsistency with respect to other ligands. Thus, it was difficult to calculate reliable 
predictions since they pointed into spatial regions that were not covered by other molecules. 
The remaining 39 compounds formed the EMQMCM-data collection (Section 3.2.6) and were 
further subdivided into a training set (thirty entries) and a test set (nine entries) according to 
the following procedure: All molecules were sorted alphanumerically with respect to their ID 
values in ascending order. The first nine molecules denoted the test set and the remaining 30 
molecules the training set (Appendix, Section 7.6). We are well aware that this procedure is 
far from a random allocation and for statistical safety random classifications and analyses 
were performed as well (vide infra). Molecular flexible alignment and CoMFA studies were 
carried out as given in Section 3.2.4. 
The CoMFA study yielded a model with the following statistical parameters for the training 
set:  q²(cv)training gave 0.617 for nine components with a conventional non  cross-validated 
correlation coefficient r² of 0.991 and a SEP of 0.679. The estimated error SEE was 0.104 
with a relatively high estimated F-test value of 246.257. In general, higher r² and F-values 
indicate higher accuracy and in most cases a high q²(cv) corresponds to a low SEP. Sterical 
properties contributed with 59.2% to the model and electrostatic properties with 40.8%. 
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Figure 5.1.1-a. Graphic plotting the experimentally obtained bioactivity data (given as pIC50-
values) vs. the predicted data for the initial model where q²(cv)training was 0.62 and q²(cv)test 
was 0.60. Black circles denote the training set members and red circles the test set members. 
Training and test set are fitted by the black regression lines. 
 
The relatively high q²(cv)training  and  r² values confirm the predictive power and the 
applicability of this model. This is also supported by Figure 5.1.1-a: Only a few molecules of 
the training set slightly deviate from the regression line, which nearly traverses the point of 
origin. Three of the test compounds deviate from the regression line by nearly one logarithmic 
unit, which is due to the fact that they bear certain functional groups which are either flexible 
or do not occur within the set of training molecules. Thus, significant changes in activity are 
associated with a certain degree of predictive error. Consequently, the q²(cv)test-value is 
marginally impaired when compared to q²(cv)training. As a rule q²(cv) values above 0.4-0.5 are 
assumed to result in a statistically significant analysis. 
To evaluate the statistical significance of the given model new subsets have been created 
and models have been derived. This was done as follows: The whole data set was divided into 
two subsets of equal size (training set: 20 entries; test set: 19 entries). The 39 molecules were 
ten times randomly assigned to one of the subsets resulting in ten different training and test 
sets. For each data set a CoMFA model was established in the same way as it was shown for 
the initial model and an average model was calculated (Table 5.1.1-a). A detailed list 
including all CoMFA parameters for each single dataset is given in the Appendix (Section 
7.6). 112 
 
Table 5.1.1-a. Results of an average CoMFA model based upon ten independent datasets. 
Parameters Mean  value  SEM 
q²(cv)training  0.507 0.036 
SEP 0.645  0.020 
Components 3.6  0.499 
F 87.122  28.874 
r²(conventional) 0.912  0.023 
SEE 0.247  0.028 
Electrostatic contributions  0.681  0.018 
Steric contributions  0.319  0.018 
 
The predictive power of this average model was significantly impaired when compared to 
the previous model. This may have two reasons. First, the more members a training set 
consists of (20 vs. 30) the more data are available leading to a gain of information to be 
exploited. Hence, the resulting model is more reliable. Second, the initial allocation of 
molecules to either the training or the test set led by chance to a model with considerable 
predictive power. 
Figure 5.1.1-b visualizes the decrease of predictive power from the initial model to the 
average model. The actual regression line significantly deviates from the ideal (dashed) 
regression line representing an ideal data distribution. Although of poorer quality than the 
initial model, the average model still has sufficient predictive capabilities. 
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Figure 5.1.1-b. Graphic plotting the experimentally obtained bioactivity data (given as pIC50-
values) vs. the predicted data showing the average of ten independent models where the mean 
q²(cv)training was 0.51. Green circles denote the molecules of the whole data set. Error bars 
indicate SEM. The black line is the resulting regression line whereas the dashed red line 
represents the ideal course of the regression line. 
 
Since steric and electrostatic interactions of CoMFA studies are sensitive to the distance 
between probe atoms and molecule atoms, there exists a considerable dependence of q² values 
on the relative orientation of the molecular aggregate with respect to the probe lattice [Böhm 
et al., 1999]. Two methods, All-Orientation Search (AOS) and All-Placement Search (APS), 
have been reported to evaluate this influence [Wang et al., 1998] (Section 3.2.4). They have 
proven to be helpful in (i) searching for the optimal orientation resulting in the highest q² 
value and in (ii) detecting the q² value of the initial model relative to all possible models. 
The result for the training set of the present CoMFA model is given in Figure 5.1.1-c. Both 
searches clearly demonstrate that the initial model is among the best 5% (AOS) and 10% 
(APS), respectively of all possible models for this particular alignment. The histogram plots 
nearly correspond to a normal (Gaussian) distribution. However, the relatively broad ranges 
of obtained q² values varying between 0.3 and 0.7 slightly impair the robustness of the model.  
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Figure 5.1.1-c. Histograms displaying the distribution of the q²(cv)training values calculated as 
LOO cross-validation of the training set after rotation of the molecular aggregate around x-, y- 
and z-axis (AOS) and after systematic translation of the grid relative to the aligned molecules 
(APS). The q²(cv) values are binned into ranges of 0.01 units size and red bins denote the 
range where the q²(cv) of the initial model is located. 
 
5.1.2 Contour  Maps 
Before analyzing the CoMFA studies it has to be emphasized that in addition to 
pharmacophore models CoMFA models remain hypotheses as long as they are not verified or 
falsified by experiments. The present spatial orientation of substituents (the molecular 
alignment) attached to the common core is the most likely arrangement i.e., the energetically 
most favored arrangement since the protein structure is not taken into account. However, the 
real orientation of the side chains of the bound ligand could differ to some extent. But it is 
assumed that the arrangement of substituents from different molecules relative to each other 
will always be similar. 
Having a closer look at the electrostatic CoMFA plots (Figure 5.1.2-a) we observed that the 
carbonyl group, connecting the aromatic with the hydrophobic moiety (“polar linker”) is 
crucial for a potent ligand. This is evidenced by a large red isocontour below and a small 
isocontour above the carbonyl oxygen. Interestingly, this map allows for visualizing an 
important feature: Methoxy-groups attached to the cyclohexane of the hydrophobic moiety in 
cis-conformation are favored against the trans-conformation. The oxygen in trans-position 
points to a large blue isopleth indicating a region where negative charges and H-bond 
acceptors are disfavored. In contrast, the oxygen in cis-position directs to a red isopleth. Here, 
the weak H-bond acceptor and negatively charged oxygen is favored. Indeed, switching from 
cis-conformation to trans-conformation in one molecule leads to a significantly attenuated 
activity. The blue bulky contour at the left end of the aromatic moiety denotes a region where Summary  115  
H-bond donors or positively charged heteroatoms or substituents are favored. It should be 
stressed that, in contrast to the “polar linker”, no prediction can be made for the quinoline 
core structure since this molecular part is retained in all structures. 
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Figure 5.1.2-a. Contour map displaying electrostatic fields for the 39 molecules of the 
EMQMCM-data collection. Blue polyhedrons denote regions were positive charges (H-bond 
donors) are favored and negative charges (H-bond acceptors) are detrimental. Red 
polyhedrons show the opposite case. 
 
The steric contour map visualizes bulky features inevitable for potent ligands not 
considering any properties related to charges or partial charges. Regarding the present model 
(Figure 5.1.2-b) we noticed that the hydrophobic moiety on the right may extend downwards 
and in particular upwards. The lack of yellow polyhedrons in this region does not necessarily 
mean that the hydrophobic residue may rotate freely into each direction. The model does not 
explore areas not covered by either type of isocontours. Thus, no conclusion could be drawn 
for this space. 116 
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Figure 5.1.2-b. Contour map displaying steric fields for the 39 molecules of the EMQMCM-
data collection. Green polyhedrons denote sterically favored regions and yellow polyhedrons 
show regions where steric bulk is disfavored. 
 
The yellow polyhedrons denote sterically detrimental regions and they can also be assumed 
as restricted volumes. Accordingly, those substituents of the quinoline core structure pointing 
to the lower left corner (mainly heterocycles) considerably diminish activity. An additional 
(hetero)cycle condensed to the quinoline scaffold or a short aliphatic side chain retains 
activity of a potent ligand. This is visualized by the green polyhedron in the upper left corner. 
Exploiting all information given by the contour maps lead to the following proposed results, 
which are summarized in Figure 5.1.2-c. Starting from the quinoline scaffold the hydrophilic 
carbonyl linker is crucial for high activity at mGluR1. The hydrophobic residue (R3) may 
contain either aromatic or alicyclic structures. A weak H-bond acceptor (methoxy group) is 
favored in p-position of the alicycle (cyclohexane) preferably in cis-conformation. Ali- or 
heterocycles (O and S as heteroatoms) condensed at the quinoline ring at position 2 (R2) and 
3 (R1) retain high activity (R214127) if they replace a short (max. 3 carbon-atoms) aliphatic 
side chain at position 3. Heterocycles (e.g., thiophene, thiazole) substituted at R2 attenuate 
activity of the ligand. 
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Figure 5.1.2-c. Overview about the structural requirements for potent quinoline derivatives as 
non-competitive mGlu1 receptor antagonists. 
 
5.1.3 Conclusions 
It has been demonstrated that the structural (relatively) consistent quinoline derivatives 
combined with precise functional activity data facilitated the development of a consistent and 
presumably reliable CoMFA model. Predictions made for a test set of molecules support this 
assumption (vide supra). However, apart from such “virtual” model evaluations no “real” 
verifications were done, i.e., no molecule was sketched based on the present model and 
afterwards synthesized or ordered to check in functional assays whether the predicted 
bioactivity could be experimentally confirmed or not. The rationale for performing CoMFA 
studies on quinolines was the visualization of steric and electrostatic properties of the 
molecules of interest in order to detect substituents important for exerting the desired 
inhibitory activity. Likewise conventional SAR studies on coumarines (Section 4.3), the 
quantitative SAR of quinolines presented herein served as a basis for suggesting a ligand 
orientation at the allosteric mGluR1 binding domain for members of this class. 
 
5.2  Cross-Activities of Group I mGluR Antagonists 
As poor selectivity of potential drug candidates is often inherently associated with 
undesired side effects in later drug development phases, target specificity plays a pivotal role 
in today’s early hit optimization processes. Therefore, the aspect of selectivity must be taken 
into account as soon as possible. Testing a given compound on a large panel of different 118 
targets is ineffective and expensive to perform and attempts have been made to find concepts 
that circumvent this step [e.g., Schnur et al., 2006; Cleves & Jain, 2006]. In the following 
chapter a simple yet effective way to predict potential cross-activities for known allosteric 
antagonists of group I metabotropic glutamate receptors will be presented. 
The principle and the application of self-organizing maps (SOM) in terms of hit finding has 
been introduced before (Section 1.5.4, Section 4.5). We used the mapping results presented in 
Section 4.5 to predict potential cross-activities for group I mGluRs. Since it turned out that the 
CATS descriptor was able to precisely discriminate antagonists of mGluR1 and mGluR5 we 
tried to exploit the SOM results of the 15x15 grid for predicting potential additional binding 
behavior of the ligands.  
 
5.2.1  Target Prediction and Proof of Cross-Activity  
First, the mGluR-data collection was complemented by the molecules from the COBRA 
database [Schneider & Schneider, 2003] containing a broad set of known drugs, leads, and 
lead candidates affecting a large number of different drug targets. Subsequently, the 
molecules were converted to a vector representation giving the scaled occurrence frequencies 
of topological potential pharmacophore point pairs (CATS2D method). In this study, 
intramolecular distances from zero to nine bonds were considered, resulting in a 150-
dimensional vector representation of each molecular compound. 
The complete COBRA database was subjected to clustering and mapping onto a two-
dimensional grid by the SOM approach (Section 4.5.1). As a result, all molecules from 
COBRA were distributed into 225 (15×15) clusters (“neurons” or “receptive fields”). The 
distribution of these compounds is also shown in Figure 5.2.1-a, panel A. It is evident that the 
SOM is devoid of large patches of empty clusters (< 3%) and pronounced densities, which 
indicates successful mapping and also reflects the diversity of the COBRA entries. After 
SOM training the mGluR data were projected onto this map and the resulting distribution 
patterns were analyzed. The two mGluR ligand classes form separate localized distributions, 
where the distribution of the mGluR5 antagonists (Figure 5.2.1-a, panel B) appears to be 
slightly more focused than the mGluR1 data (Figure 5.2.1-a, panel C). Noteworthy, only 6% 
of the two ligand classes were clustered together (Figure 4.5.1-b). The SOM was able to 
discriminate between antagonists of the two mGluR subtypes.  
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Figure 5.2.1-a. SOM projection of the complete COBRA data (A), the mGluR1 antagonists 
(B), and mGluR5 antagonists (C). The distribution of the compounds on the map was 
separately scaled for each figure. Field (6/6) was selected as the target “mGluR1 cluster”, and 
field (8/5) as the target “mGluR5 cluster”. Gray fields indicate empty clusters. Note that the 
map forms a torus. See also Section 4.5.1. 
 
Clusters (6/6) and (8/5) revealed the highest density of mGluR1 and mGluR5 reference 
molecules, respectively (Figure 5.2.1-a). For prediction of potential side effects or additional 
binding behavior of the mGluR antagonists, the targets of those COBRA ligands that were co-
located in these two clusters were listed. Based on this analysis, mGluR1 antagonists of 
cluster (6/6) and mGluR5 antagonists of cluster (8/5) were predicted to interact with human 
dopamine D2-like receptors, histamine H1 receptor, and muscarinic acetylcholine (mACh) 
receptor. For pharmacological testing, we selected representative molecules from each cluster 
and if not available structurally related compounds from a Merz molecule collection (Figure 
5.2.1-b). Except EMQMCM, R193845, M-MPEP, MTEP and D-06 all molecules were from a 
Merz library but closely resemble their pendants in the mGluR data collection. 
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Figure 5.2.1-b. Known mGluR1 (EMQMCM, R193845) and mGluR5 antagonists, which 
were selected for activity testing based on the SOM results. 
 
Representatives were defined as being closest to the cluster centroids in descriptor space. 
Four scaffold classes were found: Molecules EMQMCM, R193845, MTEP and M-MPEP 
have been described elsewhere (Section 1.4.2, Section 2.2), D-01 - D-03 are imidazo[1,2-
a]pyrazine derivatives, and D-04 - D-08 represent imidazo[1,2-a]pyridine derivatives [Mutel 
et al., 2002]. In addition, for each of these test compounds individual predictions of target 
preference were made. This prediction was based on the relative occurrence frequencies of 
known COBRA compounds in the clusters, for example in the mGluR5 cluster we found 4 × 
H1, 2 × D2, 1 × mACh ligands. Based on this crude statistics, compounds EMQMCM and 
R193845 were predicted to interact with all four targets, the remaining compounds preferably 
with H1. We also found aromatase inhibitors co-located in cluster (8/5), which was not further 
pursued but might be worthwhile testing. 
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Table 5.2.1-a. IC50 values (mACh, mGluR1, mGluR5) and Ki values (D2, D3, H1) of selected 
compounds. Underlined values indicate the predictions according to the SOM analysis. 
Identifier  mACh 
(M1) [µM]  D2  [µM]  D3 [µM] H1 [µM]  mGluR1 
[µM] 
mGluR5 
[µM] 
EMQMCM  54.7 (±.2.8) 91.6 (± 13.6)  45.4 (± 27.1)  22.0 (± 3.7)  0.008 - 
R193845  n.d.  80.7 (± 0.8)  25.4 (± 9.4)  20.6 (± 1.1)  0.080 - 
MTEP  n.d.  n.d.  76.2 (± 46.9)  26.3 (± 4.1)  - 0.005 
M-MPEP  n.d.  n.d.  75.6 (± 23.5)  33.6 (± 3.2)  - 0.010 
D-01  n.d.  n.d.  n.d.  22.9 (± 1.9)  - >  30.0 
D-02  n.d.  n.d.  90.9 (± 78.4)  16.2 (± 7.1)  - >  30.0 
D-03  n.d.  n.d.  16.0 (± 6.5)  4.6 (± 1.7)  - 28.8 
D-04  n.d.  n.d.  n.d.  36.4 (± 33)  - >  30.0 
D-05  n.d.  n.d.  53.4 (± 37.2)  4.8 (± 0.8)  - >  30.0 
D-06  n.d.  n.d.  24.3 (± 4.4)  6.5 (± 3.4)  - 8.8 
D-07  n.d.  n.d.  32.9 (± 16.7)  4.5 (± 1.1)  - >  30.0 
D-08  n.d.  n.d.  n.d.  4.3 (± 0.6)  - >  30.0 
n.d.: no detectable activity/affinity at the concentrations tested. 
 
The pharmacological assays results are summarized in Table 5.2.1-a. Although only weak 
binding constants in the low to medium micro molar range were determined, the results 
confirm the SOM predictions. Noteworthy, all tested compounds exhibit binding affinity in 
our H1 receptor assay, indicating a potential general interaction of mGluR1/5 antagonists with 
the histamine receptor. It might thus be meaningful testing affinities to other histamine 
receptor subtypes. With the exception of D-01,  D-04, and D-08, the compounds showed 
moderate binding to dopamine D3 receptors. Only EMQMCM and R193845 also exhibited 
dopamine D2 receptor binding affinity, all others were inactive at dopamine D2 receptors, 
meaning that three out of the four substance classes represent D2-selective chemotypes. The 
known mGluR1 antagonists EMQMCM and R193845 were most “promiscuous”. These are 
the only compounds that comprise additional mACh activity and dopamine D2 receptor 
binding affinity.  
 
5.2.2 Conclusions 
In summary, we successfully applied a topological pharmacophore descriptor and SOM-
based clustering to predicting potential activities of known mGluR antagonists. This 
prediction concept, which includes molecule encoding, clustering and visualization gives no 122 
hint about the potency of compounds at the predicted targets. Nevertheless, in this study the 
tested compounds exhibited weak yet detectable affinities towards the allosteric binding site 
of mGluR1 and mGluR5, respectively, with binding constants in the micro molar range. 
Whether such activity or affinity is of actual pharmacological relevance remains to be shown.  
Irrespective of the outcome of such studies for the particular compounds employed here, the 
present virtual screening concept might provide a basis for early recognition of potential side-
effects in lead discovery. Moreover, this concept could perhaps also applied to other issues or 
tasks in drug discovery. Assumed that suitable descriptors and databases are available many 
predictions regarding, e.g., toxicity and ADME properties may be proposed. 
 
5.3  Hit Optimization and SAR Analysis of Coumarines 
Since  C-07 has proven to be a potent novel allosteric antagonist of mGluR1 a hit 
optimization project for the promising coumarine core structure was raised. Compounds 
bearing this scaffold were found by the topological pharmacophore search (Section 4.3) as 
well as the self-organizing maps (Section 4.5). In both studies, the molecules were encoded 
with the CATS atom-pair descriptor. However, the five coumarine derivatives detected within 
the SOM study (S-03, S-07, S-12, S-18, S-21; Section 4.5.2 and Appendix, Section 7.5) did 
not show any affinity or activity at the mGlu1 receptor. 
 
The synthesis of all compounds described herein has been carried out at the Institute of 
Organic Synthesis (IOS, Riga, Latvia), which is a co-operation partner of Merz. Aigars 
Jirgensons, group leader in Organic Synthesis at the IOS, managed the synthesis project. 
Structure-activity relationship investigations have been performed at Merz. Synthesis 
proposals based upon bioactivity data of already assayed compounds were presented to the 
chemists of the IOS and discussed with them. The complete project was supervised by Tanja 
Weil from Merz. 
 
5.3.1 Synthesis  Strategy 
The idea of this project was to systematically explore potential influences of various 
substituents attached to the common core at all possible positions. Newly designed molecules 
should have (i) higher affinity and activity than the reference compound C-07 and (ii) they Summary  123  
should show the same or improved solubility compared to C-07. In a further step the scaffold 
was also partially modified. 
The initial strategy comprised the following modifications of C-07 (Figure 5.3.1-a): Attaching 
small hydrophobic side chains (methyl, trifluoromethyl) at several positions of the cyclohexyl 
ring at R1, R2 and R3; introducing new substituents at position R6, predominantly small and 
polar (nitro-, amino-groups and short alkylamino groups) residues; replacing the chloro-
substituent (R4) with other halogens, (C1-C6alkyl)amino-, nitro- or heteroaryl-substituents.  
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Figure 5.3.1-a. Chemical structure of C-07 and the proposed positions for side chain 
modifications of the scaffold (a) and the introduction of new ring systems (b). Black digits 
denote potential substitution positions of the common scaffold according to the IUPAC 
nomenclature. 
 
The most thorough modifications were achieved at position R5. While retaining the oxygen 
as linker, the i-propyl group was replaced, e.g., with short and flexible groups like allyl- or 
difluoromethyl-groups as well as with bulky cycloalkyl-substituents. A similar strategy was 
followed for short alkylthio- and amino-groups where the oxygen has been replaced with 
sulfur or nitrogen. Furthermore, some derivatives were synthesized where R5 was linked 
either to R4 or R6, thus adding another ring system to the coumarine scaffold (Figure 5.3.1-a, 
panel b). Other modifications aimed at opening the coumarine core structure by cleaving the 124 
ring system (Figure 5.3.1-b). Molecules with new and flexible scaffolds distinct from the 
coumarine core were yielded (B-34; Table 5.3.2-h). 
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Figure 5.3.1-b. Modifications of the core structure as a result of bond splitting at several 
bonds indicated by black arrows. 
 
The whole optimization project resulted in a focused library of approximately 200 
coumarine analogues. In order to investigate the SAR within this novel chemical series, all 
compounds were tested with respect to their ability to bind at the allosteric site of the rat 
mGlu1 receptor and to antagonize its activation. Most of the active compounds were also 
tested on the human mGlu1 receptor. A selection is given in the following tables showing 
structural diverse coumarine derivatives and their bioactivity data. 
 
5.3.2 Structure-Activity  Relationship 
The first step describes various substituents at position 9 while retaining the ether linker 
(Table 5.3.2-a). Removing the i-propyl substituent of C-07 or replacing it with flexible 
aliphatic chains, alkyl-ether substituents or a hydrogen led to a slight decrease (B-03, B-04) or 
loss (B-01) of activity. The more the substituent resembles the i-propyl structure the higher is 
the corresponding affinity (B-05). A substituent similar to the hydrophobic cyclohexyl residue Summary  125  
in the quinoline EMQMCM is also assumed to nearly retain activity (B-04). This synthesis 
allowed for comparing both scaffolds, the quinolines and coumarines and gave hints to the 
hypothesized binding mode of them at the receptor site (Section 5.4.2). 
 
Table 5.3.2-a. Pharmacological data of diverse 9-substituted coumarines (ether linker). 
Values in italic indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O O R5
Cl
 
Compound-No. R5 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
C-07  i-propoxy  0.753 (± 0.048)  0.362 (± 0.031)  9.8 (± 0.65) 
B-01  OH  >100 >100  n.t. 
B-02 
O
 
31.9 (± 1.08)  5.1 (± 0.70)  n.t. 
B-03 
O
O
 
31.6 (± 0.87)  4.8 (± 0.82)  >100 
B-04 
O
O
 
8.267 (± 1.27)  3.3 (± 0.28)  >100 
B-05  difluoromethoxy  7.1 (± 0.19)  2.8 (± 0.24)  >100 
n.t.: not tested on this target 
 
The replacement of oxygen by a sulfur at position 9 of C-07 yields B-06 with slightly 
diminished activity. A short flexible side chain containing two H-bond acceptors considerably 
improves activity (B-07) and solubility (data not shown) whereas a methylsulfonate at that 
position results in loss of activity (B-09, Table 5.3.2-b). 
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Table 5.3.2-b. Pharmacological data of diverse 9-substituted coumarines (thioether linker). 
Values in italic indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O O R5
Cl
 
Compound-No. R5 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
B-06 
S
 
10.86 (± 0.09)  1.9 (± 0.29)  n.t. 
B-07 
S
N O
 
2.728 (± 0.002)  0.123 (± 0.007)  >100 
B-08 
N
S
 
28.2 (± 0.50)  5.35 (± 0.90)  >100 
B-09  S
O O
 
>100 >100  n.t. 
n.t.: not tested on this target 
 
Since it turned out that the dimethylthiocarbamyl substituent at position 9 increases activity 
(B-07) the respective substitution pattern for this compound at R2 – R4 was investigated 
(Table 5.3.2-c). At least the presence of a non-hydrogen atom at position 8 (R4) seems to be 
crucial (B-12). Only an introduced methyl group at R3 could nearly retain activity (B-11). 
Other even minor modifications yielded inactive compounds or compounds with attenuated 
activity 
 
Table 5.3.2-c. Pharmacological data of diverse 4,5,8-substituted coumarines. Values in italic 
indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O S
N
O
O
R2
R4
R3  
Compound-
No.  R2 R3  R4 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1
IC50 (µM) 
B-10  H H  Cl 
2.728  
(± 0.002) 
0.123  
(± 0.007) 
>100 Summary  127  
B-11  H methyl  Cl 
5.243 
(± 0.52) 
0.774 
(± 0.062) 
n.t. 
B-12  H H  H 
39.6 
 (± 1.26) 
6.8  
(± 0.92) 
>100 
B-13  ethyl H  Cl 
23.4 
(± 0.37) 
>100  n.t. 
B-14  phenyl H  Cl  >100 >100  n.t. 
n.t.: not tested on this target 
 
Starting from C-07 an additional H-bond donor at position 10 (R6) led to a loss of activity 
(B-15) whereas a H-bond acceptor even as part of a bulky substituent only slightly decreased 
activity (B-17, B-19). However, in general it was found that the bulkier the moiety the weaker 
the observed activity is (Table 5.3.2-d). 
 
Table 5.3.2-d. Pharmacological data of diverse 10-substituted coumarines. Values in italic 
indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O OO
Cl
R6
 
Compound-No. R6 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
B-15  NH2  >100 >100 >100 
B-16  NO2  >100  4.5 (± 0.16)  >100 
B-17  O NH
 
16.56 (± 0.763)  1.333 (± 0.161)  n.t. 
B-18  NH
O
O
OH  
34.0 (± 0.74)  4.9 (± 0.65)  >100 
B-19  N
O O
 
17.5 (± 0.26)  3.2 (± 0.31)  n.t. 
B-20  NH
O
 
>100  6.7 (± 1.19)  >100 
n.t.: not tested on this target 
 
Changing substituents at position 8 (R4) yielded compounds with low-micro molar activity 
(Table 5.3.2-e). Either a H-bond acceptor or a short aliphatic side chain (B-21, B-22), which 128 
slightly reduced activity (IC50: 0.36 µM to 2.5µM), have been investigated. H-bond donors 
are not favorable at that position (B-24). Here, the same applies as for position 10: a too 
capacious residue decreases activity (B-23). 
 
Table 5.3.2-e. Pharmacological data of diverse 8-substituted coumarines. Values in italic 
indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O OO
R4
 
Compound-No. R4 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
C-07  Cl  0.753 (± 0.048)  0.362 (± 0.031)  9.8 (± 0.65) 
B-21  NO2  7.5 (± 0.41)  1.6 (± 0.21)  n.t. 
B-22  ethyl  2.625 (± 0.05)  2.5 (± 0.24)  n.t. 
B-23  N
H
O
 
>100  4.0 (± 0.41)  >100 
B-24  NH2  21.5 (± 0.27)  5.7 (± 0.52)  >100 
n.t.: not tested on this target 
 
Short and lipophilic side chains at positions 3, 4 and 5 (Table 5.3.2-f) were able to nearly 
maintain (B-25, B-26) or slightly enhance activity (B-27). Position 5 (R3) has even earlier 
proven to be a suitable place for the introduction of a methyl group (B-11). Unfortunately, it 
has not been further explored for other substituents. 
 
 
Table 5.3.2-f. Pharmacological data of diverse 3,4,5-substituted coumarines. Values in italic 
indicate estimated data (tested at 10µM). SEM are given in parentheses. 
O OO
Cl
R1
R2
R3  
Compound-
No.  R1 R2  R3 
rmGluR1
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1
IC50 (µM)
B-25  methyl H  H 
0.828 
(± 0.131) 
1.2  
(± 0.09) 
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B-26  H trifluoromethyl H 
2.984 
(± 1.05) 
0.574  
(± 0.052) 
n.t. 
B-27  H H  methyl 
0.691 
(± 0.047) 
0.199  
(± 0.017) 
23.6  
(± 1.41) 
n.t.: not tested on this target 
 
Eventually, removing the condensed cyclohexene and introducing an adamantylcarbonyl 
group at the new position 3 led to substantially improved activity and affinity data. Various 
kinds of additional residues (H-bond acceptors, lipophilic and more hydrophilic groups) at the 
new position 7 (R5) resulted in compounds potently binding to the allosteric site of mGluR1 
and inhibiting its DHPG-induced activity (Table 5.3.2-g). The fact that this series (i) lacks the 
common core structure and (ii) revealed highly active inhibitors led to the assumption that 
these ligands bind to the receptor in a way distinct to that of the other molecules of this 
project. Probably the crucial role, however, plays the voluminous adamantyl substituent that 
forces these molecules in a slightly “shifted” orientation relative to the other coumarines, 
according to the hypothesis (Section 5.4.1).  
 
Table 5.3.2-g. Pharmacological data of diverse 3-(Adamantane-1-carbonyl)-2H-chromen-2-
one derivatives. Values in italic indicate estimated data (tested at 10µM). SEM are given in 
parentheses. 
O O
O
R5
 
Compound-No. R5 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
B-28  methoxy  0.293 (± 0.022)  0.058 (± 0.008)  30.6 (± 1.19) 
B-29  diethylamino  0.049 (± 0.004)  <1  >100 
B-30  Br  0.431 (± 0.049)  0.197 (± 0.053)  n.t. 
B-31  dimethylamino  0.088 (± 0.011)  <1  17.6 (± 1.12) 
n.t.: not tested on this target 
 
Several attempts to modify the core structure have been made, yet most of the resulting 
structures revealed no activity (data not shown). A selection of some modifications is given in 
Table 5.3.2-h. Replacing the cyclohexyl ring in C-07 with a cyclopentyl ring nearly conserves 
inhibitory activity (B-32). Neither the extension of the ring system provided by B-33 nor 130 
cleavage of the heterocycle (B-34) led to molecules maintaining the activity of the structurally 
related compounds B-32 and C-07. 
 
Table 5.3.2-h. Pharmacological data of coumarine derivatives and related modifications. 
Values in italic indicate estimated data (tested at 10µM). SEM are given in parentheses. 
Others 
Compound-
No.  R 
rmGluR1 
Ki (µM) 
rmGluR1 
IC50 (µM) 
hmGluR1 
IC50 (µM) 
B-32 
O OO
Cl
 
3.948 (± 0.23)  0.494 (± 0.119)  >100 
B-33 
O O
N
S
O
 
>100  11.8 (± 1.28)  n.t. 
B-34 
O O
Cl
N
 
>100 >100  n.t. 
n.t.: not tested on this target 
 
 
5.3.3  Discussion and Summary 
Summarizing the results of 189 coumarine derivatives obtained by pharmacological 
experiments allows for drawing some conclusions concerning a general structure activity 
relationship for these compounds. The coumarine structure exemplified by C-07 is given in 
Figure 5.3.3-a. The potential positions for substituting are also indicated. Here, a light grey 
ellipse emphasizes the common core structure of the vast majority of derivatives. One 
important feature attached to the scaffold is the cyclohexene ring highlighted by a dark grey 
ellipse. Although this moiety is also assumed to be part of the scaffold, which is stressed by 
the red digits, it is suggested as a condensed substituent in this scheme. It could either be an 
aromatic or heteroaromatic ring but preferably a cyclohexene. Additional short aliphatic and 
hydrophobic substituents may be introduced at each position but favorably at position 5. The 
influence of separated side chains at position 7 has not been explored, only if connected with 
substituents at position 8, thus introducing an additional ring. However, they turned out to be 
disfavored in terms of bioactivity.  
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Figure 5.3.3-a. Proposed SAR scheme at a glance. The series of coumarine derivatives is 
exemplified by C-07. Red digits denote potential substitution positions of the common 
scaffold according to the IUPAC nomenclature. For more information see text. 
 
A substituent at position 8 has proven to be crucial. Here, this feature is displayed as a 
yellow ellipse. It can either consist of a halogen, a H-bond acceptor or a short aliphatic side 
chain. This strongly supports the hypothesis that preferably a short yet bulky substituent 
should be attached at position 8 (Figure 5.3.3-a). Only H-bond donors were disfavored (Table 
5.3.2-e). Another pivotal feature is the residue at position 9 highlighted by a light blue ellipse. 
It can comprise a ring system such as (B-05) although a short and relatively rigid hydrophobic 
side chain is preferred. It must contain at least one heteroatom (weak H-bond acceptor) 
directly attached to the scaffold but might also include other polar features (presumably 
because of increased solubility). The hypothesized influence of features at position 8 with 
respect to activity is detailed below (Figure 5.3.3-b). Finally, the blue-white hatched ellipse at 
position 10 denotes a region where bulky residues containing H-bond acceptors at least nearly 
retain activity whereas other features (e.g., H-bond donors) lead to a loss of activity. 
However, this substituent turned out to be of minor importance. 
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Detailed investigations have been made for the presumed interaction between substituent 8 
and a H-bond donor site at the receptor. The chloro atom at position 8 in C-07 (Figure 5.3.3-b, 
a) is a relatively small atom that can interact with a H-bond donor via weak hydrogen 
bonding. This residue seems to be meaningful but not essential since molecule c) exhibits a 
decrease but not a loss of activity (Figure 5.3.2-3, c). Furthermore, replacement with a H-bond 
donor attenuates activity, which is exemplified by B-24 (Figure 5.3.2-3, d). 
 
O OO
Cl
O OO
Cl
O O O
H R H R
a) C-07; 0.362µM
O O O
N
+ O
O
H R
b) B-21; 1.6µM
O O O
N
+ O
O
H R H R
b) B-21; 1.6µM
c) 4.5µM d) B-24; 5.7µM
O O O
N
H
H
 
Figure 5.3.3-b. Hypothesized interactions between the substituents at positions 8 and a 
hydrogen provided by the receptor. Chloro atom (a) and nitro residue (b) form a weak 
hydrogen bond thereby presumably stabilizing a certain molecular orientation. If position 8 
lacks a H-bond acceptor no interaction via hydrogen bonding can be established at that 
position. For more information see text. 
 
Eventually, another H-bond acceptor at position 8, e.g., a nitro group can also interact with 
a hydrogen provided by the receptor site, which is shown for B-21 (Figure 5.3.3-b, b). The 
decrease in activity from C-07 to B-21 might be a result of a hampered hydrogen bonding 
since the nitro group is more voluminous than the chloro atom. Noteworthy, a hydrogen bond 
R-OH···O-N-R is stronger than R-OH···Cl-C-R since the chlorine acts as a weak acceptor 
[Desiraju & Steiner, 1999]. 
Summarized, a substituent at position 8 of the coumarine scaffold should be of small size, 
act as a H-bond acceptor and should preferably have hydrophobic properties (C-07 and B-21, 
Table 5.3.2-e).Within the described hit optimization project a total of 189 compounds Summary  133  
including the first hit C-07 were synthesized and pharmacologically characterized. The 
influence of crucial features and features of less importance has been investigated for 
biological relevance. Even the scaffold itself was partly modified yet without success 
regarding the pharmacological profile. The results of all compounds have been exploited for 
SAR purpose leading to a proposed SAR scheme (Figure 5.3.3-a). 
An overall functional activity hit rate is given in Figure 5.3.3-c. The ranges of activity 
classes shown here slightly differ compared to those used for hit rates of virtual screening 
campaigns. Fourteen compounds (7.4%) including C-07 were classified as “highly active” 
(>1µM), twenty-eight compounds (14.8%) were “moderately active” (1-10µM), nineteen 
compounds (10.1%) revealed moderately to low activity (10-20µM),  twenty-nine compounds 
had low activity (15.3%) and for ninety-nine compounds (52.4%) “no activity” was observed 
(>30µM) leading to a total hit rate of approximately 22% (<10µM). This is an acceptable hit 
rate for hit optimization projects. However, it must be stressed that only few compounds were 
able to allosterically antagonize the mGlu1 receptor more potently than the initial hit. Some of 
those molecules affecting the receptor in the low nano molar range (Table 5.3.2-g) are 
assumed to have an orientation in the binding pocket distinct to the others (Section 5.4.1), 
which will be addressed in the next chapter. 
 
 
Figure 5.3.3-c. Overall hit rate for coumarine derivatives synthesized within the hit 
optimization project. Digits at the edge denote the absolute number of compounds of the 
corresponding activity subset. 
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5.3.4 Conclusions 
Based on compound C-07 we performed a hit optimization project for coumarines as 
negative allosteric modulators of mGluR1 leading to 189 coumarine related structures. 
Although no promising lead candidate emerged from this project the extensive exploration of 
the chemically feasible space of coumarine derivatives facilitated a comprehensive SAR 
description. Precise knowledge of the pharmacological relevance of various substituents at 
any scaffold position meaning their influence on ligand binding enabled or at least supported 
the hypothesized molecule orientation in the receptor (Section 5.4.1), which followed after 
analysis of the observations made in this chapter.  
 
5.4  The Hypothesized Allosteric Binding Pocket of mGluR1 
Until now, only the structures of ligands binding to group I mGluRs have been taken into 
account. Based on pharmacophore models (Section 4.2) as well as on SAR analyses (Section 
5.3) and contour maps of a CoMFA model (Section 5.1) potential interaction points of several 
allosteric mGluR1 antagonists were discussed and considered as crucial features or features, 
which are presumably favored but not essential. Here, an attempt was done to transfer the 
knowledge obtained within the mentioned chapters to evaluate a possible binding behavior of 
those ligands at the corresponding target, the binding site in the HD of the mGlu1 receptor. 
Therefore, a homology model of mGluR1 was developed (Section 3.2.5) to get an idea of a 
potential binding mode of coumarines and quinolines. 
 
5.4.1  Binding of Coumarines 
The diverse molecules C-07 and B-28 (Section 5.3) were selected as coumarine 
representatives to investigate the binding mode of coumarines at the allosteric site of 
mGluR1. The ligands were placed manually into the transmembrane region in proximity to 
the pocket where 11-cis-retinal was found in bovine rhodopsin. Preliminary results with 
automated docking methods did not lead to reasonable results, thus we decided to place the 
ligands manually in a way most consistent with our SAR data and mutational results from 
literature [Malherbe et al., 2003a] that were based on binding of EM-TBPC, a prominent 
mGluR1 antagonist, followed by energy minimization. It must be stressed that all presented 
binding modes are hypotheses fitting to our data rather than extensively evaluated and 
confirmed results. For some of the ligands the functional activity in human mGluR1 was also Summary  135  
measured (Section 5.3.2). All ligands exerted explicitly lower activity in the human receptor. 
This led us to the conclusion that the ligands had to be in contact with V757
5.47 (superscript 
indicates TM and position [Balesteros & Weinstein, 1995]), which is replaced with an leucine 
in the human mGluR1, the single difference between rat and human receptor within the 
ligand-binding region. The hydrophobic unsaturated ring was selected as candidate for this 
contact.  
Figure 5.4.1-a (panel a) displays the predicted binding mode of C-07 in the binding pocket 
of mGluR1. The unsaturated ring is in contact with the rat selective V757
5.47, which is 
surrounded by further hydrophobic residues V753
5.43 and P756
5.46 that form a hydrophobic 
cluster (panel a).  
 
Figure 5.4.1-a. Potential binding mode of C-07 (a) and B-28 (b) in the allosteric binding site 
of mGluR1. View from the extracellular side of the membrane. 
 
In the homology model, the two central coumarine-oxygens interact as hydrogen-bond 
acceptors forming a hydrogen-bonding with R661
3.29, N747
45.51. The hydrophobic isopropoxy 
substituent of C-07 interacts with the hydrophobic residues I745
45.49 and V664
3.32. The 
isopropoxy oxygen is involved in a hydrogen bond with T815
7.39. Replacing the isopropoxy 
group with a dimethylthiocarbamyl group resulted in increased activity (B-10 vs. C-07, IC50: 
0.123µM vs. 0.362µM). This might be explained by the formation of a stronger hydrogen-
bond to T815
7.39. Substituents at the chlorine site of C-07 might interact with V664
3.32 and 
T815
7.39.  
For the ligands with an adamantyl substituent (B-28 - B-31) the receptor model suggests 
that there is not sufficient space for the adamantyl group in the sub pocket covered by the 
unsaturated ring of C-07, given the binding mode of C-07. Thus, an alternative binding mode 136 
was proposed for the adamantyl-containing ligands, illustrated by B-28 (Figure 5.4.1-a, panel 
b). Here the adamantyl group fills the same part of the pocket as the unsaturated ring in C-07. 
The oxygen of the carbonyl linker of B-28 is involved in the hydrogen bond cluster containing 
R661
3.29, and the oxygen acceptor in the ring from the coumarine core forms a hydrogen-
bonding interaction with T815
7.39. 
 
R661/N747 T815
V757
O O
Cl
O
O O O
C-07
B-28
R661/N747 T815
V757
O O
Cl
O
O O O
C-07
B-28
 
Figure 5.4.1-b. Alignment of the structurally different allosteric mGluR1 antagonists C-07 
and  B-28 and visualization of crucial interaction points within the binding pocket of the 
mGluR1 homology model. 
 
The proposed binding pocket of C-07 and B-28 is located in a similar region compared with 
the negative allosteric mGluR1 modulator EM-TBPC, for which mutational data were 
published before [Malherbe et al., 2003a]. EM-TBPC is assumed to interact with V757
5.47, 
W798
6.48, F801
6.51, Y805
6.55, T815
7.39, which are all in proximity to C-07 and B-28. Mutation 
of N747
45.51 and N750
45.54 to alanine resulted in an increased effect of EM-TBPC, which 
might be caused by the lack of a hydrogen-bonding interaction partner of EM-TBPC. These 
findings are consistent with a direct interaction of N747
45.51 with our ligands. For mGluR5 it 
was also shown that mutation of R647
3.29 (R661 in mGluR1) to alanine increased the activity 
of the mGluR5 negative allosteric modulator MPEP [Malherbe et al., 2003b]. This is 
confirmed by a potential direct interaction of R647
3.29 with bound ligands.  
These data support our hypothesis for the binding mode of the series of coumarines as 
mGluR1 negative allosteric modulators presented in Section 5.3. Furthermore, the existence 
of different binding modes within the pocket could serve as an explanation for the observed Summary  137  
differences in the functional and binding assay results as well as the failed attempt to find a 
quantitative SAR (data not shown). 
 
5.4.2  Binding of Quinolines 
The aim of this chapter was the comparison of quinolines and coumarines bound to the 
allosteric recognition site of mGluR1 with focus on their orientations relative to each other. 
Based on the proposed orientation it was feasible to relate the results obtained with the 
CoMFA studies of quinolines (Section 5.1) to the SAR of the coumarines (Section 5.3). In 
this context it must be stressed that our CoMFA studies were based on functional activity data 
for mGluR1 and not on binding affinity values. 
Initially, a flexible overlay comprising one representative of each group, EMQMCM for the 
quinolines and B-04 representing the coumarines, served as a starting point for the 
hypothesized binding mode. B-04 was selected to simplify the automated aligning as it 
structurally resembles EMQMCM with respect to the cyclohexyl residue (Section 5.3.2). Both 
molecules were superimposed in a flexible manner using the Flexible Alignment tool included 
in the MOE software package Version 2005.06 [Chemical Computing Group] by applying the 
same settings as used for the flexible overlay of six reference structures in Section 4.2.2. 
Several orientations have been calculated including their corresponding energy values. One 
orientation with a low energy value and a reasonable overlay (that is the most complete 
overlay with respect to the molecule structures) was selected. It was then slightly modified 
regarding the side chains, which were adjusted to refine the overlay. The final alignment is 
given in Figure 5.4.2-a. 
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Figure 5.4.2-a. Alignment of the structurally diverse allosteric mGluR1 antagonists B-04 
(coumarine) and EMQMCM and visualization of pivotal interaction points within the binding 
pocket of the mGluR1 homology model. 
 
EMQMCM representing the quinolines is assumed to interact with the same amino acids as 
the coumarines, thus binding in the same pocket of the receptor. The nitrogen of the the core 
structure potentially interacts with R661
3.29 or N747
45.51 via an H-bond bridge. 2-Methyl and 
3-ethyl substituents point into a region where there is few yet sufficient space for another 
condensed cycle as visualized for B-04 (Figure 5.4.2-a). It might establish a hydrophobic 
interaction with V757
5.47. This is consistent with the SAR data for quinolines postulating that 
an extended ring system is favored (e.g., R214127, IC50: 2nM). Moreover, EMQMCM´s 
“polar linker” connecting the aromatic quinoline moiety with the cyclohexyl moiety acts as H-
bond acceptor, hence forming a bridge to T815
7.39. Since the p-methoxy substituent as weak 
H-bond acceptor is essential neither in B-04 nor in EMQMCM, no interacting amino acid was 
proposed. However, it has influence on activity in quinolines as cis-conformation is preferred 
(Section 5.1.2).  
Further amino acids potentially influencing the binding mode of quinolines and coumarines 
are given in Figure 4.4.2-b. V664
3.32 or I745
45.49 provide hydrophobic interactions with either 
the cyclohexyl residue or the chlorine in B-04, whereas W798
6.48
 is presumably responsible 
for π-π stacking with the coumarine or quinoline core structures, respectively. The influence 
of the mentioned amino acids was previously confirmed by mutation analyses [Malherbe et 
al., 2003a] as already described (Section 5.4.1).  Summary  139  
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Figure 5.4.2-b. Potential binding mode of B-04 and EMQMCM in the allosteric binding site 
of mGluR1. View from the extracellular side of the membrane. 
 
Summarized, the above-proposed alignment has the advantage that several criteria for 
binding with amino acids of the target are fulfilled. Among these are (i) the nitrogen of the 
quinoline core structure providing an acceptor like the oxygen in the ring system and carbonyl 
oxygen in B-04 for interaction with R661
3.29 and/or N747
45.51, (ii) the planar aromatic ring 
system - present in both structures - to satisfy W798
6.48 and (iii) another H-bond acceptor 
(carbonyl linker in EMQMCM, ether in B-04) forming a contact with T815
7.39. Moreover, the 
conclusions drawn from the CoMFA studies (Section 5.1.2, Figure 5.1.2-c) perfectly fit to the 
hypothesized  alignment, which is confirmed by the following facts: 
According to the QSAR analyses the quinoline core system can be extended to the left, 
preferably with a condensed (hetero)aromatic cycle(R1/R2 in Figure 5.1.2-c). This cycle may 
contain another acceptor (oxygen, sulfur), which is, however, not required. In fact, according 
to Figure 5.4.2-b, there is only few space left between the aligned structures and TM5. 
Furthermore, no amino acids can be detected potentially interacting with another H-bond 
acceptor in this gap. Beyond the polar linker of the quinolines there should favorably be an 
aliphatic or aromatic residue, which can include polar features (R3 in Figure 5.1.2-c). This is 
confirmed by (i) the alignment of EMQMCM and B-04 placed into the binding pocket and 140 
displaying sufficient space in the region where the cyclohexyl residue is located (Figure 5.4.2-
b) and (ii) by the SAR scheme of the coumarines (Figure 5.3.2-a) postulating that the residue, 
which is attached at position 9 via an oxygen (or sulfur) should preferably be short and rigid 
but can also include a cycle and polar atoms. 
 
5.4.3 Conclusions 
Earlier studies detected a binding cavity in the HD of the mGlu1 receptor [Malherbe et al., 
2003a]. We exploited these receptor informations regarding crucial amino acids for ligand 
binding as well as our own SAR data of coumarines (ligand information) to get insights into 
the binding mode of coumarines in the HD of mGluR1. Binding orientations of coumarines 
were proposed as exemplified by two representatives of this chemotype. Furthermore, we also 
proposed a general binding mode for quinolines as non-competitive mGluR1 antagonists. For 
this purpose we exploited SAR data of quinolines [Mabire et al., 2005] and the results of our 
own QSAR studies to detect features essential for ligand binding. 
It has been proven by experiments that representatives of coumarines and quinolines bind to 
the same cavity in the transmembrane region of mGluR1: C-07, but also B-28 and analogues 
are capable of almost completely displacing [³H]-EMQMCM from its binding site. Summary  141  
6 Summary 
6.1  Conclusions and Outlook 
Binding assays on cerebellar (mGluR1) and cortical membranes (mGluR5) were developed 
to facilitate limited throughput screening on 96-well plates. The mGluR5 binding assay, 
however, has the disadvantage that it has to be performed at low temperature (< 4°C). Even 
under these conditions control values were poorer than observed in the mGluR1 binding 
assay. As a consequence the mGluR5 binding assay on 96-well plates was only used for 
studies described in this thesis and considered as not applicable for regular in-house 
compound screening. 
In an iterative process a pharmacophor query for non-competitive mGluR1 antagonists was 
set up. It was revised in a validation step where the in-house mGluR-data collection was 
employed. The following drawbacks can be attributed to the model: (i) It is not a general 
model as it only considers some chemotypes of mGluR1 antagonists, (ii) retrospective 
screening was performed on the mGluR-data collection but not on a large dataset comprising 
“positive” and “negative” members and (ii) prospective screening was conducted only in 
combination with the data reduction tool ChemSpaceShuttle. 
Three virtual screening campaigns were applied: CATS similarity search and data reduction 
with Kohonen maps and encoder networks (ChemSpaceShuttle). The Asinex Gold Collection 
February 2003 served as test database for the first two campaigns. For data clustering with 
Kohonen maps we applied the same topological pharmacophore descriptor as for the 
similarity searches. This descriptor enabled a clear discrimination of mGluR1 and mGluR5 
antagonists and an acceptable hit rate was yielded, but the detected virtual hits can mainly be 
classified into only two chemotypes. Other descriptor sets might retrieve other scaffolds but 
have not been tested. A major pitfall of data clustering with ChemSpaceShuttle was the fact, 
that only a small subset (“focused library”) of the Asinex database described the test 
molecules: The complete database was filtered previously with the final pharmacophore query 
for mGluR1 antagonists. Recommendations for future screening: (i) Apply a large test 
database, (ii) use for neighborhood search only high potent reference compounds, (iii) select 
more virtual hits and (iv) test also other descriptors. 
General recommendations regarding virtual screening: The application of other methods 
like support vector machines or random forest classification could be tested. 142 
A CoMFA model for quinolines, a class of prominent mGluR1 antagonists, was set up to 
evaluate the influence of side chain modification on functional activity. It was developed to 
improve the understanding of ligand binding at the allosteric mGluR1 recognition site. No 
chemically modified quinolines have been synthesized and tested to confirm the predictive 
power of the CoMFA model, which might be worth proving. 
We further introduced an interesting concept to predict compound selectivity for mGluR1 
and mGluR5 antagonist. A successful prediction of cross-activities at several receptors was 
made. Some aspects have not been addressed: (i) The application of another descriptor set for 
the underlying SOM analysis and (ii) the exclusive use of potent ligands as reference 
molecules for side effect predictions. 
A hit optimization project was launched for a coumarine, acting as non-competitive 
mGluR1 antagonist. Binding affinity and inhibitory activity were improved but no lead 
candidate for follow-up was yielded. A reason might be the fact that an increase in 
affinity/activity was associated with enhanced lipophilicity and, thus, diminished solubility. 
The project was finally discontinued. 
For two classes of allosteric mGluR1 modulators, quinolines and coumarines, binding 
orientations at the known recognition site were proposed. However, they are only hypotheses 
as representatives of each group were manually placed into the binding pocket of a mGluR1 
homology model and no automated docking was performed. 
 
6.2 Summary 
The goal of this thesis was to gain further insight into the binding behavior of ligands in the 
heptahelical domain (HD) of group I metabotropic glutamate receptors (mGluRs). This was 
realized by the establishment of strategies for the detection and optimization of molecules 
acting as non-competitive antagonists of group I mGluRs (mGluR1/5). These strategies 
should guarantee high diversity in the retrieved chemotypes of the detected compounds not 
resembling original reference molecules (“scaffold-hopping”). The detection of new scaffolds, 
in turn, was divided into two approaches: First the development of pharmacological assays to 
screen compounds at a certain target for bioactivity (here: affinity towards the allosteric 
recognition site of mGluR1 and mGluR5), and second the evaluation of computer assisted 
methods for the identification of virtual hits to be screened afterwards on the pharmacological 
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activity/affinity and selectivity, their binding mode investigated and, finally, compared to 
existing lead compounds. 
Initially, membrane based binding assays for the HD of mGlu1 and mGlu5 receptors with 
enhanced throughput (shifting from 24-well plates to 96-well plates) were set up. For the 
mGluR1 assay the potent antagonist EMQMCM exhibited high affinity towards the binding 
site (Ki ~3nM), which is in accordance with published data from Mabire et al. (functional IC50 
3nM). For mGluR5 the reference antagonist MPEP binds with high affinity to the receptor 
(binding IC50 13.8nM), which confirmed earlier findings from Anderson et al. (binding IC50 
15nM). In another series of experiments the properties of rat cerebellar (mGluR1) and cortical 
membranes (mGluR5) as well as of radiotracers were investigated by means of binding 
saturation studies and kinetic experiments. Furthermore, the influence of the solvent DMSO, 
necessary for compound screening of lipophilic substances, on positive and negative controls 
was evaluated. 
As the precise architecture of the HD of mGluR1 is still not known our efforts in identifying 
new ligands for this receptor focused on the ligand-based approach. All computer assisted 
methods that were applied to virtually screen large compound collections and to retrieve 
potential hits (“activity-enriched subsets”) acting at the heptahelical domain of mGluR1 relied 
on the existence of a valid dataset of reference molecules. This was realized by an initial 
compilation of a mGluR reference data collection comprising in total 357 entries 
predominantly negative but also some positive allosteric modulators for mGluR1 and 
mGluR5. In the next step a pharmacophore model for non-competitive mGluR1 antagonists 
was constructed. It was based upon six selective, potent and structurally diverse ligands. 
Prospective virtual screening was performed using the CATS atom-pair descriptor. The 
Asinex Gold-Collection was  screened for each seed compound and some of the most similar 
compounds (according to the CATS descriptor) were ordered and tested for binding affinity 
and functional activity at mGluR1. A high hit rate of approximately 26% (IC50 < 15µM) was 
yielded confirming the applicability of this method. One compound exerted functional activity 
below one micro molar (IC50-value of C-07: 362nM ± 0.03).  
Moreover, non-linear principal component analysis was employed. Again the Asinex 
vendor database served as test database and was filtered by the pharmacophore model for 
mGluR1 established before. Test molecules that were adjacently located with mGluR1 
antagonist references were selected. 15 compounds were tested on mGluR1 in binding and 
functional assays and three of them exhibited functional activity (IC50) below 15µM. The 
most potent molecule P-06 revealed an IC50-value of 1.11µM (± 0.41). 144 
The COBRA database comprising 5,376 structurally diverse bioactive molecules affecting 
various targets was encoded with the CATS descriptor and used for training two self-
organizing maps (SOM). The encoded mGluR reference data collection was projected onto 
this map according to the SOM algorithm. This projection allowed to clearly distinguish 
between antagonists of mGluR1 and mGluR5 subtype. 28 compounds were ordered and tested 
on activity and affinity for mGluR1. They exhibited functional activity down to the sub-micro 
molar range (IC50-value of S-08: 744nM ± 0.29) yielding a final hit rate of 46% (<15µM). 
Then, the Asinex collection was screened using the SOM approach. For a predicted target 
panel including the muscarinic mACh (M1) receptor, the histamine H1-receptor and the 
dopamine D2/D3 receptors, the tested mGluR ligands exhibited the calculated binding pattern. 
This virtual screening concept might provide a basis for early recognition of potential side-
effects in lead discovery. 
We superimposed a set of 39 quinoline derivatives as non-competitive mGluR1 antagonists 
that were recently published by Mabire and co-workers. A CoMFA model (QSAR) was 
established and the influence of several side chains on functional activity was investigated. 
The coumarine derivative C-07 was obtained as a result of similarity searching. Starting 
from this compound a series of chemical derivatives was synthesized. This led to the 
discovery of potent (B-28, IC50: 58nM ± 0.008; Ki: 293nM ± 0.022) and selective (rmGluR5 
IC50: 28.6µM) mGluR1 antagonists. From a homology model of mGluR1 we derived a 
potential binding mode for coumarines within the allosteric transmembrane region. Potential 
interacting patterns with amino acids were proposed considering the difference of the binding 
pockets between rat and human receptors. The proposed binding modes for quinolines (here: 
EMQMCM) and coumarines (here: B-04) were compared and discussed considering in 
particular the influence on activity of several side chains of quinolines obtained from the 
QSAR studies. 
 
The present studies demonstrated the applicability of ligand-based virtual screening for 
non-competitive antagonists of a G-protein coupled receptor, resulting in novel, potent and 
selective agents. 
 
6.3 Zusammenfassung 
Ziel dieser Doktorarbeit war es weiteren Einblick in das  Bindungsverhalten von Liganden 
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gewinnen. Verwirklicht wurde dies durch den Entwurf von Strategien zur Auffindung und 
Optimierung von Molekülen die als nichtkompetitive Antagonisten an Gruppe I mGluRs 
(mGluR1/5) wirken. Diese Strategien sollten eine hohe Diversität der chemischen Strukturen 
der entdeckten Verbindungen gewährleisten und nicht den ursprünglichen Referenzmolekülen 
ähneln (das sogenannte „Grundgerüst-Springen“). Die Auffindung neuer Kernstrukturen 
wiederum wurde in zwei Herangehensweisen aufgeteilt: Zum einen die Entwicklung von 
pharmakologischen Tests um Substanzen auf Bioaktivität an einer bestimmten Zielstruktur zu 
untersuchen (hier: die Affinität zur allosterischen Bindungsstelle von mGluR1 und mGluR5), 
und zum anderen die Evaluierung von computergestützten Methoden für die Identifizierung 
von virtuellen Suchtreffern die dann in den zuvor etablierten pharmakologischen 
Testsystemen untersucht werden können. Basierend auf den hierin gemachten Ergebnissen 
sollten vielversprechende Moleküle bezüglich Aktivität, Affinität und Selektivität optimiert 
werden, ihr Bindungsmodus untersucht und schließlich mit dem von bereits bekannten 
Leitstrukturen verglichen werden. 
Anfangs wurden membranbasierte Bindungstests für die transmembrane Region von 
mGluR1 und mGluR5 mit erhöhtem Durchsatz entworfen (Transfer vom 24-Lochplatten- auf 
96-Lochplattenformat). In diesem Zusammenhang wurde das bereits vorhandene Wissen über 
einen zur Verfügung stehenden NMDA-Rezeptor-Bindungstest genutzt. Hierbei wurde der 
Einfluss verschiedener Parameter wie Proteinkonzentration, Inkubationszeit, 
Inkubationstemperatur, etc. erforscht. Validiert wurden die Testsysteme mit 
Affinitätsmessungen für Standardverbindungen: Für den mGluR1 Bindungsversuch zeigte der 
potente Antagonist EMQMCM hohe Affinität an der Bindungsstelle (Ki ~3nM), was in 
Übereinstimmung mit publizierten Daten von Mabire et al. steht (funtioneller IC50 3nM). Für 
mGluR5 zeigte der Referenz-Antagonist MPEP hohe Affinität am Rezeptor (Bindungs IC50 
13,8nM) was durch frühere Untersuchungen von Anderson et al. bestätigt wird (Bindungs 
IC50 15nM). In einer weiteren Experimentreihe wurden die Eigenschaften von Cerebellum-
Membranen (mGluR1) und Cortex-Membranen (mGluR5) der Ratte untersucht sowie die 
Eigenschaften eines Radioliganden, und zwar in Form von Bindungs-Sättigungsversuchen 
und Kinetik-Experimenten. Desweiteren wurde der Einfluss des Lösungsmittels DMSO, das 
für das Lösen lipophiler Substanzen notwendig war, auf Positiv- und Negativkontrolle 
geprüft. 
Da die exakte Kristallstruktur der transmembranen Region von mGluR1 noch immer 
unbekannt ist haben sich unsere Anstrengungen zur Identifizierung neuer Liganden für diesen 
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die für das virtuelle Durchforsten großer Substanzdatenbanken zur Auffindung potentieller 
Treffer angewandt wurden (sogenannter „aktivitätsangereicherte Untergruppen“) basieren auf 
der Existenz eines validen Datensatzes von Referenzmolekülen. Verwirklicht wurde dies zu 
Beginn durch das Zusammenstellen einer mGluR Referenzdatenbank mit 357 Einträgen, 
vornehmlich negative aber auch einige positive Modulatoren an mGluR1 und mGluR5. 
Anhand umfangreicher Suche in sachbezogener Literatur (Patente und Veröffentlichungen) 
wurden Angaben gesammelt. Im nächsten Schritt wurde ein Phramakophormodell für 
nichtkompetitive mGluR1 Antagonisten erstellt. Es basiert auf einigen potenten, selektiven 
und strukturell diversen Liganden aus der mGluR Referenzdatenbank. Die Entwicklung eines 
aussagekräftigen Pharmakophormodells stellte einen wichtigen Schritt dar und war Grundlage 
für folgende Struktursuchen. Die dem Modell zu Grunde liegenden Moleküle wiederum 
dienten als Referenzmoleküle für eine auf einem topologischen Pharmakophordeskriptor 
basierende Ähnnlichkeitssuche: Prospektive virtuelle Suche wurde unter Benutzung des 
CATS Atompaar-Deskriptors durchgeführt, einer konformationsfreien Korrelationsvektor-
repräsentation. Eine große Datenbank kommerziell erhältlicher Moleküle (Asinex Gold 
Collection: ~ 200.000 Einträge) wurde für jede Referenzstruktur durchsucht und einige der 
entsprechend dem CATS Deskriptor als am ähnlichsten erachteten Verbindungen wurden 
bestellt und auf Aktivität und Affinität an mGluR1 untersucht. Eine Trefferrate von ungefähr 
26% (IC50 < 15µM) die den Nutzen dieser Methode bestätigte, wurde erzielt. Darüber hinaus 
wies eine Verbindung submikromolare funktionelle Aktivität auf (IC50-Wert von C-07: 
362nM ± 31). Da dieses Cumarin auch eine vielversprechende Kernstruktur aufwies, wurde es 
direkt einer Leitstrukturoptimierung unterzogen.  
In einer weiteren Studie wurden die Vorteile von Pharmakophorsuche und Datenreduktion 
anhand nichtlinearer Hauptkomponentenanalyse kombiniert. Wiederum diente die Asinex 
Kollektion als Testdatenbank und wurde mit dem zuvor erstellten mGluR1 
Pharmakophormodell gefiltert. Die resultierende „fokussierte Datenbank“ enthielt 2211 
Einträge und wurde zusammen mit der mGluR Referenzdatenbank mit einer Vielzahl von 2D-
Deskriptoren kodiert und anhand von ChemSpaceShuttle in einen dreidimensionalen Raum 
projiziert. Testverbindungen die in räumlicher Nachbarschaft zu mGluR1 Referenzen zu 
finden waren wurden ausgewählt. Einige von ihnen wurden bestellt und auf ihre gewünschte 
Bioaktivität hin untersucht. Insgesamt wurden fünfzehn Verbindungen in funktionellen Tests 
und Bindungstest für mGluR1 gemessen wobei drei von ihnen funktionelle Aktivität unter 
15µM aufwiesen. Die potenteste Verbindung P-06 zeigte einen IC50-Wert von 1,11µM (± 
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Kohonen-Karten stellen eine Alternative zu Ähnlichkeitssuchen im Bereich der virtuellen 
Suche dar. Sie gruppieren Moleküle indem sie ähnliche Datenwerte zusammenstellen. In der 
vorliegenden Studie wurde die COBRA 3.12 Datenbank, die 5.376 strukturell 
unterschiedliche bioaktive Moleküle enthält die mit verschiedenen Rezeptoren und Enzymen 
wechselwirken, mit dem CATS Deskriptor verschlüsselt. Dann wurden zwei 
selbstorganisierende Karten (SOM) damit trainiert, eine mit 100 Neuronen und eine mit 225 
Neuronen. Anschließend wurde die kodierte mGluR Referenzdatenbank gemäß dem SOM 
Algorithmus auf diese Karten projiziert. Diese Projektion erlaubte eine klare Trennung 
zwischen Antagonisten vom Subtyp mGluR1 und mGluR5. Ermutigt durch diese Ergebnisse 
wurde die Untergruppe der mGluR1 Referenzverbindungen auf die mit der COBRA 
Datenbank trainierten Karten projiziert und diejenigen Neurone die die höchste Dichte an 
Referenzverbindungen aufwiesen ausgewählt (Neuron 8/7 auf der kleinen Karte und 6/6 auf 
der großen Karte). In diesem Sinne wurde auch mit der Asinex Datenbank verfahren und alle 
Verbindungen die sich in beiden der eben erwähnten Neurone gruppiert haben wurden 
entsprechend ihrer räumlichen Entfernung zum Zentroid des jeweiligen Neurons sortiert. 28 
der ersten 60 Molekülstrukuren wurden bestellt und auf Affinität und Aktivität an mGluR1 
getestet. Sie wiesen (inhibitorische) Aktivitäten bis in den submikromolaren Bereich auf 
(IC50-Wert von S-08: 744nM ± 290) und führten zu einer Trefferquote von 46% (<15µM). 
Die Anwendung der hier beschriebenen virtuellen Suchmethoden gewährte uns eine 
Auswahl von selektiven mGluR1 Antagonisten mit neuen Kernstrukturen. Im folgenden 
wurde ihr Bindungsmodus im Verhältnis zu dem der Referenzverbindungen untersucht und 
eine vielversprechende Verbindung, ein Cumarin-Derivat das durch die Ähnlichkeitssuche 
gefunden worden ist, wurde strukturell optimiert. 
Quantitative Struktur-Wirkungsbeziehung (QSAR) zielt darauf ab den Zusammenhang 
zwischen Ligandenstrukturen und ihren Bioaktivitätsdaten quantitativ zu beschreiben. 
Diesbezüglich haben wir einen Satz von 39 Chinolin-Derivaten der mGluR1 Antagonisten 
darstellt und kürzlich von Mabire und Mitarbeitern veröffentlicht wurde verwendet. Die 
Strukturen wurden flexibel in einer sinnvollen Anordnung überlagert und in einen 
Trainingsdatensatz (30 Moleküle) und einen Testdatensatz (9 Moleküle) aufgeteilt. Ein 
CoMFA-Modell das die beste Vorhersagefähigkeit besaß (q
2(cv):  0,617) wurde erstellt. Zur 
statistischen Absicherung wurde derselbe Gesamtdatensatz zehnmal per Zufallsprinzip in 
Trainings- (20 Moleküle) und Testdatensatz (19 Moleküle) aufgeteilt was in einem mittleren 
q
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die sterische und elektrostatische Beiträge darstellten, berechnet worden sind wurde der 
Einfluss verschiedener Seitenketten auf die funktionelle Aktivität untersucht. 
Für einige Gruppe I mGluR Referenzverbindungen wurden, basierend auf den Ergebnissen 
der virtuellen Suche mit den Kohonen-Karten, Selektivitätsbetrachtungen durchgeführt. Die 
Kombination eines topologischen Pharmakophor-Deskriptors (CATS) und der SOMs wurde 
für die Vorhersage von multiplen Rezeptorinteraktionen von bekannten Gruppe I mGluR 
Antagonisten verwendet. Moleküle der mGluR Referenz-Sammlung und der COBRA 
Datenbank, die als Testdatensatz diente, wurden mit den CATS Deskriptor kodiert und einer 
Klassifizierung und Projektion gemäß dem SOM Algorithmus unterzogen. Für eine 
vorausgesagte Auswahl an Rezeptoren, darunter der muskarinische mACh (M1) Rezeptor, der 
Histamin H1-Rezeptor und die Dopamin D2/D3 Rezeptoren, konnten die gemessenen mGluR 
Liganden die berechneten Interaktionen aufweisen. Dieses Konzept des virtuellen Suchens 
könnte eine Basis für die frühe Erkennung von potentiellen Wechselwirkungen in der 
Arzneiforschung darstellen.  
Das Cumarin-Derivat C-07 wurde im Rahmen der Ähnlichkeitssuche mit dem CATS 
Deskriptor gefunden. Ausgehend von dieser Verbindung wurde in dem folgenden Aktivitäts-
Optimierungsprogramm eine Reihe von chemischen Derivaten synthetisiert. Das führte zur 
Entdeckung von potenten (B-28, IC50: 58nM ± 8; Ki: 293nM ± 22) und selektiven (rmGluR5 
IC50: 28,6µM) mGluR1 Antagonisten. Auf Grundlage unseres Homologiemodells haben wir 
einen potentiellen Bindungsmodus für Cumarine innerhalb der transmembranen Region 
ermittelt, was am Beispiel von C-07  und B-28 gezeigt wurde. Es wurden potentielle 
Interaktionsmuster mit Aminosäuren vorgeschlagen, die auch den Unterschied der 
Bindetaschen vom Ratten- und Humanrezeptor berücksichtigen. Desweiteren wurden die 
vermuteten Bidungsmodi für Chinoline (hier: EMQMCM) und Cumarine (hier: B-04) 
verglichen und diskutiert, und zwar unter besonderer Berücksichtigung des Einflusses von 
verschiedenen Chinolin-Seitenketten auf die Aktivität gemäß den vorausgegangenen QSAR 
Studien.  
 
Die vorliegenden Untersuchungen veranschaulichen den Nutzen von ligandbasierten 
virtuellen Suchen für nichtkompetitive Antagonisten von G-Protein gekoppelten Rezeptoren 
was in der Auffindung neuer, potenter und selektiver Verbindungen mündete. Appendix  149  
7 Appendix 
7.1  Complete mGluR-Data Collection 
Table 7.1-a. In-house collection of mGluR-reference compounds (release 08.03). Each 
molecule is depicted as SMILES string. 
Molecule Action  IC50 
O1CCCc2cc3cc(ccc3[nH0]c12)Cc1ccccc1 mGluR1  85  nM 
O=C(OC)[C@H](NC(=O)[C@](Oc1ccccc1C(=NO)[C@H](C1)2)12)Cc1cc mGluR1  930  nM 
Clc1ccc2[nH0]c(SCCO)[nH0]c(NC3C4CCC3CC4)c2c1 mGluR1  44  nM 
O(C)CCOc1[nH0][nH0]c(C#N)c([nH0]1)N1CCc2ccccc2CC1 mGluR1  3000  nM 
OCCNc1[nH0][nH0]c(C#N)c([nH0]1)N1CCc2ccccc2CC1 mGluR1  31  nM 
OC(C)CNc1[nH0][nH0]c(C#N)c([nH0]1)N1CCc2ccccc2CC1 mGluR1  27  nM 
s1ccc2CCN(CCc12)c1[nH0]c([nH0]c(OCC)c1[N+](=O)[O-])C mGluR1  440  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCc2ccccc21 mGluR1  245  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1COc2ccccc2C1 mGluR1  115  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C12CC3CC(CC(C3)C2)C1 mGluR1  125  nM 
O=C(CC(C)C)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  162  nM 
O=C(Cc1cccc(OC)c1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  135  nM 
O=C(NC1CCC(OC)CC1)c1ccc2[nH0]c(O)c(cc2c1)CC mGluR1  10000  nM 
ON=C(c1ccc2[nH0]c(O)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  10000  nM 
Fc1cccc(c1)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  48  nM 
N#Cc1[nH0][nH0]c(N)[nH0]c1N1CCc2ccccc2CC1 mGluR1  27  nM 
O=C(OCCCC)c1[nH]c(C)c(c1C)C(=O)OC(C)(C)C mGluR1  160  nM 
O=C(c1ccccc1)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  5.7  nM 
O=C(Cc1ccccc1)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  5.8  nM 
Brc1ccc2c(SC=3CC(C)(C)CCC=3C2=O)c1 mGluR1  9  nM 
Clc1cc2SC=3CC(CCC=3C(=O)c2cc1F)CC mGluR1  97  nM 
S1c2cc(ccc2C(=O)C=2CCC(C)(C)CC1=2)c1cccc(C#N)c1 mGluR1  21  nM 
S1c2cc(NC(=O)CC)ccc2C(=O)C=2CCC(CC1=2)CC mGluR1  35  nM 
S1c2cc(ccc2C(=O)C=2CCC(C)(C)CC1=2)c1c[nH0]ccc1 mGluR1  31  nM 
S1c2cc(ccc2C(=O)C=2CCC(CC1=2)CC)c1cccc(C#N)c1 mGluR1  23  nM 
S1c2cc(N3CCCCC3)ccc2C(=O)C=2CCC(CC1=2)CC mGluR1  13  nM 
S1c2cc(N3CCCCC3)c(F)cc2C(=O)C=2CCC(CC1=2)CC mGluR1  28  nM 
S1c2cc(N(C)COCC)ccc2C(=O)C=2CCC(CC1=2)CC mGluR1  22  nM 
S1c2cc(ccc2C(=O)C=2CCC(CC1=2)CC)c1c[nH0]c[nH0]c1 mGluR1  35  nM 
S1c2cc(ccc2C(=O)C=2CCC(CC1=2)CC)C1=NOC(=O)N1 mGluR1  81  nM 
S1c2cc(N[S+2]([O-])([O-])C3CC3)ccc2C(=O)C=2CCC(CC1=2)CC mGluR1  25  nM 
Clc1[nH0]c([nH0]c(N2CCN(CC2)c2ccccc2)c1C#N)NCC1CC1 mGluR1  25  nM 
Fc1ccc(N2CCN(CC2)C=2N=C(N(CCO)C(=O)C=2[N+](=O)[O-])C)cc1 mGluR1  42  nM 
Fc1ccc(N2CCN(CC2)c2[nH0]c([nH0]c(OCCO)c2[N+](=O)[O-])C)cc1 mGluR1  58  nM 
Fc1ccc(N2CCN(CC2)C=2N=C(N(CC)C(=O)C=2[N+](=O)[O-])C)cc1 mGluR1  49  nM 
N#Cc1c([nH0]c([nH0]c1N1CCN(CC1)c1ccccc1)NC1CC1)NC1CC1 mGluR1  64  nM 
OCCNc1[nH0]c([nH0]c(N2CCN(CC2)c2ccccc2)c1C#N)NC1CC1 mGluR1  33  nM 
OCCNc1[nH0]c([nH0]c(N2CCC(CC2)c2ccccc2)c1C#N)NCc1c[nH0]ccc mGluR1  30  nM 
O=C(OCCC)c1[nH]cc(c1)C(=O)OC(C)C(C)(C)C mGluR1  15.8  nM 
Fc1ccc(N2CCN(CC2)c2[nH0]c([nH0]c(OCC)c2[N+](=O)[O-])C)cc1 mGluR1  180  nM 
O=[N+]([O-])C=1C(=O)NC(=NC=1N1CCC(CC1)c1ccccc1)C mGluR1  63  nM 
Fc1ccc(N2CCN(CC2)C=2N=C(NC(=O)C=2[N+](=O)[O-])C)cc1 mGluR1  810  nM 
S(C)c1ccccc1N1CCN(CC1)c1[nH0]c([nH0]c(NCCO)c1C#N)NCCO mGluR1  350  nM 
Fc1ccc(cc1)C1CCN(CC1)C=1N=C(N(CCCCO)C(=O)C=1[N+](=O)[O-])C mGluR1  280  nM 
Fc1ccccc1N1CCN(CC1)c1[nH0]c([nH0]c(NCCO)c1C#N)NCCO mGluR1  290  nM 
O=[N+]([O-])c1ccccc1N1CCN(CC1)c1[nH0]c([nH0]c(NCCO)c1C#N)N mGluR1  750  nM 
Fc1ccc(cc1)C1CCN(CC1)c1[nH0]c([nH0]c(NCCO)c1C#N)NCCO mGluR1  700  nM 
Fc1ccc(cc1)C1=CCN(CC1)c1[nH0]c([nH0]c(NCCO)c1C#N)NCCO mGluR1  390  nM 
OCCNc1[nH0]c(NCCO)c(C#N)c([nH0]1)N1CCC(CC1)c1ccc(C#N)cc1 mGluR1  1800  nM 
N#Cc1c([nH0]c([nH0]c1N1CCC(CC1)c1ccccc1)NCc1[nH0]cccc1)NCc mGluR1  1500  nM 
OCCNc1[nH0]c([nH0]c(N2CCN(CC2)c2ccccc2)c1C#N)NCc1c[nH0]ccc mGluR1  150  nM 
Clc1[nH0]c([nH0]c(N2CCC(CC2)c2ccc(F)cc2)c1C#N)NCCO mGluR1  140  nM 
S(C)c1[nH0]c(N)[nH0]c(N2CCN(CC2)c2ccc(F)cc2)c1C#N mGluR1  210  nM 
S(C)c1[nH0]c(N)[nH0]c(N2CCC(CC2)c2ccc(F)cc2)c1C#N mGluR1  159  nM 
N#Cc1[nH0]c(CC)c([nH0]c1N1CCN(CC1)c1ccccc1)C mGluR1  17  nM 
N#Cc1[nH0]c(C)c([nH0]c1N1CCN(CC1)c1ccccc1)CC mGluR1  23  nM 
Fc1ccc(N2CCN(CC2)c2[nH0]c(NCCO)c[nH0]c2C#N)cc1 mGluR1  1000  nM 
OCCNc1[nH0][nH0]c(C#N)c([nH0]1)N1CC=C(CC1)c1ccccc1 mGluR1  660  nM 
Fc1ccc(N2CCN(CC2)c2[nH0]c(C)c([nH0+]([O-])c2C#N)CC)cc1 mGluR1  25  nM 
O=C(c1ccc2[nH0]c3OCCCc3cc2c1)C1CCC(OC)CC1 mGluR1  3.2  nM 
Clc1[nH0]c2ccc(cc2cc1CC)C(=O)C1CCC(OC)CC1 mGluR1  4  nM 
Fc1[nH0]c2ccc(cc2cc1CC)C(=O)C1CCC(OC)CC1 mGluR1  4.2  nM 150 
O=C(c1ccc2[nH0]c3OCCc3cc2c1)C1CCC(OC)CC1  mGluR1  4.2 nM 
S1CCCc2cc3cc(c(C)cc3[nH0]c12)C(=O)Cc1ccccc1 mGluR1  3.3  nM 
O=C(c1ccc2[nH0]c3CCCc3cc2c1)C1CCC(OC)CC1 mGluR1  4.4  nM 
S1CCCc2cc3cc(ccc3[nH0]c12)C(=O)C1CCC(OC)CC1 mGluR1  4.7  nM 
Clc1[nH0]c2cc(C)c(cc2cc1CC)C(=O)C1CCC(OC)CC1 mGluR1  4.8  nM 
O=C(c1ccc2[nH0]c(ccc2c1)CCC)C1CCC(OC)CC1 mGluR1  5.3  nM 
FC1(CCC(OC)CC1)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  5.4  nM 
O=C(Cc1ccccc1)c1cc2cc3CCCOc3[nH0]c2cc1C mGluR1  5.4  nM 
Fc1ccccc1CC(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  5.6  nM 
S1CCCc2cc3cc(ccc3[nH0]c12)C(=O)Cc1ccccc1 mGluR1  9.5  nM 
O=C(CC1C[C@@H](CCC1C1)1)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  9.4  nM 
S1CCCc2cc3cc(ccc3[nH0]c12)C(=O)Cc1ccccc1F mGluR1  10  nM 
s1ccc(c1)CC(=O)c1ccc2cc3OCCCc3cc2c1 mGluR1  7.2  nM 
S1CCc2cc3cc(ccc3[nH0]c12)C(=O)C1CCC(OC)CC1 mGluR1  9  nM 
O=C(Cc1ccccc1)c1ccc2[nH0]c3OC(C)Cc3cc2c1 mGluR1  8.8  nM 
S1CCc2cc3cc(ccc3[nH0]c12)C(=O)C1CCCCC1 mGluR1  7.7  nM 
O=C(c1ccc2[nH0]c(N)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  7.2  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CCC)C1CCC(OC)CC1 mGluR1  7.4  nM 
O=C(c1cc2cc(CC)c([nH0]c2cc1C)C)C1CCC(OC)CC1 mGluR1  5.9  nM 
O=C(c1ccc2[nH0]c3CCCCc3cc2c1)C1CCC(OC)CC1 mGluR1  7.3  nM 
O(C)c1ccc2[nH0]c[nH0]c(NC3CC4CCC3C4)c2c1 mGluR1  2430  nM 
O(C)c1ccc2[nH0]c[nH0]c(NC3CCCCC3)c2c1 mGluR1  328  nM 
Clc1[nH0]c(NC2Cc3ccccc3C2)c2cc(OC)ccc2[nH0]1 mGluR1  30  nM 
Clc1ccccc1CCNc1[nH0]c[nH0]c2ccc(OC)cc12 mGluR1  300  nM 
Clc1[nH0]c(Nc2ccc(OC)cc2)c2cc(OC)ccc2[nH0]1 mGluR1  40  nM 
Clc1[nH0]c(NC2Cc3ccccc3C2)c2cc(Cl)ccc2[nH0]1 mGluR1  18  nM 
Clc1[nH0]c(NCCc2ccccc2Cl)c2cc(OC)ccc2[nH0]1 mGluR1  23  nM 
Clc1ccc2[nH0]c[nH0]c(NC3CC4CCC3C4)c2c1 mGluR1  1130  nM 
S(CC)c1[nH0]c(NCC(F)c2ccccc2)c2CCCCc2[nH0]1 mGluR1  10  nM 
S(CC)c1[nH0]c(NOC)c2CCCCc2[nH0]1 mGluR1  32  nM 
Clc1ccccc1C(O)CNc1[nH0]c(SCC)[nH0]c2CCCCc12 mGluR1  23  nM 
S(CC)c1[nH0]c(NCC(F)(F)c2ccccc2)c2CCCCc2[nH0]1 mGluR1  15  nM 
Clc1ccccc1CCNc1[nH0]c(SCC)[nH0]c2CCCCc12 mGluR1  24  nM 
S(CC)c1[nH0]c(Nc2ccc(F)cc2)c2CCCCc2[nH0]1 mGluR1  32  nM 
S(CC)c1[nH0]c(NC2Cc3ccccc3C2)c2CCCCc2[nH0]1 mGluR1  39  nM 
Clc1cccc(Cl)c1CSCCNc1[nH0]c(SCC)[nH0]c2CCCCc12 mGluR1  246  nM 
S(CC)c1[nH0]c(NN2Cc3ccccc3C2)c2CCCCc2[nH0]1 mGluR1  550  nM 
Clc1ccccc1C(OC)CNc1[nH0]c(SCC)[nH0]c2CCCCc12 mGluR1  610  nM 
Clc1ccccc1OCCNc1[nH0]c(SCC)[nH0]c2CCCCc12 mGluR1  1000  nM 
S(CC)c1[nH0]c(NC2CC3CCC2C3)c2CCCCc2[nH0]1 mGluR1  320  nM 
O=C(OCC)c1[nH]cc(c1C)C(=O)OC(C)(C)C mGluR1  340  nM 
O=C(OCCC)c1[nH]cc(c1C)C(=O)OC(C)(C)C mGluR1  75  nM 
O=C(OCc1[nH]c(c(C)c1C(=O)OC(C)(C)C)C(=O)OCCC)C mGluR1  2700  nM 
O=Cc1[nH]c(c(C)c1C(=O)OC(C)(C)C)C(=O)OCCC mGluR1  2000  nM 
O=C(OC)c1[nH]c(c(C)c1C(=O)OC(C)(C)C)C(=O)OCCC mGluR1  3200  nM 
O=C(OCCC)c1[nH]c(c(c1C)C(=O)OC(C)(C)C)C(=O)NCC1CC1 mGluR1  2500  nM 
O=C(OC(C)(C)C)c1[nH]cc(c1C)C(=O)OC(C)(C)C mGluR1  100  nM 
O=C(OCc1occc1)c1[nH]cc(c1C)C(=O)OC(C)(C)C mGluR1  1200  nM 
O=C(OCC1CC1)c1[nH]cc(c1C)C(=O)OC(C)(C)C mGluR1  48  nM 
O=C(OCCC)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  4  nM 
O=C(OC(C)(C)C)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  17  nM 
Fc1c(F)c(F)c(OC(=O)c2[nH]cc(c2C)C(=O)OC(C)C(C)(C)C)c(F)c1F mGluR1  160  nM 
O=C(OC(C)CN(C)C)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  390  nM 
Clc1[nH]c(c(C)c1C(=O)OC(C)C(C)(C)C)C(=O)OCCC mGluR1  160  nM 
O=C(Oc1c[nH0]ccc1)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  720  nM 
O=C(OC1CN(CC1)CC)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  260  nM 
O=C(Oc1[nH0]c[nH0]cc1)c1[nH]cc(c1C)C(=O)OC(C)C(C)(C)C mGluR1  1450  nM 
O=C(OCCC)c1[nH0](C)c(C)c(c1C)C(=O)OC(C)(C)C mGluR1  1000  nM 
O=C(OCCC)c1[nH0](CCCO)c(C)c(c1C)C(=O)OC(C)C(C)(C)C mGluR1  5800  nM 
O=C(OC(C)C(C)(C)C)c1[nH0][nH0](C)c(c1)C(=O)OCCC mGluR1  3200  nM 
O=C(OCCC)c1[nH0][nH0](C)c(c1)C(=O)OC(C)C(C)(C)C mGluR1  3200  nM 
O=C(OC(C)C(C)(C)C)c1[nH0][nH0](C)c(c1)C(=O)OC(C)C(C)(C)C mGluR1  1500  nM 
O=C(OC(C)C(C)(C)C)c1[nH0][nH0](C)c(c1)C(=O)OCC mGluR1  6900  nM 
O=C(OCCCC)c1[nH0][nH]c(c1)C(=O)OC(C)C(C)(C)C  mGluR1  3400 nM 
O=C(OCCC)c1[nH0][nH]c(c1)C(=O)OC(C)C(C)(C)C mGluR1  3400  nM 
s1c(N)c(c(C)c1C(=O)OC)C(=O)OCC mGluR1  8000  nM 
s1c(C)c(c(N)c1C(=O)OCC)C(=O)OCC mGluR1  6000  nM 
s1cc(c(C)c1C(=O)OCC)C(=O)OCC mGluR1  4000  nM 
s1cc(c(C)c1C(=O)OCCC)C(=O)OC(C)(C)C mGluR1  160  nM 
s1cc(c(C)c1C(=O)OCCC)C(=O)OC(C)C(C)(C)C mGluR1  32  nM 
s1c(N)c(c(C)c1C(=O)OCCC)C(=O)OC(C)C(C)(C)C mGluR1  320  nM 
O=C(OCCC)c1ccc(cc1)C(=O)OCCC mGluR1  4000  nM 
O=C(OCCC)c1ccc(cc1)C(=O)OC(C)(C)C mGluR1  400  nM 
O=C(OCCC)c1ccc(cc1)C(=O)OC(C)C(C)(C)C mGluR1  63  nM 
O=C(OCC1CC1)c1ccc(cc1)C(=O)OC(C)C(C)(C)C mGluR1  26  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  3  nM 
O=C(c1ccc2[nH0]c(OC)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  20  nM 
O=C(c1ccc2[nH0]cc(cc2c1)CC)C1CCC(OC)CC1 mGluR1  3.5  nM Appendix  151  
Clc1[nH0]c2cc(C)c(cc2cc1CC)C(=O)C1CCC(OC)CC1 mGluR1  4.8  nM 
O=C(c1ccc2[nH0]c(N(C)C)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  31  nM 
O=C(OCc1[nH0]c2ccc(cc2cc1CC)C(=O)C1CCC(OC)CC1)C mGluR1  91  nM 
O=C(c1ccc2[nH0]c(O)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  14  nM 
O=C(Cc1ccccc1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  9.8  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CC2CCC1C2 mGluR1  13  nM 
O=C(CC1CCC(OC)CC1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  15  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCC(C)CC1 mGluR1  15  nM 
FC1(CCC(OC)CC1)C(=O)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  17  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1Cc2ccccc2C1 mGluR1  56  nM 
O=C(CC1C[C@@H](CCC1C1)1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  60  nM 
O=C(Cc1ccccc1OC)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  67  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1Oc2ccccc2OC1 mGluR1  83  nM 
O=C(c1ccc2[nH0]c(C#N)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  11.5  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCC(O)CC1 mGluR1  19  nM 
S1CCc2cc3cc(ccc3[nH0]c12)C(=O)C1CCC(OC)CC1 mGluR1  2.6  nM 
O=C(c1ccc2[nH0]c3N(C)CCCc3cc2c1)C1CCC(OC)CC1 mGluR1  8.1  nM 
O=C1Nc2ccc(cc2C=C1CC)C(=O)C1CCC(OC)CC1 mGluR1  8.7  nM 
O=C(c1ccc2[nH0]c(C)c([nH0]c2c1)C)C1CCC(OC)CC1 mGluR1  36  nM 
O=C(c1ccc2[nH0]3[nH0][nH0][nH0]c3C(=Cc2c1)CC)C1CCC(OC)CC1 mGluR1  44  nM 
s1ccc(c1)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  7.2  nM 
Brc1ccc(cc1)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  17  nM 
Fc1ccc(cc1)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  20  nM 
Fc1cccc(c1F)C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  74  nM 
Fc1ccccc1C(=O)c1ccc2[nH0]c3OCCCc3cc2c1 mGluR1  42  nM 
O=C(NC12CC3CC(CC(C3)C2)C1)c1[nH0]c2ccccc2[nH0]c1 mGluR1  5  nM 
O=C(OCC)C12Oc3ccccc3C(=NO)C2C1 mGluR1  3400  nM 
O=C(OCC)[C@@](Oc1ccccc1C(=NO)[C@@H](C1)2)12 mGluR1  3000  nM 
O=C(OCC)[C@](Oc1ccccc1C(=NO)[C@H](C1)2)12 mGluR1  1500  nM 
O=C(OC)[C@@H](NC(=O)[C@](Oc1ccccc1C(=NO)[C@H](C1)2)12)Cc1c mGluR1  430  nM 
O=C(OC)[C@H](NC(=O)C12Oc3ccccc3C(=NO)C2C1)Cc1ccccc1 mGluR1  1400  nM 
O=C(OC)[C@@H](NC(=O)C12Oc3ccccc3C(=NO)C2C1)Cc1ccccc1 mGluR1  1200  nM 
S(CCO)c1[nH0]c(NC2Cc3ccccc3C2)c2CCCCc2[nH0]1 mGluR1  1  nM 
S(CCO)c1[nH0]c(Nc2ccc(OC)cc2)c2cc(OC)ccc2[nH0]1 mGluR1  11  nM 
Clc1cccc(Cl)c1CSCCNc1[nH0]c([nH0]c2CCCCc12)C mGluR1  7  nM 
Clc1cccc(Cl)c1CSCCNc1[nH0]c[nH0]c2ccccc12 mGluR1  46  nM 
O(C)c1ccc(Nc2[nH0]c[nH0]c3ccc(OC)cc23)cc1 mGluR1  96  nM 
Clc1ccc2[nH0]c[nH0]c(NC3C4CCC3CC4)c2c1 mGluR1  400  nM 
Clc1cccc2c([nH0]c[nH0]c12)NC1C2CCC1CC2 mGluR1  1895  nM 
N#Cc1[nH0][nH0]c(N)[nH0]c1N1CCc2ccccc2CC1 mGluR1  27  nM 
N#Cc1[nH0][nH0]c([nH0]c1N1CCc2ccccc2CC1)N(C)C mGluR1  1380  nM 
N#Cc1[nH0][nH0]c([nH0]c1N1CCc2ccccc2CC1)NCC1CC1 mGluR1  5  nM 
N#Cc1[nH0][nH0]c([nH0]c1N1CCc2ccccc2CC1)NN mGluR1  370  nM 
O=C(OC(C)(C)C)NCCNc1[nH0][nH0]c(C#N)c([nH0]1)N1CCc2ccccc2C mGluR1  27  nM 
N#Cc1[nH0][nH0]c([nH0]c1N1CCc2ccccc2CC1)NCCc1c[nH0]ccc1 mGluR1  29  nM 
N#Cc1[nH0]c(CC)c([nH0]c1N1CCc2ccccc2CC1)C mGluR1  6  nM 
N#Cc1[nH0]c(C)c([nH0]c1N1CCc2ccccc2CC1)CC mGluR1  103  nM 
N#Cc1[nH0]cc[nH0]c1N1CCc2ccccc2CC1 mGluR1  470  nM 
N#Cc1[nH0]c(c([nH0]c1N1CCc2ccccc2CC1)C)c1ccccc1  mGluR1  45 nM 
OCCNc1[nH0]c(N2CCc3ccccc3CC2)c([nH0]c1)C#N mGluR1  500  nM 
s1c2CCN(CCc2[nH0]c1C)C=1N=C(NC(=O)C=1[N+](=O)[O-])C mGluR1  30000  nM 
s1c2CCN(CCc2[nH0]c1C)c1[nH0]c([nH0]c(OCC)c1[N+](=O)[O-])C mGluR1  4200  nM 
s1c2CCN(CCc2[nH0]c1C)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C mGluR1  2100  nM 
s1c2CCN(CCc2[nH0]c1N)C=1N=C(NC(=O)C=1[N+](=O)[O-])C mGluR1  49000  nM 
s1c2CCN(CCc2[nH0]c1N)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C mGluR1  6000  nM 
s1c[nH0]c2CCN(CCc12)C=1N=C(NC(=O)C=1[N+](=O)[O-])C mGluR1  43000  nM 
s1ccc2CCN(CCc12)C=1N=C(NC(=O)C=1[N+](=O)[O-])C mGluR1  1900  nM 
s1ccc2CCN(CCc12)C=1N=C(N(CC)C(=O)C=1[N+](=O)[O-])C mGluR1  69  nM 
O=C(c1ccc2[nH0]c(N3CCCCC3)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  3630  nM 
O=C(c1ccc2[nH0]c(c(cc2c1)CC)c1occc1)C1CCC(OC)CC1 mGluR1  257nM 
O=C(Nc1ccc2[nH0]c(O)c(cc2c1)CC)C1CCC(OC)CC1 mGluR1  10000  nM 
O=C(N(C)c1ccccc1)C12Oc3ccccc3C(=NO)C2C1 mGluR1  2000  nM 
O=C(c1ccccc1)c1ccc2cc3CCCOc3[nH0]c2c1 mGluR1  8300  nM 
O=C(Nc1ccc(cc1)C(=O)C1CCC(OC)CC1)C mGluR1  7585  nM 
O=C(c1ccc2[nH0]c([nH]c2c1)C)C1CCC(OC)CC1 mGluR1  575  nM 
O=C(CCc1ccccc1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  229  nM 
O=C(Cc1ccc(N(C)C)cc1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  646  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCNCC1 mGluR1  10000  nM 
O=C(c1ccc2[nH0]c(C)c(cc2c1)CC)C1CCC(N(C)C)CC1 mGluR1  10000  nM 
O=C(c1ccc(OC)c(OC)c1)c1ccc2[nH0]c(C)c(cc2c1)CC mGluR1  10000  nM 
S1c2cc(ccc2C(=O)C=2CCC(CC1=2)CC)c1[nH0][nH0][nH0][nH]1 mGluR1 9  nM 
FC(F)(F)COc1[nH0]c([nH0]c(N2CCC(CC2)c2ccccc2)c1C#N)NCCO mGluR1  36  nM 
O=C(OCC)NC(=O)C(c1ccccc1)c1ccccc1  mGluR1 (pos.)  170 nM 
O=C(OCC)NC(=O)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  9 nM 
[S+2]([O-])([O-])(N1CCC[C@H]1(c1ccc(C)cc1))c1ccc(C)cc1  mGluR1 (pos.)  200 nM 
O=C(Nc1[nH0]oc([nH0]1)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  52 nM 
O=C(Nc1[nH0]oc([nH0]1)CC)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  6 nM 
O=C(Nc1[nH0]oc([nH0]1)C(C)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  22 nM 152 
O=C(Nc1[nH0]oc([nH0]1)CCC)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  25 nM 
O=C(Nc1[nH0]oc([nH0]1)C1CC1)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  23 nM 
O=C(Nc1[nH0]oc([nH0]1)CC(C)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  10 nM 
O=C(Nc1[nH0][nH0][nH0]([nH0]1)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  180 nM 
O=C(Nc1[nH0][nH0][nH0]([nH0]1)CC)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  65 nM 
O=C(Nc1[nH0][nH0][nH0]([nH0]1)CCC)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  29 nM 
O=C(Nc1[nH0][nH0][nH0]([nH0]1)C(C)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  29 nM 
O=C(Nc1[nH0][nH0][nH0]([nH0]1)CC(C)C)C1c2ccccc2Oc2ccccc21  mGluR1 (pos.)  34 nM 
O=C(NCc1cccc2ccccc21)c1[nH0]cc(cc1)CCCC  mGluR1 (pos.)  135 nM 
N(c1ccccc1)C1CC(C)(C)CC(C)(C)C1  mGluR1 (pos.)  158 nM 
[nH0]1ccccc1CC=C(c1ccccc1)c1ccccc1  mGluR1 (pos.)  151 nM 
s1c([nH0]cc1C(=O)N1CCc2cc(OC)c(OC)cc2C1)C  mGluR1 (pos.)  164 nM 
O=C(N1CCCCCC1)c1[nH0][nH0]2c(N=C(C=C2C)c2ccccc2)c1  mGluR1 (pos.)  164 nM 
O=[N+]([O-])c1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  10000  nM 
[nH0]1c(C)cccc1C#Cc1ccccc1 mGluR5  30  nM 
[nH0]1c(C)cccc1C=Cc1ccccc1 mGluR5  3500  nM 
O=C(C=Cc1ccccc1)c1[nH0]c(C)ccc1 mGluR5  10000  nM 
N#Cc1ccc(C#Cc2[nH0]c(C)ccc2)cc1 mGluR5  1000  nM 
[nH0]1cc(C)ccc1C#Cc1ccccc1 mGluR5  640  nM 
N#Cc1ccccc1C#Cc1[nH0]c(C)ccc1 mGluR5  360  nM 
N#Cc1cccc(C#Cc2[nH0]c(C)ccc2)c1 mGluR5  2  nM 
Oc1ccccc1C#Cc1[nH0]c(C)ccc1 mGluR5  360  nM 
[nH0]1c(C)cccc1C#Cc1ccccc1C mGluR5  48  nM 
[nH0]1c(C)cccc1C#Cc1cccc(C)c1 mGluR5  33  nM 
O=C(Nc1ccccc1)c1[nH0]c(C)ccc1 mGluR5  3500  nM 
Oc1ccc(C#Cc2[nH0]c(C)ccc2)cc1 mGluR5  1200  nM 
Oc1cccc(C#Cc2[nH0]c(C)ccc2)c1 mGluR5  2  nM 
O(C)c1ccccc1C#Cc1[nH0]c(C)ccc1 mGluR5  66  nM 
O(C)c1ccc(C#Cc2[nH0]c(C)ccc2)cc1 mGluR5  1700  nM 
O(C)c1cccc(C#Cc2[nH0]c(C)ccc2)c1 mGluR5  10  nM 
[nH0]1c(C)cccc1C#Cc1ccc(C)cc1 mGluR5  50000  nM 
s1cc([nH0]c1C)C#Cc1c[nH0]ccc1 mGluR5  5  nM 
s1cc([nH0]c1C)C#Cc1[nH0]cccc1 mGluR5  53  nM 
s1cc([nH0]c1C)C#Cc1cc[nH0]cc1  mGluR5  120 nM 
s1cc([nH0]c1C)C#Cc1ccccc1 mGluR5  14  nM 
s1c[nH0]c(C#Cc2ccccc2)c1 mGluR5  97  nM 
s1cc[nH0]c1C#Cc1ccccc1 mGluR5  80  nM 
O(C)c1ccc(cc1OC)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  6800  nM 
O(C)C=1C=C[nH0]2cc([nH0]c2C=1)c1ccc(OC)c(OC)c1 mGluR5  3300  nM 
O(C)c1cc(ccc1OCc1ccccc1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  830  nM 
Brc1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  950  nM 
Ic1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  970  nM 
Clc1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  1230  nM 
[nH0]1c2[nH0](C=CC=C2)cc1c1cccc(C)c1 mGluR5  1550  nM 
FC(F)(F)c1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  2790  nM 
Fc1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  3410  nM 
[nH0]1c2[nH0](C=CC(=C2)CC)cc1c1ccc(C)c(C)c1 mGluR5  3640  nM 
s1c(C)ccc1c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  6130  nM 
[nH0]1c2[nH0](C=CC(C)=C2)cc1c1ccccc1 mGluR5  7500  nM 
[nH0]1c2[nH0](C=CC=C2)cc1c1ccc(C)cc1 mGluR5  8770  nM 
O(C)c1cccc(c1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  1650  nM 
O(C)c1ccc(cc1OC)c1[nH0]c2[nH0](C=C(C)C=C2)c1 mGluR5  8300  nM 
O1C=C(OC2C=CC=CC12)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  990  nM 
[nH0]1c2[nH0](C=C(C)C=C2)cc1c1ccc(C)cc1 mGluR5  10000  nM 
[nH0]1c2[nH0](C=CC=C2)cc1c1ccc2CCCc2c1 mGluR5  930  nM 
o1c2ccccc2cc1c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  1660  nM 
s1cc(c2ccccc12)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  2760  nM 
O1CCc2cc(ccc12)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  2860  nM 
s1cc([nH0]c1C#Cc1ccccc1)C mGluR5  13  nM 
S(CC(=O)OCC)c1[nH0]cc(Cc2[nH0](C)ccc2)c(N)[nH0]1 mGluR5  380  nM 
Clc1ccc(c(Cl)c1)c1c[nH0]c(SCC(=O)OCC)[nH0]c1N mGluR5  3850  nM 
S(CC(=O)COCC)c1[nH0]cc(c(N)[nH0]1)C(=O)OCC mGluR5  270  nM 
s1cccc1Cc1c[nH0]c(SCC(=O)OCC)[nH0]c1NCC mGluR5  600  nM 
s1cccc1Cc1c[nH0]c(SC(C)C)[nH0]c1N mGluR5  1390  nM 
S(CC(=O)OCC1CC1C)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  630  nM 
S(CC(=O)OCC1CCC1)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  1460  nM 
S(CC(=O)OCC1CC1)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  200  nM 
S(Cc1o[nH0]c([nH0]1)C1CC1)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  450  nM 
s1cccc1Cc1c[nH0]c(SCC=C)[nH0]c1N mGluR5  2790  nM 
s1cccc1Cc1c[nH0]c(SCc2[nH0]oc[nH0]2)[nH0]c1N mGluR5  400  nM 
O=C(OCC)c1[nH0](C)c([nH0]c1C)C#Cc1ccccc1 mGluR5  250  nM 
O=C(OCC)c1[nH]c([nH0]c1C)C#Cc1ccccc1 mGluR5  2400  nM 
O(C)c1cccc(C#Cc2[nH0]c(C)c[nH0]2C)c1 mGluR5  350  nM 
[nH0]1cc[nH0](C)c1C#Cc1ccccc1 mGluR5  720  nM 
[nH0]1cc[nH]c1C#Cc1ccccc1 mGluR5  200  nM 
O=[N+]([O-])c1[nH0](CCO)c([nH0]c1)C#Cc1ccccc1 mGluR5  2110  nM 
Clc1cccc(Cl)c1C#Cc1[nH0]c(C)c([nH0]1C)C(=O)OCC mGluR5  1000  nM 
O=C(OCC)c1[nH0]c([nH0](c2ccccc2)c1C)C#Cc1ccccc1 mGluR5  not  available Appendix  153  
O=C(OCC)c1[nH0](C)c([nH0]c1C)C#Cc1cccc(C)c1 mGluR5  130  nM 
O=C(Nc1cccc(C#Cc2[nH0]c(C)c([nH0]2C)C(=O)OCC)c1)C mGluR5  2120  nM 
O=C(OCC)c1[nH0](C)c([nH0]c1C)C#Cc1cccc(N2CC=CC2)c1 mGluR5  180  nM 
o1[nH0]c([nH0]c1c1[nH0](C)c([nH0]c1C)C#Cc1ccccc1)C mGluR5  11  nM 
Clc1ccc(C#Cc2[nH0]c(C)c([nH0]2C)C(=O)OCC)cc1 mGluR5  not  available 
Fc1ccc(C#Cc2[nH0]c(C)c([nH0]2C)C(=O)OCC)cc1 mGluR5  250  nM 
O=C(OCC)c1[nH0](C)c([nH0]c1C)C#Cc1ccc(cc1)c1ccccc1 mGluR5  210  nM 
Fc1ccccc1C#Cc1[nH0]c(C)c([nH0]1C)C(=O)OCC mGluR5  90  nM 
Fc1ccccc1C#Cc1[nH0]cc[nH0]1C mGluR5  70  nM 
O=C(OCC)c1[nH0](C)c([nH0]c1C)C#Cc1ccc(N)cc1 mGluR5  1530  nM 
Clc1ccccc1C#Cc1[nH0]cc[nH0]1C mGluR5  1100  nM 
Clc1[nH0]c([nH0](CC(=O)OCC)c1Cl)C#Cc1ccccc1 mGluR5  520  nM 
[nH0]1c[nH0](C)c(C#Cc2ccccc2)c1 mGluR5  220  nM 
O=C(NCCc1c2cc(OC)ccc2[nH]c1C#Cc1ccccc1)C mGluR5  580  nM 
S1Cc2[nH0](c[nH0]c2C#Cc2ccccc2)c2ccc[nH0]c12 mGluR5  150  nM 
O1Cc2[nH0](c[nH0]c2C#Cc2ccccc2)c2ccccc12 mGluR5  70  nM 
ClCC(O)C[nH0]1c([nH0]c(C#Cc2ccccc2)c1[N+](=O)[O-])C mGluR5  230  nM 
O=Cc1[nH0](C)c[nH0]c1C#Cc1ccccc1 mGluR5  1790  nM 
[nH0]1c[nH]cc1C#Cc1ccccc1  mGluR5  3360 nM 
[nH0]1c[nH0](C)cc1C#Cc1ccccc1 mGluR5  500  nM 
O=[N+]([O-])c1[nH0](C)c([nH0]c1C#Cc1ccccc1)C mGluR5  20  nM 
[nH0]1[nH0](C)c(C#Cc2ccccc2)cc1C mGluR5  5000-10000  nM 
[nH0]1c([nH0](C)c(c1C(C)C)C(C)C)C=Cc1ccccc1 mGluR5  1820  nM 
Fc1ccc(cc1)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  5000-10000  nM 
Clc1ccc(cc1)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  5000-10000  nM 
O(CCCC)c1ccc(cc1)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  5000-10000  nM 
O(C)c1cc(C)c(C=Cc2[nH0]c(c([nH0]2C)C(C)C)C(C)C)c(C)c1C mGluR5  5000-10000  nM 
O(C)c1ccc(cc1)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  5000-10000  nM 
Clc1ccc(cc1F)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  10000  nM 
O(CC)c1ccc(cc1)C=Cc1[nH0]c(c([nH0]1C)C(C)C)C(C)C mGluR5  10000  nM 
O(C)c1ccc(C=Cc2[nH0]c(c([nH0]2C)C(C)C)C(C)C)c(OC)c1OC mGluR5  10000  nM 
Clc1ccc(C=Cc2[nH0]c(c([nH0]2C)C(C)C)C(C)C)c(Cl)c1 mGluR5  10000  nM 
[nH0]1c([nH0](C)c(c1C(C)C)C(C)C)C=Cc1ccc(C)cc1 mGluR5  3250  nM 
Brc1[nH0]c[nH0](C)c1C=Cc1ccccc1 mGluR5  3060  nM 
[nH0]1c[nH0](C)c(c1)C=Cc1ccccc1 mGluR5  8000  nM 
O=C(OC)N1CC[C@H]([C@H]1(CCC[C@@](O)(C#Cc1cccc(C)c1)1))1 mGluR5  20  nM 
O(C)c1cc(OC)cc(c1)C=Cc1[nH0]c(C)ccc1 mGluR5  30  nM 
Clc1cc(ccc1CC#N)c1oc2ccccc2[nH0]1 mGluR5  6  nM 
o1c2ccccc2[nH0]c1c1ccc(CC#N)c(OC)c1 mGluR5  3  nM 
o1c2ccccc2[nH0]c1c1ccc(c(OC)c1)c1[nH0]cccc1 mGluR5  41  nM 
o1c2ccccc2[nH0]c1c1ccc(c(OC)c1)c1c[nH0]ccc1 mGluR5  416  nM 
O(C)c1cc(ccc1c1c[nH0]ccc1)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  22  nM 
S1C=C[nH0]2cc([nH0]c12)c1ccc(c(OC)c1)c1c[nH0]ccc1 mGluR5  23  nM 
S1CC[nH0]2cc([nH0]c12)c1ccc(c(OC)c1)c1c[nH0]ccc1 mGluR5  325  nM 
o1[nH0]c([nH0]c1c1cccc(C#N)c1)c1[nH0]cccc1 mGluR5  42  nM 
o1cc([nH0]c1c1cccc(C#N)c1)c1[nH0]cccc1 mGluR5  45  nM 
S(CC(=O)OCC)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  140  nM 
Brc1ccc(cc1)Cc1c[nH0]c(SCC(=O)OCC)[nH0]c1N mGluR5  180  nM 
s1ccc(c1)Cc1c[nH0]c(SCC(=O)OCC)[nH0]c1N mGluR5  180  nM 
S(CC(=O)OCC)c1[nH0]cc(Cc2cocc2)c(N)[nH0]1 mGluR5  160  nM 
S(CC(=O)OCC=C)c1[nH0]cc(Cc2ccccc2)c(N)[nH0]1 mGluR5  120  nM 
s1cccc1Cc1c[nH0]c(SCC(=O)OCC)[nH0]c1NCC(C)C mGluR5  160  nM 
ClC=1C=C[nH0]2cc([nH0]c2C=1)c1ccc(C)c(C)c1 mGluR5  100  nM 
O(C)C=1C=C[nH0]2cc([nH0]c2C=1)c1ccc(C)c(C)c1 mGluR5  140  nM 
[nH0]1c2[nH0](C=CC=C2)cc1c1ccc(C)c(C)c1 mGluR5  37  nM 
[nH0]1c2[nH0](C=CC(C)=C2)cc1c1ccc(C)c(C)c1 mGluR5  280  nM 
Brc1cc(ccc1F)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  690  nM 
s1c(C)cc(c1C)c1[nH0]c2[nH0](C=CC=C2)c1 mGluR5  580  nM 
Oc1ccc([nH0]c1N=Nc1ccccc1)C mGluR5  3700  nM 
O(C)c1ccc(cc1OC)c1[nH0]c2[nH0](C=CC(C)=C2)c1 mGluR5  1880  nM 
Fc1cccc(c1)C=NN=Cc1cccc(F)c1  mGluR5 (pos.)  2000 nM 
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7.2   Register of Pharmacophore Features  
Table 7.2-a. Annotation points defined by the PCH pharmacophore scheme in MOE Version 
2003.02 (Section 4.2.2) 
Type Definition 
H-bond donor (Don)  Hydrogen bond donors, not including tautomeric donors (e.g.: 
primary and secondary amines, hydroxy-groups). 
H-bond acceptor (Acc)  Hydrogen bond acceptors, not including tautomeric acceptors 
(e.g.: carbonyl-groups, unsaturated nitrogens). 
Cation (Cat)  Cations, including resonance cations (e.g.: protonated amines) 
Anion (Ani)  Anions, including resonance anions (e.g.: carboxylate-anions). 
Aromatic centers (Aro)  Centers of aromatic homocycles or heterocycles (e.g.,: benzenes, 
pyridines, quinolines). 
Hydrophobic areas (Hyd)  Areas of hydrophobic properties (e.g.: aliphatic chains, 
cycloalkanes) Appendix  155  
7.3  Similarity Lists obtained in Section 4.3 
Table 7.3-a. List containing the top 100 test compounds of the CATS run for reference 
molecule R-01. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  R-02  0.1461 51  BAS_2276958    0.5408 
2  BAS_0391501  0.3368 52  BAS_1027129    0.5417 
3  BAS_0399020  0.3986 53  BAS_0719950    0.5419 
4  BAS_2276984  0.4144 54  BAS_0316110    0.5428 
5  BAS_0399026  0.4279 55  BAS_0466184    0.5432 
6  BAS_0398973  0.4279 56  BAS_0733586    0.5448 
7 BAS_1280297  0.4477  57 BAS_0733331    0.5448 
8  BAS_1293648  0.4569 58  R-03   0.5450 
9 BAS_3200195  0.4643  59 BAS_0721849    0.5480 
10 BAS_3200194  0.4643  60  BAS_0316106    0.5487 
11 BAS_0726193  0.4644  61  BAS_0549667    0.5502 
12 BAS_1293659  0.4690  62  BAS_0872503    0.5504 
13 BAS_3569630  0.4770  63  BAS_0116912    0.5507 
14 BAS_3840865  0.4841  64  BAS_0119421    0.5510 
15 BAS_0726155  0.4848  65  BAS_0491076   0.5511 
16 BAS_2276957  0.4855  66  BAS_0829447    0.5528 
17 BAS_0434242  0.4885  67  BAS_0115283    0.5540 
18 BAS_0484981  0.4888  68  BAS_1293655   0.5541 
19 BAS_1280306  0.4937  69  BAS_0997506    0.5546 
20 BAS_0032180  0.4969  70  BAS_0369581    0.5583 
21 BAS_0457554  0.5008  71  BAS_0450775    0.5590 
22 BAS_0369588  0.5017  72  BAS_1044756    0.5645 
23 BAS_0637934  0.5022  73  BAS_0619947    0.5658 
24  BAS_1293653  0.5031 74  BAS_0600286   0.5666 
25 BAS_3147583  0.5048  75  BAS_0069082   0.5670 
26 BAS_1123649  0.5069  76  BAS_0672186    0.5681 
27 BAS_1293647  0.5103  77  BAS_1585664   0.5684 
28 BAS_5307694  0.5111  78  BAS_0232984    0.5686 
29 BAS_0457561  0.5134  79  BAS_0481364    0.5694 
30 BAS_1053334  0.5170  80  BAS_0308659    0.5696 
31 BAS_0726256  0.5175  81  BAS_0396059    0.5703 
32  BAS_2303581  0.5196 82  BAS_1077633    0.5707 
33 BAS_0899874  0.5198  83  BAS_2236264    0.5710 
34 BAS_1293657  0.5209  84  BAS_2236261    0.5710 
35 BAS_1280314  0.5215  85  BAS_0745008    0.5715 
36 BAS_0530782  0.5228  86  BAS_0671951    0.5722 
37 BAS_0369580  0.5267  87  BAS_0247237    0.5743 
38  BAS_2603597  0.5275 88  BAS_0069084    0.5744 
39 BAS_1365856  0.5287  89  BAS_0834407    0.5770 
40 BAS_1077624  0.5306  90  BAS_0784504    0.5781 
41 BAS_0139098  0.5306  91  BAS_1044763    0.5784 
42 BAS_0099446  0.5307  92  BAS_1018141    0.5810 
43  BAS_0069083  0.5326 93  BAS_0733420    0.5818 
44  BAS_0129908  0.5345 94  BAS_1123751    0.5822 
45 BAS_0529716  0.5361  95  BAS_1123652    0.5822 
46 BAS_0459058  0.5372  96  BAS_0329602    0.5824 
47 BAS_0672162  0.5385  97  BAS_0834813    0.5829 
48 BAS_1123749  0.5393  98  BAS_0066965    0.5835 
49 BAS_1123654  0.5393  99  BAS_5621609    0.5840 
50 BAS_1293630  0.5401  100 BAS_1280290   0.5847 156 
Table 7.3-b. List containing the top 100 test compounds of the CATS run for reference 
molecule R-02. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  R-01   0.1461  51  BAS_1123654   0.5246 
2  BAS_0399020   0.3671  52  BAS_0719950   0.5253 
3  BAS_1280297   0.3956  53  BAS_0454887   0.5263 
4  BAS_0391501   0.3958  54  BAS_0069082   0.5313 
5  BAS_0399026   0.4031  55  BAS_1053334   0.5336 
6  BAS_0398973   0.4031  56  BAS_0530782   0.5339 
7  BAS_2276984   0.4083  57  BAS_0997506   0.5343 
8  BAS_1293648   0.4312  58  BAS_0726256   0.5350 
9  BAS_0726193   0.4389  59  BAS_0491076   0.5364 
10  BAS_1293653   0.4405  60  BAS_0329364   0.5398 
11  BAS_1293659   0.4427  61  BAS_0829447   0.5398 
12  BAS_1365856   0.4604  62  BAS_1123747   0.5401 
13  BAS_3840865   0.4636  63  BAS_0637766   0.5416 
14  BAS_1293647   0.4700  64  BAS_0659984   0.5437 
15  BAS_0899874   0.4732  65  BAS_0066155   0.5437 
16  BAS_0032180   0.4733  66  BAS_1280290   0.5445 
17  BAS_3569630   0.4733  67  BAS_2236264   0.5450 
18  BAS_2303581   0.4763  68  BAS_2236261   0.5450 
19  BAS_1280314   0.4763  69  BAS_0119421   0.5481 
20  BAS_1280306   0.4772  70  BAS_1118531   0.5508 
21  BAS_3147583   0.4874  71  BAS_0733447   0.5525 
22  BAS_0726155   0.4883  72  BAS_1365860   0.5540 
23  BAS_1293630   0.4886  73  BAS_0726125   0.5555 
24  BAS_0529716   0.4920  74  BAS_0872503   0.5560 
25  BAS_1293657   0.4923  75  BAS_0672162   0.5571 
26  BAS_0129908   0.4938  76  BAS_5621609   0.5574 
27  BAS_1293655   0.4949  77  BAS_0327258   0.5575 
28  BAS_0484981   0.4962  78  BAS_2236262   0.5576 
29  BAS_0600286   0.5014  79  BAS_0834813   0.5592 
30  BAS_0450775   0.5031  80  BAS_0726207   0.5595 
31  R-03   0.5042  81  BAS_0725815   0.5595 
32  BAS_1123649   0.5043  82  BAS_0457561   0.5622 
33  BAS_0834407   0.5053  83  BAS_0705143   0.5624 
34  BAS_0733586   0.5065  84  BAS_1077633   0.5629 
35  BAS_0733331   0.5065  85  BAS_0667696   0.5631 
36  BAS_0637934   0.5074  86  BAS_5432992   0.5637 
37  BAS_0459058   0.5087  87  BAS_0329602   0.5652 
38  BAS_0069083   0.5095  88  BAS_4912490   0.5657 
39  BAS_5307694   0.5103  89  BAS_1256720   0.5657 
40  BAS_0745008   0.5112  90  BAS_0069084   0.5664 
41  BAS_1585664   0.5114  91  BAS_1209494   0.5671 
42  BAS_0369588   0.5149  92  BAS_0119417   0.5675 
43  BAS_2276957   0.5185  93  BAS_1293627   0.5677 
44  BAS_1077624   0.5193  94  BAS_1293625   0.5677 
45  BAS_0139098   0.5193  95  BAS_0099446   0.5678 
46  BAS_0434242   0.5201  96  BAS_0872247   0.5695 
47  BAS_3200195   0.5203  97  BAS_0066965   0.5698 
48  BAS_3200194   0.5203  98  BAS_1018141   0.5704 
49  BAS_0457554   0.5226  99  BAS_2603597   0.5711 
50  BAS_1123749   0.5246  100  BAS_1317855   0.5715 Appendix  157  
Table 7.3-c. List containing the top 100 test compounds of the CATS run for reference 
molecule R-03. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  BAS_1293657   0.2863  51  BAS_0187775   0.4318 
2  BAS_0154462   0.3369  52  BAS_0398896   0.4325 
3  BAS_2236262   0.3470  53  BAS_0329591   0.4330 
4  BAS_2236264   0.3475  54  BAS_0015466   0.4353 
5  BAS_2236261   0.3475  55  BAS_0015465   0.4353 
6  BAS_0997507   0.3558  56  BAS_2171303   0.4357 
7  BAS_3603162   0.3596  57  BAS_1026950   0.4366 
8  BAS_0872246   0.3625  58  BAS_0872536   0.4386 
9  BAS_0872247   0.3644  59  BAS_0872357   0.4386 
10  BAS_0872298   0.3650  60  BAS_2556540   0.4399 
11  BAS_1152576   0.3712  61  BAS_0435696   0.4433 
12  BAS_1152575   0.3712  62  BAS_1293655   0.4436 
13  BAS_0872537   0.3712  63  BAS_0363772   0.4443 
14  BAS_0872358   0.3712  64  BAS_3077368   0.4450 
15  BAS_0231929   0.3876  65  BAS_0849059   0.4454 
16  BAS_0491076   0.3886  66  BAS_0637766   0.4463 
17  BAS_0883093   0.3936  67  BAS_0573103   0.4468 
18  BAS_1969380   0.3949  68  BAS_0631939   0.4468 
19  BAS_0872244   0.3954  69  BAS_2988684   0.4480 
20  BAS_0872538   0.3961  70  BAS_1839775   0.4480 
21  BAS_0872359   0.3961  71  BAS_0848995   0.4489 
22  BAS_0454671   0.3975  72  BAS_1585664   0.4495 
23  BAS_0872483   0.3983  73  BAS_1808748   0.4496 
24  BAS_0872486   0.4014  74  BAS_4085088   0.4498 
25  BAS_1121722   0.4014  75  BAS_0129908   0.4498 
26  BAS_0872485   0.4019  76  BAS_0600286   0.4505 
27  BAS_2236263   0.4098  77  BAS_0190164   0.4516 
28  BAS_0872613   0.4118  78  BAS_0363869   0.4521 
29  BAS_1053338   0.4125  79  BAS_0024127   0.4525 
30  BAS_0669878   0.4125  80  BAS_0991456   0.4526 
31  BAS_1355775   0.4132  81  BAS_0726125   0.4536 
32  BAS_0218058   0.4159  82  BAS_2785758   0.4540 
33  BAS_0653659   0.4160  83  BAS_0872534   0.4544 
34  BAS_0653662   0.4168  84  BAS_0872355   0.4544 
35  BAS_0203131   0.4168  85  BAS_0818838   0.4546 
36  BAS_4912490   0.4182  86  BAS_0917444   0.4552 
37  BAS_2556549   0.4185  87  BAS_0069083   0.4552 
38  BAS_1293648   0.4187  88  BAS_1312687   0.4563 
39  BAS_0534732   0.4188  89  BAS_0757453   0.4565 
40  BAS_1280290   0.4200  90  BAS_0584664   0.4565 
41  BAS_0869325   0.4211  91  BAS_0069082   0.4568 
42  BAS_0899656   0.4213  92  BAS_1123747   0.4568 
43  BAS_0129155   0.4249  93  BAS_0015469   0.4569 
44  BAS_0472011   0.4253  94  BAS_0872503   0.4569 
45  BAS_0345519   0.4260  95  BAS_2303581   0.4570 
46  BAS_1293653   0.4280  96  BAS_0997477   0.4590 
47  BAS_0717216   0.4282  97  BAS_0640325   0.4607 
48  BAS_5497245   0.4287  98  BAS_0399408   0.4610 
49  BAS_0119464   0.4302  99  BAS_0484084   0.4614 
50  BAS_0872277   0.4312  100  BAS_0389731   0.4616 158 
Table 7.3-d. List containing the top 100 test compounds of the CATS run for reference 
molecule R-04. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  BAS_0712884   0.2897  51  BAS_0369027   0.5719 
2  BAS_2167520   0.3401  52  BAS_1939695   0.5720 
3  BAS_1939555   0.3616  53  BAS_0579882   0.5737 
4  BAS_1939648   0.3795  54  BAS_0407475   0.5737 
5  BAS_1939535   0.4046  55  BAS_0712780   0.5739 
6  BAS_1939546   0.4143  56  BAS_1316926   0.5742 
7  BAS_1939573   0.4280  57  BAS_1269260   0.5742 
8  BAS_1939536   0.4466  58  BAS_0579549   0.5742 
9  BAS_1939639   0.4507  59  BAS_1403566   0.5745 
10  BAS_0924173   0.4510  60  BAS_0369030   0.5755 
11  BAS_1939665   0.4714  61  BAS_0579885   0.5774 
12  BAS_1939551   0.4896  62  BAS_0369028   0.5779 
13  BAS_1939628   0.4931  63  BAS_0800382   0.5779 
14  BAS_1939563   0.5015  64  BAS_1939644   0.5788 
15  BAS_1939603   0.5047  65  BAS_0406838   0.5797 
16  BAS_1939570   0.5068  66  BAS_0578146   0.5803 
17  BAS_0368608   0.5132  67  BAS_0408214   0.5806 
18  BAS_1939531   0.5167  68  BAS_0542433   0.5806 
19  BAS_1939533   0.5204  69  BAS_1120137   0.5812 
20  BAS_1939629   0.5220  70  BAS_0579515   0.5812 
21  BAS_0798537   0.5377  71  BAS_0542784   0.5817 
22  BAS_1939534   0.5389  72  BAS_0579393   0.5821 
23  BAS_0798536   0.5404  73  BAS_0712763   0.5832 
24  BAS_1939567   0.5407  74  BAS_0579878   0.5844 
25  BAS_1939565   0.5407  75  BAS_0407476   0.5851 
26  BAS_0579385   0.5411  76  BAS_0838067   0.5859 
27  BAS_0406832   0.5427  77  BAS_0441450   0.5862 
28  BAS_0476182   0.5438  78  BAS_0579884   0.5876 
29  BAS_0579396   0.5450  79  BAS_0407062   0.5898 
30  BAS_1939654   0.5466  80  BAS_2778871   0.5900 
31  BAS_0369029   0.5475  81  BAS_0408213   0.5945 
32  BAS_1058381   0.5485  82  BAS_0579493   0.5963 
33  BAS_1939537   0.5495  83  BAS_0579482   0.5963 
34  BAS_1939562   0.5499  84  BAS_0369091   0.5964 
35  BAS_1939554   0.5499  85  BAS_0753957   0.5965 
36  BAS_1939548   0.5499  86  BAS_0408217   0.5966 
37  BAS_1939547   0.5499  87  BAS_1269241   0.5971 
38  BAS_0579407   0.5507  88  BAS_0758992   0.5979 
39  BAS_0369033   0.5601  89  BAS_0579428   0.5985 
40  BAS_0542311   0.5611  90  BAS_0579418   0.5985 
41  BAS_0368609   0.5626  91  BAS_0712754   0.5985 
42  BAS_0712762   0.5641  92  BAS_0579538   0.5990 
43  BAS_2975101   0.5659  93  BAS_0441433   0.5991 
44  BAS_0754427   0.5664  94  BAS_1939630   0.5992 
45  BAS_1939661   0.5667  95  BAS_0543754   0.5993 
46  BAS_0579879   0.5675  96  BAS_0712795   0.6007 
47  BAS_0084847   0.5712  97  BAS_0407482   0.6008 
48  BAS_0407336   0.5712  98  BAS_3374461   0.6008 
49  BAS_0661907   0.5713  99  BAS_0579890   0.6010 
50  BAS_0712798   0.5718  100  BAS_1939624   0.6016 Appendix  159  
Table 7.3-e. List containing the top 100 test compounds of the CATS run for reference 
molecule R-05. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  BAS_0253277   0.7360  51  BAS_3058581   0.9345 
2  BAS_6264800   0.7521  52  BAS_0620124   0.9367 
3  BAS_0355555   0.8153  53  BAS_0774663   0.9369 
4  R-06   0.8470  54  BAS_0618998   0.9378 
5  BAS_6264802   0.8664  55  BAS_0341130   0.9379 
6  BAS_0253275   0.8716  56  BAS_0844616   0.9405 
7  BAS_4363443   0.8821  57  BAS_0844538   0.9405 
8  BAS_2720963   0.8916  58  BAS_0222891   0.9415 
9  BAS_6264827   0.8917  59  BAS_0732880   0.9416 
10  BAS_1377675   0.8939  60  BAS_1122474   0.9430 
11  BAS_4363433   0.8944  61  BAS_1004862   0.9435 
12  BAS_0022054   0.8946  62  BAS_0844509   0.9441 
13  BAS_0844542   0.8947  63  BAS_3387264   0.9455 
14  BAS_3387057   0.8981  64  BAS_0732884   0.9457 
15  BAS_0732895   0.8991  65  BAS_3387139   0.9461 
16  BAS_0964142   0.8993  66  BAS_0620125   0.9463 
17  BAS_3387347   0.9006  67  BAS_0222899   0.9468 
18  BAS_2725225   0.9035  68  BAS_1122473   0.9469 
19  BAS_3387060   0.9039  69  BAS_0844557   0.9491 
20  BAS_1122488   0.9087  70  BAS_0844502   0.9516 
21  BAS_5990601   0.9137  71  BAS_1122490   0.9532 
22  BAS_3635578   0.9140  72  BAS_2987851   0.9543 
23  BAS_0844556   0.9152  73  BAS_5022080   0.9547 
24  BAS_5990712   0.9156  74  BAS_0964143   0.9553 
25  BAS_0222915   0.9161  75  BAS_0732894   0.9557 
26  BAS_0222918   0.9165  76  BAS_2725212   0.9559 
27  BAS_4363483   0.9165  77  BAS_5829411   0.9563 
28  BAS_0222916   0.9176  78  BAS_0341126   0.9563 
29  BAS_0341128   0.9180  79  BAS_1228891   0.9564 
30  BAS_3387180   0.9201  80  BAS_0414917   0.9569 
31  BAS_1122472   0.9211  81  BAS_3387138   0.9569 
32  BAS_0021983   0.9237  82  BAS_5291804   0.9570 
33  BAS_0844559   0.9238  83  BAS_0222892   0.9579 
34  BAS_0896617   0.9241  84  BAS_0491907   0.9583 
35  BAS_0964141   0.9242  85  BAS_3301920   0.9587 
36  BAS_2600118   0.9246  86  BAS_0844541   0.9589 
37  BAS_0236268   0.9250  87  BAS_0253265   0.9592 
38  BAS_0732891   0.9251  88  BAS_2549735   0.9598 
39  BAS_6264821   0.9256  89  BAS_0253264   0.9601 
40  BAS_1322638   0.9256  90  BAS_3819173   0.9605 
41  BAS_3635676   0.9257  91  BAS_0620074   0.9622 
42  BAS_3301924   0.9264  92  BAS_5829394   0.9622 
43  BAS_6481840   0.9270  93  BAS_0844558   0.9642 
44  BAS_1322652   0.9277  94  BAS_0844523   0.9644 
45  BAS_0491826   0.9277  95  BAS_0844498   0.9644 
46  BAS_0222910   0.9280  96  BAS_1059074   0.9652 
47  BAS_0340791   0.9285  97  BAS_3386113   0.9657 
48  BAS_4914705   0.9294  98  BAS_0620113   0.9659 
49  BAS_0340790   0.9302  99  BAS_0620060   0.9661 
50  BAS_1002446   0.9302  100  BAS_1118258   0.9661 160 
Table 7.3-f. List containing the top 100 test compounds of the CATS run for reference 
molecule R-06. Molecules with blue ID were ordered, molecules with bold ID were ordered 
and delivered. 
Rank ID  Similarity  Score  Rank ID  Similarity  Score 
1  BAS_4299532   0.5254  51  BAS_5291883   0.6818 
2  BAS_3387180   0.5467  52  BAS_0606759   0.6849 
3  BAS_0393306   0.5640  53  BAS_3635673   0.6853 
4  BAS_1004866   0.5804  54  BAS_1403566   0.6862 
5  BAS_3387347   0.5807  55  BAS_0705188   0.6885 
6  BAS_3635578   0.5883  56  BAS_3386040   0.6889 
7  BAS_3387264   0.5934  57  BAS_1416427   0.6906 
8  BAS_4328488   0.5940  58  BAS_6264800   0.6907 
9  BAS_3387139   0.5947  59  BAS_0253264   0.6923 
10  BAS_0406650   0.5953  60  BAS_1322643   0.6938 
11  BAS_0702290   0.6069  61  BAS_0705221   0.6950 
12  BAS_0606878   0.6106  62  BAS_1259647   0.6962 
13  BAS_0161075   0.6137  63  BAS_5932036   0.6964 
14  BAS_3387138   0.6189  64  BAS_0705220   0.6964 
15  BAS_3635676   0.6226  65  BAS_0523555   0.6964 
16  BAS_3387057   0.6263  66  BAS_1002424   0.6979 
17  BAS_1268028   0.6272  67  BAS_5291802   0.7013 
18  BAS_1002446   0.6317  68  BAS_3387311   0.7055 
19  BAS_1004861   0.6347  69  BAS_3245128   0.7055 
20  BAS_3245127   0.6384  70  BAS_3386029   0.7056 
21  BAS_0406649   0.6389  71  BAS_0606854   0.7066 
22  BAS_3386064   0.6436  72  BAS_0253265   0.7066 
23  BAS_0686464   0.6450  73  BAS_1002513   0.7080 
24  BAS_1002477   0.6482  74  BAS_0630784   0.7089 
25  BAS_0774662   0.6509  75  BAS_0630770   0.7089 
26  BAS_5932079   0.6514  76  BAS_5932057   0.7095 
27  BAS_2987877   0.6543  77  BAS_0774663   0.7112 
28  BAS_0406651   0.6550  78  BAS_1426717   0.7114 
29  BAS_1416455   0.6556  79  BAS_0630769   0.7114 
30  BAS_1002428   0.6560  80  BAS_1095379   0.7115 
31  BAS_2987861   0.6567  81  BAS_0236242   0.7117 
32  BAS_1403567   0.6573  82  BAS_3387344   0.7138 
33  BAS_3387060   0.6575  83  BAS_0599010   0.7152 
34  BAS_1403569   0.6577  84  BAS_0443481   0.7168 
35  BAS_1268033   0.6589  85  BAS_1322631   0.7170 
36  BAS_5291892   0.6590  86  BAS_2987851   0.7179 
37  BAS_1004862   0.6592  87  BAS_1322652   0.7190 
38  BAS_1403573   0.6592  88  BAS_1677419   0.7190 
39  BAS_5931987   0.6593  89  BAS_3387473   0.7206 
40  BAS_0630794   0.6600  90  BAS_3387474   0.7236 
41  BAS_5291804   0.6601  91  BAS_2987946   0.7267 
42  BAS_1004869   0.6628  92  BAS_2937446   0.7274 
43  BAS_1004840   0.6647  93  BAS_0606853   0.7288 
44  BAS_1074213   0.6650  94  BAS_0443480   0.7291 
45  BAS_1003171   0.6652  95  BAS_1002476   0.7297 
46  BAS_0851285   0.6677  96  BAS_0687521   0.7302 
47  BAS_1322638   0.6694  97  BAS_0253261   0.7304 
48  BAS_0606868   0.6735  98  BAS_2937456   0.7310 
49  BAS_0606855   0.6735  99  BAS_0606749   0.7314 
50  BAS_3387305   0.6775  100  BAS_0606736   0.7314 Appendix  161  
7.4  Collection of Virtual Hits obtained in Section 4.4 
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Figure 7.4-a. Set of compounds that were retrieved from the Asinex Gold Collection 2003 
using the pharmacophore search and ChemSpaceShuttle (Section 4.4.3). 
 
Table 7.4-a. List containing all 18 compounds that were selected by neighborhoodsearch in 
ChemSpaceShuttle and ordered (Section 4.4.3). Entries with no internal number were ordered 
but not delivered. 
Vendor ID  Number  Vendor ID  Number 
BAS_0165203 P-02 BAS_0918495 P-04 
BAS_0192172 - BAS_1121507  P-01 
BAS_0272674 - BAS_1356608  P-12 
BAS_0311677 P-10 BAS_1365657 P-06 
BAS_0318830 P-11 BAS_2054004 P-05 
BAS_0332029 P-09 BAS_2104611 P-13 
BAS_0565291 P-03 BAS_2255568 P-14 
BAS_0866717 - BAS_3108856  P-15 
BAS_0914660 P-08 BAS_3847150 P-07 162 
7.5  Collection of Virtual Hits obtained in Section 4.5 
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Figure 7.5-a. Set of compounds that were retrieved from the Asinex Gold Collection 2003 
using the SOM approach (Section 4.5.2). Molecules were assigned to subsets according to 
their core structure. 164 
Table 7.5-a. List displaying the 50 best ranked compounds retrieved from the Asinex 
database by the SOM approach (Section 4.5.2). Entries are sorted by ascending order with 
respect to their distance to the centroid of neuron 6/6 (15x15 map). Molecules with blue ID 
were ordered, molecules with bold ID were ordered and delivered. 
Vendor ID  Number  Distance (10x10)  Distance (15x15) 
BAS_0395916   -  0.329  0.275 
BAS_0395917  S-02 0.329  0.275 
BAS_0511006  S-01 0.328  0.285 
BAS_1123567   -  0.318  0.287 
BAS_1018007   -  0.315  0.289 
BAS_1018066   -  0.315  0.289 
BAS_0872503  S-03 0.336  0.293 
BAS_0395926   -  0.339  0.299 
BAS_1123565  S-04 0.346  0.306 
BAS_2276953  S-05 0.342  0.308 
BAS_0084923 -    0.345  0.310 
BAS_0726371 -    0.338  0.314 
BAS_2276957  S-06 0.355  0.316 
BAS_0872364  S-07 0.377  0.318 
BAS_2276986  S-08 0.356  0.324 
BAS_0297500 -  0.381  0.326 
BAS_2276985  S-09 0.370  0.327 
BAS_0084926  S-10 0.358  0.328 
BAS_2276955  S-11 0.392  0.328 
BAS_0872424  S-12 0.348  0.332 
BAS_0794556  S-13 0.363  0.334 
BAS_1123720   -  0.318  0.334 
BAS_0434242   -  0.382  0.336 
BAS_1293648   -  0.374  0.336 
BAS_0203181  S-14 0.399  0.338 
BAS_1416611  S-15 0.391  0.338 
BAS_0308659  S-16 0.410  0.340 
BAS_0594844  S-17 0.383  0.342 
BAS_0872398  S-18 0.378  0.347 
BAS_1018019  S-19 0.376  0.348 
BAS_1018064 -    0.375  0.348 
BAS_2276958 -    0.382  0.348 
BAS_0316110  S-20 0.370  0.351 
BAS_0872419  S-21 0.371  0.352 
BAS_0329602  S-22 0.358  0.354 
BAS_0099446 -    0.397  0.355 
BAS_0530782  S-23 0.399  0.356 
BAS_0129956 -    0.423  0.357 
BAS_0260628  S-24 0.372  0.359 
BAS_1293659  S-25 0.396  0.359 
BAS_0369559 -    0.405  0.361 
BAS_0395869 -    0.385  0.361 
BAS_0119417  S-26 0.371  0.362 
BAS_0872214   -  0.420  0.362 
BAS_2276984   -  0.399  0.364 
BAS_0530807   -  0.392  0.365 
BAS_0162450   -  0.415  0.369 
BAS_0393988  S-27 0.397  0.369 
BAS_0669563  S-28 0.371  0.370 
BAS_0203174   -  0.415  0.372 Appendix  165  
7.6  Statistical Indices and Compounds from Section 5.1.1 
 
Table 7.6-a. Statistical indices for ten independent CoMFA models. All 39 molecules were 
randomly assigned either to the training or the test set, both of which having nearly equivalent 
size (training set: 20; test set: 19). For each model the same molecular alignment in the same 
spatial orientation was used. 
 
Model  q² (cv)  SEP  Components F  r²  SEE  % steric  % electr. 
1  0.576  0.625 4 107.576  0.966  0.176  70.2 29.8 
2 0.503  0.721  3  55.115  0.912  0.304 65.9  34.1 
3 0.294  0.679  2  34.856  0.804  0.358 78.0  22.0 
4 0.598  0.661  4  59.741  0.941  0.253 68.8  31.2 
5 0.616  0.645  3  62.371  0.921  0.292 70.1  29.9 
6 0.553  0.519  1  56.260  0.758  0.382 56.2  43.8 
7 0.389  0.675  4  70.535  0.950  0.194 69.8  30.2 
8 0.523  0.667  4  77.466  0.951  0.214 70.0  30.0 
9 0.389  0.557  4  43.546  0.921  0.208 62.1  37.9 
10  0.626  0.700 7 303.750  0.994  0.086  70.0 30.0 
Mean 0.507  0.645  3.6  87.122 0.912  0.247  68.1  31.9 
SEM 0.036  0.020  0.5  24.874 0.023  0.028  1.8  1.8 
 
 
Table 7.6-b. Series of 39 quinoline derivatives used for the present CoMFA study. Entries are 
sorted with respect to their internal ID number. 
 
Molecule-ID Structure  pIC50-value Dataset 
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